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VIII. Summary 
 
 
The ATPase p97 plays a role in diverse cellular activities such as cell cycle progression, 
membrane fusion, DNA repair and ubiquitin-dependent protein degradation (including 
endoplasmic reticulum-associated protein degradation, ERAD). The functional diversity 
of p97 is achieved by its association with a large number of cofactors including the 13 
human UBX-domain containing proteins. My PhD projects focused on two of the UBX-
domain proteins, UBXN7 and UBXN8. 
 
Among human UBA-UBX proteins, UBXN7 is the most proficient in interacting with 
CRL (cullin-RING E3 ligase) subunits, in particular CUL2, and it was assumed that 
these interactions were indirect, mediated by ubiquitylated substrates. However, we 
show that UBXN7 interaction with CUL2 is independent of ubiquitin- and substrate 
binding. Instead, it involves the direct docking of the ubiquitin interaction motif (UIM) 
in UBXN7 onto the neddylated cullin. Furthermore, we found that UBXN7 
overexpression keeps the E3 ligase CUL2 (a member of the CRL2 complex) in its 
neddylated form and causes the accumulation of non-ubiquitylated HIF1α (CRL2 
substrate). Both effects are strictly UIM-dependent and occur only when UBXN7 
contains an intact UIM. We also show that HIF1α carrying long ubiquitin-chains can 
interact with an alternative ubiquitin-binding protein, which is independent from p97’s 
segregase activity. We therefore propose that UBXN7 negatively regulates the 
ubiquitin-ligase activity of CRL2 by sequestering CUL2 in its neddylated form and that 
this might prevent recruitment of ubiquitin-receptors other than p97 to HIF1α. 
 
The mass spectrometry analysis of Flag-UBXN8 immunoprecipitates identified several 
DNA damage-related proteins, including the Fanconi anaemia proteins FANCD2 and 
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FANCI. I could show that homodimeric UBXN8 interacts directly with non-
ubiquitylated FANCD2 and FANCI. The direct binding of UBXN8 to the non-
ubiquitylated FA proteins supports the notion that UBX-only proteins interact with 
substrates in an ubiquitin-independent manner. Furthermore, FANCD2 and FANCI are 
released from UBXN8 upon DNA damage, that in case of FANCI requires p97 binding 
to UBXN8. 
My data indicate that UBXN8 acts as a negative regulator in the DNA damage response, 
because UBXN8 silenced cells show increased resistance to ICL-inducing agents. This 
phenotype was supported by my finding that UBXN8 silenced cells have increased 
levels of FANCD2 and FANCI mono-ubiquitylation as well as increased dimer 
formation and FANCD2 foci formation in the presence and absence of DNA damage. 
UBXN8 overexpression had the opposite effect on FANCD2 and FANCI modification 
and dimerization. I therefore propose that UBXN8 has an inhibitory effect on FANCD2 
and FANCI that may prevent their ectopic activation in the absence of DNA damage. 
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Chapter 1 
1. Introduction 
1.1 The ATPase p97  
The ATP-dependent molecular chaperone p97 is an essential protein, and is 
evolutionarily conserved from archaebacteria to mammals. As an ATPase, p97 uses the 
energy derived from ATP hydrolysis to unfold proteins, or to dissociate proteins from 
large cellular structures such as chromatin or the endoplasmic reticulum (ER) 
membrane (White and Lauring, 2007). It is involved in a wide variety of cellular 
processes ranging from cell cycle regulation and DNA damage repair, to membrane 
fusion and ubiquitin-dependent protein degradation (including endoplasmic reticulum-
associated protein degradation, ERAD) (Ye, 2006, Haines, 2010a). 
 
The functional diversity of p97 is achieved by its association with a large number of 
cofactors. Their interaction with p97 is mediated through conserved p97 binding 
domains/motifs such as the UBX (ubiquitin regulatory X) domain, BS1 (binding site 1) 
sequence, VCP-binding motif (VBM), PUB (PNGase/UBA or UBX) domain, and VCP-
interacting motif (VIM) (Yeung et al., 2008). Some of these cofactors contain additional 
ubiquitin-binding motifs that allow simultaneous binding with p97 and ubiquitylated 
substrates (Buchberger, 2002, Alexandru et al., 2008, Meyer et al., 2002). 
Based on their biological roles, these cofactors can be classified in two main groups: 
substrate-recruiting cofactors, and substrate-processing cofactors (Jentsch and Rumpf, 
2007). 
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The substrate-recruiting cofactors (such as UBX-domain proteins, UFD1 and NPL4) 
bind protein substrates, either directly or via modifications (most commonly 
ubiquitylation), and thereby mediate the interactions of p97 with its substrates (Madsen 
et al., 2009, Jentsch and Rumpf, 2007).  
The group of substrate-processing cofactors includes E3 enzymes (HRD1, gp78), E4 
enzymes (E4B) and deubiquitylation enzymes (e.g. VCIP135) that control the degree of 
ubiquitylation of the bound substrates by either promoting polyubiquitylation or 
deubiquitylation (Madsen et al., 2009, Jentsch and Rumpf, 2007). 
It has been shown that some of these cofactors (e.g. UBXN7, NPL4, UFD1) can coexist 
in the same p97 complex (Alexandru et al., 2008), whereas other cofactors (e.g., UFD1 
versus p47) compete for the same docking site on p97 N-termini (Schuberth and 
Buchberger, 2008). 
 
1.1.1 Domains and structure of p97 
Irrespective of its bound cofactors, p97 is believed to convert the energy derived from 
ATP hydrolysis into mechanical force to disassemble protein complexes or segregate 
proteins from intracellular structures such as the chromatin or the ER membrane. 
The p97 protomer consists of an N-terminal region that functions as adaptor protein 
binding domain, two tandem AAA ATPase domains D1 and D2, separated by a D1–D2 
linker region, and a disordered C-terminal region (Huyton et al., 2003, Zhang et al., 
2000) (Figure 1.1). Each D1 and D2 domain contains a signature nucleotide-binding 
Walker A and B motif, and a second region of homology (SRH) region that play a 
critical roles in mediating ATP binding and hydrolysis (Ogura et al., 2004, Song et al., 
2003). In cells, p97 acts as a hexamer, with the D1 and D2 domains stacked in a ‘head-
to-tail’ fashion forming a hexameric double ring (Huyton et al., 2003). The D1 domain 
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is a degenerate ATPase domain that is responsible for the stability of the hexameric 
state (Wang et al., 2003), whereas the D2 domain is the major ATPase domain of p97 
that facilitates the ATP hydrolysis and generates the main driving force (Song et al., 
2003). Mutations in D2, that abrogate ATP binding or hydrolysis through the D2 
domain, result in dominant-negative variants that bind, but cannot release substrates 
(Song et al., 2003). During ATP hydrolysis, both the D1 and D2, as well as the N-
terminal domain, experience dramatic conformational changes (DeLaBarre and 
Brunger, 2005). The rings formed by D1 and D2 rotate with respect to each other, and 
the sizes of their axial openings fluctuate (Yeung et al., 2014). Although ATP 
hydrolysis is carried out mainly by the D2 domain recent studies have shown that the 
interplay of conformational changes between the rings and mobility of the N-terminal 
domain is important for efficient ATPase activity (Niwa et al., 2012). Furthermore, the 
D2 domain as major ATPase domain and the N-domain as principal substrate binding 
domain reside at opposite ends of the proteins. Hence, the ATP hydrolysis-induced 
motion must be transmitted trough the length of the entire molecule.  
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Figure 1.1: The hexameric ATPase p97 
Top: Schematic showing the domains of p97 (N: N-terminus; D1: ATPase D1; D2: ATPase 
D2), the Walker A and B motifs within the ATPase domains and the second region of 
homology (SRH). 
Bottom: Structure of p97 shown in two orientations (left: top view and right: side view). N-
terminus (green), ATPase D1 (dark blue), ATPase D2 (light blue). The cartoon representation 
of the p97 hexamer was drawn using the PDB 1R7R in Pymol.  
 
 
1.1.2 Mammalian p97 interacts with multiple UBX domain-containing cofactors 
UBX-domain proteins represent the largest group of p97 cofactors (13 members in 
human) that interact directly with p97 via their UBX domains (Alexandru et al., 2008, 
Dreveny et al., 2004, Schuberth and Buchberger, 2008, Liang et al., 2006) (Figure 1.2). 
Five of the UBX-domain proteins, the UBA–UBX proteins (UBXN7, UBXD8, FAF1, 
SAKS1, p47) contain an additional N-terminal UBA (ubiquitin-associated) domain, 
which enables them to bind ubiquitylated proteins (Alexandru et al., 2008). UBA–UBX 
cofactors can interact with a large spectrum of substrates carrying a ubiquitin 
modification, therefore they function as substrate-binding adaptors for p97 (Schuberth 
and Buchberger, 2008). 
The remaining eight UBX-only proteins (p37, UBXN2A, UBXN4, UBXN8, UBXN6, 
UBXN10, UBXN11, ASPL) lack the UBA domain and the ability to bind ubiquitin, 
which might limit their substrate specificity. Furthermore, the expression of several 
UBX-only proteins is tissue-dependent and therefore their function might be restricted 
to specific cell types (Yamabe et al., 1997, Carim-Todd et al., 2001). 
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Figure 1.2: The 13 UBX-domain cofactors of p97 in mammalian cells 
Schematics show the 13 human UBX-domain proteins and their various domains. UBX: 
Regulatory X domain; UBA: ubiquitin-associated domain; UAS: ubiquitin-associating 
domain; UIM: ubiquitin-interaction motif; UBL: ubiquitin-like; SEP: Shp, eyes-closed, p47; 
TM: transmembrane domain; PUB: PNGase/UBA or UBX; ThF: Thioredoxin-like fold 
 
1.1.3 p97 and its diverse functions in the cell 
As already mentioned, p97 is involved in a wide variety of cellular processes. In this 
subchapter, I tried to list some of the functions that have been assigned to p97. 
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Endoplasmic reticulum-associated protein degradation  
The role of p97 in the endoplasmic reticulum-associated protein degradation (ERAD) is 
the best-described function of p97 in proteolysis. The ERAD pathway mediates the 
degradation of misfolded or misassembled proteins at the ER. These proteins are retro-
translocated from the ER lumen into the cytoplasm to facilitate their ubiquitylation and 
ubiquitin-dependent protein degradation via the proteasome (Vembar and Brodsky, 
2008, Ye, 2006, Liu and Ye, 2012).  
The first step of the ERAD pathway is the recognition of the misfolded or unassembled 
polypeptides by ER chaperones that target these proteins to a retro-translocation 
complex in the membrane (Liu and Ye, 2012). This retro-translocation complex 
comprises of at least one E3 ubiquitin ligase (for example HRD1 or gp78 in mammals 
(Kikkert et al., 2004, Fang et al., 2001)) that ubiquitylates the substrate emerging from 
the ER membrane at the cytoplasmic side. The retro-translocation of the targeted 
polypeptides to the cytoplasm requires the p97–UFD1–NPL4 complex (Ye et al., 2003) 
that is recruited to the ER through ER membrane proteins such as UBXD8 and UBXD2 
(Liang et al., 2006, Olzmann et al., 2013). The recognition of the polypeptide by p97 in 
the cytoplasm is mediated by the ubiquitin-binding motif in UFD1 that binds the 
ubiquitin chains attached to the polypeptide (Ye et al., 2003, Park et al., 2005). The 
energy derived from ATP hydrolysis by p97 generates the driving force to pull the 
substrate into the cytoplasm (Ye et al., 2003). The substrate is then delivered to the 26S 
proteasome for ubiquitin-dependent protein degradation (Raasi and Wolf, 2007). 
   
The ubiquitin-dependent degradation of outer mitochondrial membrane-associated 
proteins also requires p97 and follows a similar mechanism as described for ERAD 
(Taylor and Rutter, 2011). Upon mitochondrial stress, VMS1 recruits p97 and NPL4 to 
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the mitochondrial membrane where it retro-translocates ubiquitylated substrates into the 
cytoplasm (Xu et al., 2011, Heo et al., 2010). The E3 ligase Parkin binds to the outer 
mitochondrial membrane and ubiquitylates the emerging substrates at the cytoplasmic 
side (Narendra et al., 2008). After the retro-translocation into the cytoplasm, the 
ubiquitylated proteins are targeted for proteasome-dependent degradation (Taylor and 
Rutter, 2011). 
 
Autophagy 
Autophagy is an intracellular degradation system that eliminates protein aggregates and 
organelles by the lysosome.  
The role of p97 in autophagy has been first described in the context of IBMPFD 
(inclusion body myopathy associated with Paget’s disease of the bone and fronto-
temporal dementia), in which mutations in p97 lead to the accumulation of protein 
aggregates caused by defective autophagy (Ju et al., 2009, Tresse et al., 2010).  
Autophagy is mediated by the autophagosome that engulfs cellular components and 
subsequently fuses with the lysosome (forms autolysosome) for their degradation. 
(Mizushima, 2007). The autophagosome maturation, a process including 
autophagosome-lysosome fusion and autolysosome formation, requires p97. Hence, the 
expression of disease-causing p97 mutants results in the accumulation of 
autophagosomes (Ju et al., 2009). Furthermore, the majority of accumulated 
autophagosomes contain ubiquitin conjugates, suggesting that p97 may be required for 
the autophagic degradation of ubiquitylated substrates (Tresse et al., 2010)  
 
 
 
	  	  	  	  
8	  
Membrane fusion 
During mitosis, p97 is described to be involved in the reformation of the endoplasmic 
reticulum, the Golgi complex (Uchiyama and Kondo, 2005) and the nuclear envelope 
(Hetzer et al., 2001). In mammalian cells, the three organelles are fragmented into 
vesicles at the onset of mitosis and reassembled at the end of mitosis to allow the 
formation of new organelles in the daughter cells. 
The reassembling of the ER and the Golgi requires membrane fusion that is mediated by 
p97 together with its co-factors p47 and VCP135 (Uchiyama et al., 2002, Kondo et al., 
1997, Uchiyama and Kondo, 2005). Furthermore, another membrane fusion pathway 
that involves the p97–p37 complex is required for Golgi and ER maintenance during 
interphase and their re-assembly at the end of mitosis (Uchiyama et al., 2006). 
The nuclear envelope formation requires the re-assembly of a tubular network on the 
chromatin surface resulting in a closed envelope, which then expands (Guettinger et al., 
2009). p97 is involved in two steps of the nuclear envelope re-assembly: sealing of the 
nuclear envelope (mediated by p97–UFD1–NPL4) and nuclear growth (mediated by 
p97–p47) (Hetzer et al., 2001). 
 
Chromatin-associated functions of p97 in the DNA-damage response 
Recent publications have identified the p97–UFD1–NPL4 complex as an essential 
factor in the ubiquitin-dependent DNA damage response, highlighting its importance in 
guarding genome stability (Meerang et al., 2011, Dantuma and Hoppe, 2012). 
The ubiquitin ligases RNF8 and RNF168 are recruited to DNA double-strand breaks 
(DSBs) and assemble ubiquitin chains at sites of DNA damage (Mailand et al., 2007, 
Huen et al., 2007). This results in recruitment of DNA damage repair proteins such as 
BRCA1, RAD18, and 53BP1 that are required to facilitate DNA repair (Mailand et al., 
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2007, Huen et al., 2007). Recent publications show that RNF8-mediated ubiquitylation 
triggers recruitment of p97 and its cofactors UFD1–NPL4 to DSBs (Ramadan, 2012, 
Meerang et al., 2011). Inhibiting the p97–UFD1–NPL4 function resulted in prolonged 
accumulation of K48 ubiquitin conjugates and defective recruitment of BRCA1, 
RAD51, and 53BP1 to DSBs (Meerang et al., 2011). 
Furthermore, recent publications have shown that RNF8-mediated recruitment of p97 to 
DNA damage sites results in removal of the K48-conjugated substrate proteins, such as 
L3MBTL1 (Acs et al., 2011) or the TLS (Translesion DNA synthesis) polymerase     
Polη(Davis et al., 2012). Substrate removal from the DNA damage site then allows 
proper assembly of downstream signalling factors, including Rad51, BRCA1 and 
53BP1 (Acs et al., 2011) (Meerang et al., 2011). Furthermore, the depletion of p97, 
UFD1 and NPL4 in mammalian cells and worms leads to hypersensitivity to DSB-
inducing agents, consistent with a role for this complex in the cellular response to DNA 
damage (Meerang et al., 2011, Acs et al., 2011).  
 
1.1.4 The role of p97 and its UBX-domain cofactors in health and disease 
The involvement of p97 in a wide variety of cellular processes suggests that it plays an 
important role in health and disease. Indeed, p97 has been implicated in the direct 
regulation of several cancer-relevant proteins, such as HIF1α (Alexandru et al., 2008), 
IκBα (Dai et al., 1998), Aurora B (Ramadan et al., 2007), and NF1 (Phan et al., 2010). 
Furthermore, elevated levels of p97 have been reported in a number of human 
malignancies including cancers of breast, liver, lung, pancreas, ovary, and colon, often 
with aggressive and poor outcomes (Yamamoto et al., 2005, Yamamoto et al., 2003, 
Valle et al., 2011, Yamamoto et al., 2004). A possible explanation for the increased p97 
levels in malignant cells could be the protein damage-induced stress signals that are 
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elevated in cancer cells. The induction of elevated p97 levels could help in the clearance 
of abundant, misfolded/aggregate-prone, and potentially toxic proteins from malignant 
cells and facilitate their survival (Haines, 2010b). 
Mutations in human p97 have been identified in neurodegenerative diseases such as 
IBMPFD (patient develop frontotemporal dementia) (Watts et al., 2004) and 
amyotrophic lateral sclerosis (ALS, degeneration of motor neurons) (Johnson et al., 
2010). The majority of mutations are located within or close to the N- and D1-domains. 
These domains are required for the transmission of the conformational changes derived 
from ATP hydrolysis to the co-factors and/or substrate proteins (Tang et al., 2010, 
Halawani et al., 2009, Fernandez-Saiz and Buchberger, 2010). Hence, mutations 
affecting these domains cause impaired autophagy and degradation of ERAD substrates 
(Weihl et al., 2006, Ju et al., 2009). 
 
Furthermore, altered expression levels of the p97 cofactor FAF1 and ASPL (UBXD9) 
have been reported in tumour cells. FAF1 down-regulation has been shown in gastric 
cancers (Bjorling-Poulsen et al., 2003) and in malignant mesothelioma cell lines and 
primary tumours (Altomare et al., 2009), suggesting that FAF1 is likely to be involved 
in cancer progression. The underlying mechanism is not clear.  
The expression of the UBX-only cofactor ASPL is altered in the rare and unusual 
cancer, alveolar soft part sarcoma, that is caused by translocation between chromosomes 
X and 17 (Kuroda et al., 2012). The translocations involving ASPL result in the 
replacement of the amino terminal region of transcription factor TFE3 with the amino 
terminal half of ASPL (Ladanyi et al., 2001, Argani et al., 2001). How the translocation 
affects the activity of both proteins is not clear. 
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1.2 The p97 co-factor UBXN7 
1.2.1 The p97 co-factor UBXN7 and its domains 
UBXN7 (also known as UBXD7) is one of the five UBA–UBX proteins in mammalian 
cells that binds p97 via its UBX domain and ubiquitylated substrates via its UBA 
domain (Alexandru et al., 2008). In addition to the UBA domain at its N-terminus and 
the UBX domain at its C-terminus, UBXN7 harbours an UAS domain and an ubiquitin 
interaction motif (UIM) in the middle of its sequence (Figure 1.3). Studies on UBA and 
UIM domains from various proteins have shown that these modules are capable of 
interacting with mono- and poly-ubiquitin chains (Hicke et al., 2005). Additionally, in 
vitro studies have illustrated that, for example, the UIM of HRS and the UBA domain 
of NUB1 can also interact with the ubiquitin-like modifier NEDD8 (Oved et al., 2006, 
Tanaka et al., 2003). NEDD8 exhibits a similar hydrophobic surface to the one that 
allows ubiquitin to interact with ubiquitin binding domains (Whitby et al., 1998). 
Whereas the UBA domain of UBXN7 binds ubiquitylated substrates, the role of the 
UIM is yet to be discovered. The function of the UBXN7 UAS domain is also 
unknown, but a recent study suggests that the UAS domain	  in the UBA–UBX proteins 
UBXD8 or FAF1 mediates their polymerization upon interaction with long-chain 
unsaturated fatty acids (Kim et al., 2013). 
 
	  
Figure 1.3: Schematic representation of human UBXN7 highlighting its various domains including 
reported protein-interactions  UBA:	   ubiquitin-­‐associated	   domain;	   UAS;	   UIM:	   ubiquitin-­‐interaction	   motif;	   UBX:	  
Ubiquitin regulatory X	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1.2.1 UBXN7 is the UBA–UBX protein that shows the most extensive interaction with 
cullin-RING E3 ligase subunits 
The study performed by Alexandru et al. (2008) not only revealed that p97 interacts 
with all 13 mammalian UBX-domain proteins, but also that five of the UBA–UBX 
proteins (UBXN7, UBXD8, FAF1, SAKS1, p47) interact with a large variety of E3 
ubiquitin ligases (Alexandru et al., 2008). The comparative MudPIT (Multidimensional 
Protein Identification Technology) analysis of Flag-(UBA–UBX) protein 
immunoprecipitates identified multiple components of cullin-RING E3 ligase 
complexes as well as single subunit RING- and HECT-domain E3s. Notably, among the 
UBA–UBX proteins, UBXN7 is the most proficient to interact with CRL subunits 
(Alexandru et al., 2008). 
 
1.2.2 The cullin-RING E3 ligase complex 
The cullin-RING E3 ligase complexes (CRLs) are conserved from yeast to humans. 
They comprise the largest group of ubiquitin ligases and mediate the ubiquitylation of 
numerous protein substrates, which are subsequently targeted for proteasomal 
degradation. By controlling the stability of various key regulators, CRLs influence 
many cellular and biological processes, such as gene expression, cell cycle progression, 
DNA damage response, or cell signalling (Kamura et al., 2000, Bloom et al., 2003, 
Karin and Ben-Neriah, 2000, Sato et al., 2012a).  
The CRLs are multi-subunit complexes assembled by three core components – a cullin, 
a RING finger protein, and (except for CUL3-based CRLs) a cullin-specific adaptor 
protein (Deshaies and Joazeiro, 2009) (Figure 1.4). Humans express seven cullins 
(CUL1, 2, 3, 4A, 4B, 5 and 7), each acting as scaffold for ubiquitin ligases (E3). The C-
terminus of the cullin binds the RING-finger protein that facilitates the direct transfer of 
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the ubiquitin from an ubiquitin-conjugated E2 enzyme to lysine residues on the target 
substrate. The N-terminus of the cullin binds cullin-specific adaptors. These adaptors 
bind interchangeable substrate specific receptors, which in turn recruit substrates for 
ubiquitylation (Figure 1.4A). For instance, within the CRL2 complex, Cullin 2 (CUL2) 
acts as a scaffold that binds, with its C-terminus, the RING-finger protein RBX1 and, 
with its N-terminus, the adaptor complex Elongin B/C (Kamura et al., 1999). Elongin C 
directly binds the substrate receptor VHL, which in turn recruits the substrate for 
ubiquitylation (Stebbins et al., 1999, Ivan and Kaelin, 2001).  
Ubiquitylation of a substrate is initiated by the slow transfer of a ubiquitin molecule to a 
lysine in the substrate, this is proposed to have a proofreading function (Petroski and 
Deshaies, 2005) (Figure 1.4A). The attachment of this first ubiquitin is then followed by 
rapid elongation of the ubiquitin chain (Saha and Deshaies, 2008). The poly-
ubiquitylated proteins are subsequently targeted for degradation by the 26S proteasome 
(Figure 1.4B). 
 
 
Figure 1.4: CRL complexes mediate proteasome-dependent degradation  
A) The general CRL complex is assembled by a RING finger protein (RING), a cullin, and a 
cullin-specific adaptor (Adaptor). The RING finger protein binds an ubiquitin-conjugated E2-
enzyme (E2) and facilitates the direct transfer of ubiquitin to the substrate. The adaptor binds 
interchangeable substrate receptors, which in turn recruit substrates for ubiquitylation. The 
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slow transfer of the first ubiquitin molecule initiates substrate ubiquitylation. B) After the 
initial ubiquitylation, rapid elongation of the ubiquitin chain and proteasome-dependent 
degradation of the substrate follows. 
 
1.2.2.1 Regulation of the CRL complexes 
The activation of the CRLs is achieved through the post-translational modification of a 
conserved C-terminal lysine residue in cullins with the ubiquitin-like modifier NEDD8 
(Pan et al., 2004, Osaka et al., 1998, Duda et al., 2008). Early modelling studies have 
shown an approximately 50Å gap between the catalytic cysteine of the RBX1-bound E2 
and the substrate conjugation site (Zheng et al., 2002b) (Figure 1.5A). The NEDD8 
conjugation induces a conformational flexibility of the RING domain (Duda et al., 
2008, Boh et al., 2011) (Figure 1.5B). This flexibility allows positioning of the RING-
domain and its bound activated-E2 enzyme in close proximity to the acceptor lysine of 
the substrate, thus stimulating the transfer of the ubiquitin molecule (Saha and Deshaies, 
2008, Duda et al., 2008).  
 
Figure 1.5: NEDD8 conjugation promotes the activation of cullin-RING ligases by inducing 
conformational flexibility of the RING domain 
A) The assembled but unmodified CRLs show an approximately 50Å gap between the 
catalytic cysteine of the RBX1-bound E2 and the substrate. 
B) Duda et al. (2008) showed that NEDD8 conjugation on the cullin induces the 
conformational flexibility of the RING domain. This allows the positioning of the RING-
domain and its bound activated-E2 enzyme in close proximity to the acceptor lysine of the 
substrate, thus stimulating the transfer of the ubiquitin molecule. 
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Cycles of neddylation and deneddylation play a crucial part in the dynamic regulation of 
CRLs (Wu et al., 2005, Bosu and Kipreos, 2008). Neddylation of the CRLs is 
performed by the cullin-directed Nedd8 E3 ligase, DCN1. The RING subunit of the 
CRL complex allows DCN1 to bring the E2-conjugating enzyme specific for NEDD8 
and the cullin in close proximity (Kurz et al., 2008, Kurz et al., 2005, Scott et al., 2010).   
Deneddylation of the CRLs is mediated by the COP9 signalosome (CSN), an eight-
subunit (CSN1–CSN8) complex with CSN5 acting as isopeptidase (Cope et al., 2002, 
Lyapina et al., 2001). CSN binds neddylated-CRLs for NEDD8-deconjugation, but is 
also shown to bind unneddylated-CRLs to keep them in a low activity conformation 
(Emberley et al., 2012). This suggests a model where CSN binds neddylated CRLs, 
removes the neddylation and keeps CRLs in an assembled but inactive state (Figure 
1.6). Furthermore, in vitro data show that the addition of ligand (cyclin E peptides) for 
the substrate receptor relieves CSN from the CRLs (Emberley et al., 2012). This is 
supported by structural studies showing CSN subunits (CSN1/CSN3) engaging the 
substrate receptor Skp2/Csk1 of the CUL1 SCFSkp2/Csk1 ligase (Enchev et al., 2012). The 
competition between substrate and CSN binding suggests a potential mechanism to 
control the assembly of CRLs, however this needs further proof in vivo. 
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Figure 1.6: The COP9 signalosome deneddylates cullin-E3 ligases and maintains them in a low 
activity state 
Upon substrate depletion, the COP9 signalosome (CSN) binds and deneddylates CRLs. The 
CSN stays associated with the assembled CRL complexes and maintains them in a low 
activity conformation. Structural and in vitro studies suggest that the increase of available 
substrate can trigger the release of the CSN from CRLs, which would allow their activation 
through NEDD8 conjugation. (SR: substrate receptor) 
 
 
Another CRL regulator is the protein CAND1 (cullin-associated-Nedd8-dissociated-1) 
that interacts with CRLs at the N-terminus, where it competes with the substrate adaptor 
for binding, and at the C-terminus, where it masks the neddylation site (Goldenberg et 
al., 2004). Thus, CAND1 interaction with the cullin is mutually exclusive with substrate 
adaptor binding and neddylation (Liu et al., 2002, Zheng et al., 2002a). Initially, 
CAND1 was described to sequester CRLs, thereby causing the inhibition of ligase 
assembly and activation (Goldenberg et al., 2004). However, it has become evident that 
CAND1 is actually required for CRL activity, by allowing substrate adaptor exchange 
and, consequently, the formation of other specific CRL complexes (Bosu and Kipreos, 
2008, Zemla et al., 2013, Pierce et al., 2013) (Figure 1.7).  
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Figure 1.7: CAND1 is required for the adaptor exchange on the CRLs 
This model is based on the proposed role of CAND1 as adaptor exchange factor. 
A) The COP9-signalosome deneddylates CRLs and dissociates from the complex to allow 
CAND1 binding. The binding of CAND1 leads to dissociation of the cullin-specific adaptor 
and allows the association of a pre-existing or newly synthesized adaptor. 
B) After the adaptor exchange, CAND1 is released, allowing CRLs activation through NEDD8 
conjugation and the subsequent degradation of the substrate. 
C) Upon substrate depletion, the COP9 signalosome (CSN) binds and deneddylates CRLs. 
 
 
1.2.3 UBXN7 links p97 to the ubiquitin ligase CUL2/VHL and its substrate hypoxia-
inducible factor 1alpha (HIF1α) 
The mass spectrometry analysis of the five UBA–UBX proteins revealed their 
interaction with a large variety of ubiquitin E3 ligases. Among human UBA–UBX 
proteins, UBXN7 is the most proficient in interacting with CRL subunits (Alexandru et 
al., 2008). 
The mass spectrometry analysis identified all CRL2 complex components in Flag-
UBXN7 immunoprecipitates: CUL2, RBX1, Elongin B/C and VHL. The Western blot 
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analysis of Flag-UBXN7 immunoprecipitates revealed that UBXN7 has a remarkable 
ability to bind CUL2. Furthermore, brief inhibition of the proteasome did not affect this 
binding, suggesting that substrate binding does not regulate the interaction between 
UBXN7 and CUL2. In contrast, the substrate receptor VHL was only detectable upon 
proteasome inhibition (Alexandru et al., 2008). 
Upon proteasome inhibition, Flag-UBXN7 also co-immunoprecipitates the most 
prominent CRL2 substrate HIF1α (Alexandru et al., 2008). HIF1α is part of a 
heterodimeric transcription factor (consisting of HIF1α and HIF1β) that is essential 
during hypoxia for triggering the expression of specific proteins required to counteract 
hypoxic stress (Wang et al., 1995, Jiang et al., 1996). Under normoxia conditions, 
HIF1α is hydroxylated, recognized by the CUL2/VHL ubiquitin ligase, and 
subsequently degraded by the proteasome. However, HIF1β appears to be constitutively 
stable (Ivan and Kaelin, 2001, Maxwell et al., 1999).  
By investigating further the interaction between UBXN7, p97 and the CRL2 complex, 
including its substrate HIF1α, Alexandru et al. could demonstrate the following main 
points: 
1) Treatment with p97 siRNA did not alter the interaction between UBXN7 and CUL2, 
indicating that this interaction does not depend on p97. 
2) Myc-p97 immunoprecipitation showed diminished CUL2- and HIF1α-binding to 
myc-p97 in UBXN7-silenced cells, suggesting that UBXN7 mediates p97 interaction 
with CUL2 and its substrate HIF1α (Figure 1.8). 
3) Silencing of p97 caused HIF1α accumulation, an effect that was more pronounced 
after proteasome inhibition, which introduces HIF1α as a novel p97 substrate. 
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4) Upon proteasome inhibition, UBXN7 and p97 interact mainly with ubiquitylated 
HIF1α, suggesting UBXN7 and p97 may participate in HIF1α degradation via the 
ubiquitin-proteasome system (UPS) (Figure 1.8). 
5) UBXN7 silencing causes a reduction in HIF1α levels, a paradoxical observation, 
considering that silencing of p97 leads to HIF1α accumulation. This result might 
indicate that UBXN7 involvement in HIF1α degradation is more complex than initially 
anticipated. 
Taken together, Alexandru et al. could establish that UBXN7 is the substrate-binding 
adaptor for HIF1α whose degradation requires p97, thereby expanding p97 function 
beyond ERAD (Figure 1.8).  
 
 
Figure 1.8: UBXN7 recruits p97 to the ubiquitin ligase CUL2/VHL and its substrate HIF1α  
This model summarizes some of the findings obtained by Alexandru et al, 2008: The 
interaction between UBXN7 and CUL2 does not depend on p97. p97 is recruited to the CRL2 
complex via UBXN7, which mediates interaction with CRL2 substrate HIF1α. Since UBXN7 
and p97 interact mainly with ubiquitylated HIF1α upon proteasome inhibition, this suggests 
they may participate in HIF1α degradation via the ubiquitin-proteasome system. 
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1.3 The p97 co-factor UBXN8 
1.3.1 UBXN8 interacts with p97 via its UBX domain 
UBXN8, also called UBXD6 and REP8, is conserved in vertebrates, but not present in 
lower eukaryotes. Full-length UBXN8 has a molecular weight of 30.5 kDa (Yamabe et 
al., 1997) and contains a transmembrane domain at the N-terminus, followed by a 
predicted coiled-coil region, and a UBX domain at the C-terminus (Figure 1.9). The 
transmembrane domain anchors UBXN8 at the ER membrane, while the UBX domain 
mediates its interaction with the N-terminus of p97 (Madsen et al., 2011). The function 
of the coiled-coil domain is currently unknown. As one of the UBX-only p97 co-
factors, UBXN8 lacks the UBA domain and cannot bind ubiquitin directly. The 
interaction between UBXN8 and other proteins must therefore be mediated in a 
different manner. 
Based on alternative splicing, two additional UBXN8 isoforms are predicted: Isoform 2 
that lacks a region between the coiled-coil region and the UBX domain, and isoform 3 
that lacks the transmembrane domain (Figure 1.9). 
 
 
Figure 1.9: Schematic representation of the three predicted UBXN8 isoforms Based	  on	  alternative	   splicing,	   three	   isoforms	  are	  predicted	   for	  UBXN8	  with	   isoform	  1	  representing	  full-­‐length	  UBXN8.	  TMD:	  Transmenbrane	  domain;	  UBX:	  	  Ubiquitin regulatory X	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1.3.2 UBXN8 is highly expressed in reproductive tissues 
As mentioned before, the expression of several UBX-only proteins is tissue dependent 
(Yamabe et al., 1997, Carim-Todd et al., 2001). This is also true for UBXN8, whose 
mRNA, as well as protein levels are highly increased in the reproductive tissues: testes 
and ovaries (Yamabe et al., 1997, Madsen et al., 2011).  
In testes, the UBXN8 mRNA expression was studied in more detail, and revealed that 
the high levels of UBXN8 expression are caused by its up-regulated expression in the 
post-meiotic, round spermatids (Madsen et al., 2011). Furthermore, in situ hybridisation 
experiments with developing germ cells in adult testes showed that the up-regulation of 
UBXN8 expression is specific during the late stages of round spermatid differentiation. 
The early stages of round spermatid differentiation, and the elongated spermatids, 
showed low to undetectable UBXN8 expression (Madsen et al., 2011).  
In ovaries, UBXN8 mRNA is abundant in somatic granulosa cells that surround the 
oocyte in the developing follicles (Madsen et al., 2011). The high UBXN8 expression 
within somatic cells in ovaries is in contrast to its high expression within germ cells in 
testis. This might indicate that there is no common UBXN8 expression cell lineage in 
male and female gonads (Madsen et al., 2011).  
 
1.3.3 UBXN8 is an ER membrane protein and is implicated in ERAD 
UBXN8 subcellular localisation, its membrane topology and its role in ERAD were 
studied in more detail in cancer cells (Madsen et al., 2011).  
In HeLa cells, UBXN8-GFP localises at the ER membrane with the C-terminal UBX 
domain facing into the cytoplasm. By binding p97 via its UBX domain, UBXN8 tethers 
p97 at the ER membrane. Accordingly, the amount of ER-associated p97 is reduced in 
UBXN8 siRNA treated cells (Madsen et al., 2011).  
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Furthermore, the data presented by Madsen et al. indicate that UBXN8 participates in 
ERAD. They show that the degradation of the ERAD substrates TCRα and CD3δ is 
slightly reduced in melanoma cells (MelJuSo) treated with UBXN8 siRNA. In contrast, 
the degradation of the cytoplasmic model substrate ubiquitin-G76V-YFP is not affected 
by UBXN8 silencing, suggesting that UBXN8 specifically targets ER-derived 
proteasome substrates (Madsen et al., 2011).  
 
1.3.4 UBXN8, a tumour suppressor gene candidate 
A recent publication from Li et al. (2014) identified host genes frequently targeted for 
hepatitis B virus (HBV) integration, and revealed that UBXN8 is one of the recurrent 
candidate genes (Li et al., 2014). The integration of HBV DNA into the genome of 
hepatocytes is one of the major causes of hepatocarcinogenesis (Shafritz et al., 1981), 
which is the third leading cause of global cancer death (Forner et al., 2012). The 
identification of host genes targeted by HBV integration could be therefore important to 
understand the process of carcinogenesis associated with HBV integration. 
In hepatocellular carcinoma (HCC) tissues, expression of UBXN8 was shown to be 
significantly down-regulated compared to non-tumorous tissue, particularly in the HCC 
tissue with the HBV integration within the intron of UBXN8 (Li et al., 2014). The 
function of UBXN8 in the process of carcinogenesis was evaluated by overexpressing 
UBXN8 in various HCC cell lines. In the HCC cell lines carrying the wild type TP53 
gene, ectopic expression of UBXN8 slowed proliferation and induced G1/S transition 
retardation. Furthermore, the UBXN8 overexpression was shown to cause increased p53 
and p21WAF1/CIP1 levels accompanied by decreased cyclin D1 levels (Li et al., 2014). 
TP53 encodes for the tumour suppressor protein p53, which is inactivated in many 
human cancers (Kern et al., 1991). p53 up-regulates the expression of other genes, such 
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as the G1 cyclin-dependent kinase inhibitor p21WAF1/CIP1 leading to cell cycle arrest 
(Gartel and Radhakrishnan, 2005, el-Deiry et al., 1994). Therefore, the data from Li et 
al. suggest that UBXN8 overexpression might negatively regulate cell cycle progression 
by inducing a delay in the G1/S transition via a p53/p21WAF1/CIP1 -dependent 
mechanism. Cyclin D1 drives the G1/S transition (Resnitzky and Reed, 1995) and its 
reduction would also promote the G1 arrest. Because the effects caused by UBXN8 
overexpression were not observed for HCC cell lines harbouring mutated TP53, the 
function of UBXN8 seems to be p53-dependent (Li et al., 2014).  
 
1.3.5 Fanconi Anaemia 
The analysis of Flag-UBXN8 immunoprecipitates by mass spectrometry identified the 
Fanconi anaemia (FA) key proteins, FANCD2 and FANCI, as UBXN8 interaction 
partners (unpublished results by Gabriela Alexandru). This interaction links UBXN8 to 
the rare genetic disease FA, which can be caused by mutations in any of the currently 
known 15 FA genes, resulting in defective DNA crosslink repair (Moldovan and 
D'Andrea, 2009, Kitao and Takata, 2011, Kim and D'Andrea, 2012). DNA interstrand 
crosslinks (ICL) are very toxic lesions that covalently link both strands of the DNA 
helix, thereby blocking replication (resulting in stalled replication forks) and 
transcription (Scharer, 2005, Noll et al., 2006). They can be caused by byproducts of 
metabolism (e.g. malondialdehyde produced during lipid peroxidation) (Niedernhofer et 
al., 2003), cellular metabolites (e.g. activated oestrogens) (Dai and Lui, 2000), or bi-
functional crosslinking agents (e.g. cisplatin, mitomycin C) (Noll et al., 2006, Scharer, 
2005). Because the FA pathway plays a major role in removing these crosslinks, FA 
proteins are required for maintaining genome stability and preventing cancer (Kee and 
D'Andrea, 2010). 
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FA is a rare autosomal or X-linked recessive disorder characterized by progressive bone 
marrow failure, multiple congenital abnormalities, and cancer predisposition (Kee and 
D'Andrea, 2012). Although FA is a rare disease, the FA pathway provides an attractive 
model for studying DNA repair, cancer progression, and the role of ubiquitin signalling 
(Moldovan and D'Andrea, 2009). 
Clinically, FA is very heterogeneous. Most FA patients develop anaemia as a 
consequence of bone marrow failure during childhood (Kim and D'Andrea, 2012). Later 
in life, individuals with FA are at high risk of developing cancer, especially acute 
myelogenous leukaemia (AML), squamous cell carcinoma (SCC) of the head and neck, 
and hepatocellular carcinoma (HCC) (Bakker et al., 2013). 
Genetically, FA is caused by mutations in any of the 15 currently known FA genes 
(FANCA, -B, -C, -D1 (BRCA2), D2, -E, -F, -G, -I, -J (BACH1), -L, -M, -N, -O 
(RAD51C), and -P (SLX4)) coding for proteins that function together in the FA pathway 
(Kim and D'Andrea, 2012, Kee and D'Andrea, 2012). Approximately 85% of FA 
patients are defective in one of the most common disease-causing genes FANCA, 
FANCC or FANCG (Auerbach, 2009). Mutations in FANCD2 and FANCI account for 
approximately 3% of the mutations found in FA patients (Auerbach, 2009). To date, 
some patients still remain unassigned, which indicates the possibility that there are FA 
genes still to be identified.  
The FA pathway is a DNA repair pathway, which is essential to resolve ICLs 
encountered during replication. Accordingly, FA patient-derived cells are 
hypersensitive to DNA interstrand crosslink-inducing agents, such as mitomycin C 
(MMC), cisplatin and diepoxybutane (DEB), resulting in a dramatic increase in 
chromosomal aberrations (including translocations and radial chromosomes). The 
hypersensitivity of FA cells to ICL-inducing agents and the consequential increase of 
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chromosomal aberrations provide a cellular marker to diagnose FA in the context of 
chromosomal breakage tests (Auerbach and Wolman, 1976).  
 
1.3.5.1 The Fanconi anaemia pathway and its key players 
The FA pathway consists of three types of member proteins: the FA core complex, the 
FA FANCD2/I (ID) complex and downstream members that facilitate the ICL repair.  
The FA core complex contains eight FA proteins (FANCA, -B, -C, -E, -F, -G, -L, -M) 
and forms a multi-subunit ubiquitin E3 ligase complex (Kim and D'Andrea, 2012). The 
DNA lesion is recognised by FANCM that forms a heterodimer with the FA-associated 
protein FAAP24 and binds DNA directly (Ciccia et al., 2007) (Figure 1.10). The stable 
association of FANCM with chromatin is further maintained through its binding to the 
histone fold-containing proteins, MHF1 and MHF2 (Singh et al., 2010, Yan et al., 
2010). The heterodimer FANCM/FAAP24 has multiple roles in pathway activation by 
recognising the DNA lesion and recruiting the FA core complex, stabilizing the stalled 
replication fork, and initiating the ATR-mediated checkpoint signalling (FA pathway 
independent) (Ciccia et al., 2007, Collis et al., 2008, Schwab et al., 2010). The 
association of FANCM with other FA core complex members is mediated by its 
interaction with FANCF (Deans and West, 2009) (Figure 1.10).  
The FA core complex subunit FANCL acts as E3 ubiquitin ligase and catalyses mono-
ubiquitylation of FANCD2 and FANCI together with UBE2T as an E2 enzyme (Cole et 
al., 2010, Machida et al., 2006, Hodson et al., 2014) (Figure 1.10). Mono-ubiquitylation 
of the two FA proteins by the FA core complex is considered to be the key regulatory 
step in the FA pathway. In human cells, FANCL/UBE2T conjugates a single ubiquitin 
moiety to Lys561 of human FANCD2 and Lys523 of human FANCI (Garcia-Higuera et 
al., 2001, Smogorzewska et al., 2007). The modifications on FANCD2 and FANCI and 
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their regulatory function will be discussed in more detail below. The E3 ligase FANCL 
is the only member of the FA core complex that is conserved in lower multicellular 
eukaryotes (together with FANCD2 and FANCI) and is able to mono-ubiquitylate its 
substrates in vitro in the absence of the other subunits of the complex (Alpi et al., 2008). 
Although the mono-ubiquitylation event in vitro requires only FANCL, it is clear from 
patient mutations that all members of the FA core complex are required in vivo. Certain 
multicellular animals such as flies and worms seem to lack the majority of FA core 
complex proteins (Marek and Bale, 2006, Patel and Joenje, 2007, Collis et al., 2006, 
Lee et al., 2013). Lower eukaryotes might therefore exhibit a simplified FA pathway, 
where the ubiquitin-activating enzyme E1, Ube2t, FANCL, and FANCI may be 
sufficient for FANCD2 mono-ubiquitylation.  
 
Figure 1.10: Schematic representation showing the activation of the FA pathway 
ICLs can occur naturally or by ICL-inducing agents such as MMC or cisplatin. During S-
phase, replication forks converge from different directions and stall on the DNA ICL that 
covalently links the two strands of DNA. 
1) The DNA lesion is recognised by FANCM that forms a heterodimer with the FA-
associated protein FAAP24. Additionally, FANCM binds the histone fold-containing 
proteins, MHF1 and MHF2 that stably associate FANCM with chromatin. 
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2) FANCM recruits the FA core complex to the DNA through its interaction with FANCF. 
FA core complex subunit FANCL acts as E3 ubiquitin ligase. 
3) FANCD2 and FANCI are recruited to the DNA lesion and are mono-ubiquitylated by 
FANCL together with UBE2T as an E2 enzyme. 
 
The FA pathway orchestrates the coordinated action of three critical DNA repair 
processes: nucleolytic incision, translesion DNA synthesis (TLS), and homologous 
recombination (HR); and facilitates the ICL repair in S-phase (Kim and D'Andrea, 
2012). 
After the modification of the ID complex, mono-ubiquitylated FANCD2 recruits the 
nucleases FAN1 (FA-associated nuclease 1) and FANCP (SLX4) to the ICL lesion in 
order to initiate nucleolytic incision (MacKay et al., 2010, Yamamoto et al., 2011) 
(Figure 1.11). Both nucleases harbour the UBZ4 (ubiquitin binding zinc finger 4) 
domain, which is an ubiquitin-binding domain specifically recognising the ubiquitin-
modification on FANCD2 (Yamamoto et al., 2011, MacKay et al., 2010).  
FANCP acts as a scaffold for multiple nucleases that are required for ICL repair and 
HR, and it recruits the heterodimeric nucleases MUS81-EME1 and XFP-ERCC1 
(Fekairi et al., 2009) (Figure 1.11, [1]). These structure-specific endonucleases promote 
incisions flanking the region of the ICL, which unhook the ICL (Hanada et al., 2006, 
Niedernhofer et al., 2004). Polymerases of the translesion DNA synthesis then bypass 
the lesion and extend the leading strand (Ho et al., 2011, Waters et al., 2009) (Figure 
1.11, [2]).  
Furthermore, the ICL unhooking creates a DSB in the other sister chromatid (Figure 
1.11, [3]). Homologous recombination resolves the DSB by using the homologous 
template restored by TLS. The repair of the DSB by homologous recombination 
involves the loading of RAD51 onto the DNA lesion, and the RAD51-mediated strand 
invasion of the sister chromatid strands (Krejci et al., 2012). The downstream FA 
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proteins FANCD1, -J, -N and –O are required for these processes. FANCD1 (BRCA2) 
interacts with RAD51 and promotes its loading to single-strand DNA (Jensen et al., 
2010, Subramanyam et al., 2013). FANCN (PALP2) binds FANCD1 and regulates its 
intranuclear localisation and stability (Xia et al., 2006). FANCJ works downstream of 
RAD51 and dissociates RAD51 from single-strand DNA in order to allow the 
completion of HR repair (Litman et al., 2005, Sommers et al., 2009, Wu et al., 2010). 
FANCO (RAD51C) is also required for RAD51 loading, and for resolving Holliday 
junction intermediates at a later step of HR (Liu et al., 2007, French et al., 2002).  
After finishing DNA repair, mono-ubiquitylated FANCD2 and FANCI are de-
ubiquitylated by the deubiquitylating enzyme USP1 (Nijman et al., 2005) (Figure 1.11, 
[4]). USP1 forms a heterodimeric complex with UAF1 that acts as an activator of USP1, 
by stimulating its activity towards the substrate (Cohn et al., 2007). Under normal 
conditions, the USP1/UAF1 complex keeps FANCD2 ubiquitylation in check. Upon 
DNA damage, the expression of USP1 is turned off, while the remaining USP1 protein 
is degraded by the proteasome (Huang et al., 2006). These two mechanisms of USP1 
repression allow the accumulation of mono-ubiquitylated FANCD2 and FANCI. 
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Figure 1.11: Schematic representation of replication-dependent ICL repair after FANCD2/I 
activation 
1. Mono-ubiquitylated FANCD2 recruits FANCP (SLX4) to the ICL lesion in order to 
initiate nucleolytic incision. FANCP recruits the heterodimeric nucleases MUS81-EME1 
and XFP–ERCC1. These structure-specific endonucleases promote incisions flanking the 
region of the ICL, which unhook the ICL. 
2. Polymerases of the translesion DNA synthesis then bypass the lesion and extend the 
leading strand. 
3. The ICL unhooking creates a double-strand break (DSB) in the other sister chromatid. 
Homologous recombination (HR) resolves the DSB by using the homologous template 
restored by TLS. RAD51 is loaded onto the DNA lesion (dark cycles) and mediates strand 
invasion of the sister chromatid strands. The downstream FA proteins FANCD1, -J, -N and 
-O are required for these processes. Nucleotide excision repair (NER) excises the remaining 
adducts. 
4. At the end of DNA repair, mono-ubiquitylated FANCD2 and FANCI are de-
ubiquitylated by the deubiquitylating enzyme USP1 that forms a heterodimeric complex 
with UAF1. 
 
1.3.5.2 Regulation of FANCD2 and FANCI through phosphorylation and 
ubiquitylation  
FANCD2 and FANCI form the ID complex that is associated with chromatin in 
response to DNA damage. Both FA proteins are mono-ubiquitylated and 
phosphorylated to regulate their activity (Ishiai et al., 2008, Zhi et al., 2009, 
Smogorzewska et al., 2007, Garcia-Higuera et al., 2001). 
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Stalled replication forks at the site of DNA damage lead to the activation of the S-phase 
checkpoint mediated by the protein kinase ATR (ATM and Rad3-related) (Cimprich 
and Cortez, 2008). ATR is recruited to RPA-coated single strand DNA that is exposed 
at the site of DNA damage during replication. ATR then phosphorylates numerous 
proteins involved in checkpoint function and DNA repair (Andreassen et al., 2004, Zou 
and Elledge, 2003).  
Several FA proteins are phosphorylated by ATR in response to DNA damage, including 
FANCD2 and FANCI, which leads to S-phase dependent activation of the FA pathway 
(Andreassen et al., 2004, Qiao et al., 2004, Wang et al., 2007, Ishiai et al., 2008).  
The phosphorylation of FANCD2 at the residues Ser331, Ser717 and Thr691 was 
shown to promote FANCD2 ubiquitylation and resistance to ICL-inducing agents (Ho 
et al., 2006, Zhi et al., 2009, Andreassen et al., 2004).  
The ATR-mediated phosphorylation of a S/TQ cluster in FANCI close to the 
ubiquitylation site is essential for FANCD2 mono-ubiquitylation and the localization of 
FANCD2 and FANCI to nuclear foci (Ishiai et al., 2008, Shigechi et al., 2012). 
Mimicking phosphorylation at six S/TQ sites in chicken FANCI is sufficient to induce 
FANCD2 mono-ubiquitylation and efficient repair, even in the absence of FANCD2 or 
core complex phosphorylation through ATM/ATR inhibition. (Ishiai et al., 2008). The 
phosphorylation of FANCI is therefore described as the molecular switch that turns on 
the FA pathway (Ishiai et al., 2008). 
 
The formation of foci and the mono-ubiquitylation of FANCD2 and FANCI are key 
regulatory steps for the activation of the FA pathway. In mammalian cells, mono-
ubiquitylation on FANCI is required for FANCD2 mono-ubiquitylation and foci 
formation. Reciprocally, FANCD2 mono-ubiquitylation is required for FANCI mono-
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ubiquitylation (Smogorzewska et al., 2007). The interdependent nature of FANCD2 and 
FANCI mono-ubiquitylation was also shown in vitro in ubiquitylation assays using the 
ID complex containing either FANCD2 K561R or FANCI K523R (Longerich et al., 
2014). In contrast, in chicken cells, the mono-ubiquitylation of FANCI is described to 
be dispensable for resistance to ICLs, indicating regulatory and functional differences 
between chicken and human FANCI (Ishiai et al., 2008).  
Although the mono-ubiquitylations of FANCD2 and FANCI within the ID complex are 
interdependent, they are described to serve different purposes. While FANCD2 mono-
ubiquitylation is essential for the recruitment of downstream repair proteins to the DNA 
damage site (MacKay et al., 2010, Yamamoto et al., 2011), FANCI mono-
ubiquitylation is described to promote the stability of the FANCD2/I heterodimer by 
interacting with the CUE (coupling of ubiquitin conjugation to endoplasmic reticulum 
degradation)-domain in FANCD2 (Rego et al., 2012). The mutations of the 
ubiquitylation sites in FANCD2 or FANCI result in defective ICL repair 
(Smogorzewska et al., 2007, Garcia-Higuera et al., 2001). 
 
The crystal structure of the mouse ID-complex revealed that both FANCD2 and FANCI 
fold into a saxophone-like structure, and they interact along a ∼560 residue-long region 
within this shape (Joo et al., 2011). The mono-ubiquitylation and phosphorylation sites 
of FANCD2 and FANCI are imbedded in the interface of the ID complex. Although 
conjugated ubiquitin to these lysine residues does not cause steric hindrance with the 
surrounding residues in the ID complex, the access for the ubiquitin-conjugating (E2) 
enzyme to the lysine residue is occluded. Therefore, the crystal structure of the ID 
complex suggests that the mono-ubiquitylation of FANCD2 and FANCI either happens 
on the monomeric proteins followed by their dimerization, or that the ID complex has to 
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undergo a conformational change to allow access to the ubiquitylation sites (Joo et al., 
2011). Since both FA protein, FANCD2 and FANCI, possess DNA binding activity, it 
has been suggested that binding of the ID complex to DNA might facilitate the required 
conformational change (Joo et al., 2011, Yuan et al., 2009, Longerich et al., 2009).  
This was confirmed in recent publications with human or chicken FANCD2 and FANCI 
proteins, showing that DNA ligands (double-strand DNA or single-strand DNA with 
secondary structures) indeed stimulate the mono-ubiquitylation of FANCD2 and 
FANCI in the context of the ID complex, in vitro (Longerich et al., 2014, Sato et al., 
2012b). The mono-ubiquitylation of FANCD2 induced by DNA is stronger than that of 
FANCI, which was only modestly modified. Furthermore, reduced DNA binding 
activity of FANCI leads to decreased mono-ubiquitylation of FANCD2, even in the 
presence of DNA, suggesting that DNA binding of FANCI is required for FANCD2 
mono-ubiquitylation (Longerich et al., 2014). The described ubiquitylation assays are 
performed with human UBE1, UBE2T and FANCL only. Therefore, it is likely that 
other components of the FA core complex and/or post-translational modifications on 
FANCD2 and/or FANCI are required for increased FANCI mono-ubiquitylation within 
the ID complex in cells. However, in the absence of FANCD2, mono-ubiquitylation of 
FANCI was greatly enhanced by various types of DNA (poor mono-ubiquitylation 
without DNA) (Longerich et al., 2014). This indicates that mono-ubiquitylation of 
monomeric FANCI is DNA stimulated as well, but that within the ID complex, FANCI 
mono-ubiquitylation is attenuated relative to free FANCI (Longerich et al., 2014). 
 
1.4 Aim of the thesis 
The diverse cellular functions of p97 are determined through its binding to a large 
number of different co-factors, that in turn recruit substrates to p97. The largest family 
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of p97 co-factors are the UBX-domain proteins that can be classified into two 
subgroups: UBA-UBX proteins and UBX-only proteins (Alexandru et al., 2008). The 
UBA-UBX proteins have ubiquitin-binding capabilities and facilitate p97 function as an 
ubiquitin-receptor, while UBX-only proteins appear to direct p97 to ubiquitin-
independent functions. The identification of specific cellular targets for the UBX-
domain proteins will help to define the subset of p97 functions they regulate and can 
help us to understand the role of p97 at the molecular level.  
In this thesis, I describe two projects, one focussing on the UBA-UBX protein UBXN7 
and the other on the UBX-only protein UBXN8.  
 
Among human UBA-UBX proteins, UBXN7 is the most proficient in interacting with 
CRL subunits, in particular CUL2, and it was assumed that these interactions were 
indirect, mediated by their ubiquitylated substrates (Alexandru et al., 2008). The aim of 
this project was to determine whether UBXN7 interaction with cullins is direct or 
mediated by its ubiquitylated targets bound to the UBA domain. 
 
My main project was initiated by results obtained in the MS analysis of Flag-UBXN8 
immunoprecipitates that identified the two key FA proteins FANCD2 and FANCI as 
potential UBXN8 interaction partners (unpublished results by Gabriela Alexandru). The 
identification of both FA proteins may link UBXN8 to the rare genetic disease FA, 
which is caused by defective ICL repair. The aim of this project was to investigate the 
interaction between UBXN8 and the FA proteins FANCD2 and FANCI, to shed light on 
the functional relevance of these interactions, as well as gain a better understanding of 
the role of UBXN8 in the DNA damage response. 
 
 
	  	  	  	  
34	  
 
Chapter 2 
2. Materials and Methods 
2.1 Materials 
2.1.1 Instruments 
The pipettes and pipetting aid were from Gilson. The Thermomixer/shakers and 
multipipette® steam were from Eppendorf. The pH meters and electrodes were from 
VWR. The incubators for incubating bacteria’s were from Binder. Tissue culture class 
II safety cabinets were from Medical Air Technology. CO2 incubators were from 
Mackay and Lynn. Centrifuge tubes, rotors and centrifuges were from Beckmann. The 
NanoDrop used to measure DNA concentrations was the Nano Vue Plus from GE 
Healthcare. The UV/Visible Spetrophotometer for measuring protein concentrations 
was the UltroSpec 2100 pro from Amersham Bioscience. The Electrophorese Power 
Supply used for DNA gel-electrophoresis was from Thermo. The Power Supplies used 
for running polyacrylamide gels were from Amersham Bioscience and BioRad. The X-
Cell SureLock Mini-cell electrophoresis systems were from Invitrogen. The Mini Trans-
Blot cell was from BioRad. Stained polyacryamid gels were dried with the DryEase 
Mini-Gel Drying system from Invitrogen. The SpeedVac, rotator with Clips (used to 
incubate IPs) as well as the microcentrifuges Heraeus Pico or Fresco 17 were from 
Thermo Scientific. The mini orbital shaker was from Bibby Scientific and Vortex-
Genie® 2 was purchased from Scientific Industries. The Konica automatic film 
processor was from Konica Corporation. The LiCOR odyssey infrared imaging system 
was from LiCOR biosciences (Cambridge, UK). The mass spectrometry samples were 
acquired on an LTQ Orbitrap Velos mass spectrometer (Thermo Scientific). The FACS 
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analyses were performed with FACSCalibur flow cytometer (BD Biosciences).  The 
microscopes used in immunofluorescence experiments were the DeltaVision Spectris 
and the DeltaVision OMX Blaze (GE Healthcare). 
 
2.1.2 Commercial chemicals 
Table 2.1 enlist the reagents used in this thesis and their supplier  
 
Table 2.1: Commercial chemicals	  
Product name Supplier 
4-(2-Amino-ethyl) benzenesulfonyl (AEBSF)  
4’,6-Diamidino-2-phenylindole dihydrochloride (DAPI) 
Adenosine 5′-triphosphate (ATP) 
Anti-FLAG-agarose  
Benzamidine  
Benzonase 
Bovine serum albumin (BSA) 
Bromophenol blue  
Cisplatin 
Dimethyl pimelimidate (DMP) 
Dimethyl sulphoxide (DMSO) 
Ethanolamine 
Ethidium bromide 
Ethylene glycol tetraacetic acid (EGTA) 
Ethylene diamine tetraacetic acid (EDTA) 
Hydroxyurea 
Iodoacetamide 
Kodak BioMax MR film 
Magnesium chloride (MgCl2) 
Mitomycin C (MMC) 
Nocodazole 
Phenylmethanesulphonylfluoride (PMSF) 
Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) 
Ponceau S 
Protein-A agarose 
Ribonuclease A 
Sodium chloride 
Sodium dodecyl sulphate (SDS) 
Sodium tetraborate  
Thymidine 
Sigma Aldrich 
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Triethylammonium bicarbonate 
Triton-X-100 
Tween-20 
Urea 
β-mercaptoethanol 
Sodium chloride (NaCl) 
Tris(hydroxymethyl)aminomethane (Tris-HCl) 
Glycerol 
Ethanol 
Sucrose 
Giemsa staining solution 
Sodium hydroxide (NaOH) 
Potassium hydroxide (KOH)  
Potassium chloride (NaCl) 
VWR 
Lipofectamin RNAiMax 
NuPAGE Tris-Acetate running buffer (20X) 
NuPAGE transfer buffer 
Propidium Iodid 
Agarose 
Precast 4-20% and 8% Novex Tris-Glycine gels 
3-8% NuPAGE Tris-Acetate gels 
Invitrogen 
Bio-Rad Protein Assay 
Horseradish peroxidase (HRP)-conjugated secondary antibodies 
Micro Bio-Spin Chromatography columns Precision	  Plus	  Protein	  all	  blue	  Standards BioRad 
5x siRNA buffer 
RNAse free water 
Dharmacon 
Endoproteinase Lys-c (Sequencing grade) 
Protease inhibitor cocktail tablets 
Trypsin (modified, sequencing grade) 
Roche 
Hyperfilm MP 
Protein A-agarose 
GE Healthcare 
Instant Blue staining solution Expedion 
Coomassie protein assay reagent (Bradford reagent) Pierce 
Protran BA nitrocellulose membrane (pore size - 0.45µm and 
0.20µm) 
Schleicher and 
Schuell 
HA-Ubiquitin Boston Biochem 
Plasmid MiniPrep Kit Qiagen 
The Maxi Pep kit Machery&Nagel 
3MM chromatography paper Whatman 
Dithiothreitol (DTT) 
N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) 
Formidium 
16% Formaldehyd Solution Thermo Scientific 
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Western Lightning® Plus-Enhanced chemiluminescence (ECL) Perkin Elmer 
DNA ladder (1 kbp) Biolabs 
TransIT-LT1 transfection reagent Mirus 
MG132 (Proteasome inhibitor) Enzo 
Hydromount (mounting media) 
Potassium acetate 
Fisher Scientific 
NP-40 Calbiochem 
 
 
2.1.3 Tissue culture reagents 
McCoy’s 5A medium, Minimum Essential Medium (MEM)-medium, Leibovitz’s 
medium (for Live cell imaging), OptiMEM reduced serum media, Fetal bovine serum 
(FBS), tissue culture grade Dulbecco’s phosphate buffered serum (PBS), 
Trypsin/EDTA solution, L-glutamine and sodium pyruvate were from GIBCO.  
Hygromycin, Penicillin/Streptomycin solution, Blasticidin and Zeocin were purchased 
from Invitrogen. Six-well plates, cell culture dishes and cryovials were from Corning 
Incorporated. Tetracycline was purchased from Bioline. As transfection reagents were 
used TransIT-LT1 fom Mirus and Lipofectamin RNAiMax from Invitrogen. 
	  
	  
2.1.4 In-house reagents 
Luria Bertani (LB) broth and LB agar plates supplemented with 200 µg/ml ampicillin as 
well as 10x Tris-buffered saline (TBS), 10x PBS and 50x Tris-acetate-EDTA (TAE) 
buffer were supplied by the University of Dundee media kitchen facility. The protein 
purification of recombinant human Flag-UBXN8, Xenopus lavis Flag-FANCI wild-
type, Xenopus lavis Flag-FANCI S556D S559D S565D S596D, human UBA1 and 
UBE2T were carried out by the Protein Production and Assay Development (PPAD) 
team.  
 
	  	  	  	  
38	  
2.1.5 Plasmids 
The plasmids used in this thesis are described in Table 2.2. Plasmids were constructed 
by Nicola Wood and Melanie Wightman (Cloning Team, DSTT, University of Dundee). 
The correctness of the construct sequences were verified by the DNA Sequencing 
Service (University of Dundee). 
 
Table 2.2: Plasmids 
DU 
Number Expressed Vector 
DU20791 FLAG-UBXN8 isoform 1 pCMV 
DU21722 FLAG-UBXN8 P238G pCMV 
DU20792 FLAG-UBXN8 isoform 2 pCMV 
DU20793 FLAG-UBXN8 isoform 3 pCMV 
DU22873 UBXN8-FLAG pCMV 
DU22749 HA-UBXN8 pCMV5D 
DU22822 mCherry-UBXN8 pCMV5D 
DU22439 FLAG-UBXN8 Iso1 Del aa 67-91 pCMV  
DU22393 FLAG-UBXN8 isoform1 pcDNA5 FRT/TO 
DU22394 FLAG-UBXN8 (P238G) isoform 1 pcDNA5 FRT/TO 
DU22416 FLAG-UBXN8 isoform 3 pcNDA5 FRT/TO 
DU24190 GST-TEV-Flag-UBXN8 aa92-270 (end) pGEX 
DU22438 GST-TEV-Flag-UBXN8 aa67-270 (end) pGEX 
DU20778 GST-UBXN8 isoform 1 67-270) pGEX 
DU20767 6His-UBXN8 67-270 pET 
DU33156 FLAG-FANCI pcDNA5-FRT/TO 
DU24038 FLAG-FANCI R1285Q pcDNA5-FRT/TO 
DU33181 FLAG-FANCI K523R pcDNA5-FRT/TO 
DU33165 GFP-FANCI pcDNA5-FRT/TO 
DU22475 FLAG-FANCI S556D/S559D/S565D/S596D pcDNA5-FRT/TO 
DU22465 FLAG-FANCI S556A/S559A/S565A/S596A pcDNA5-FRT/TO 
DU22489 FLAG-FANCI S556D/S559D/S565D/S596D/S617D/S629D pcDNA5-FRT/TO 
DU22471 FLAG-FANCI S556A/S559A/S565A/S596A/S617A/S629A pcDNA5 FRT/TO 
DU22668 FLAG-FANCI K523R S556D S559D S565D S596D pcDNA5 FRT/TO 
DU22654 FLAG-FANCI K523R S556A S559A S565A S596A pcDNA5 FRT/TO 
DU22790 FLAG-FANCI K898E K980E pcDNA5- FRT/TO 
DU22791 FLAG-FANCI S556D S559D S565D S596D K898E K980E pcDNA5- FRT/TO 
DU22615 GST-Tev-FANCI pGEX  
DU22631 GST-Tev-FANCI S556D S559D S565D S596D pGEX 
DU22632 GST-Tev-FANCI S556A S559A S565A S596A pGEX 
DU22648 GST TEV FANCI pGEX 
DU22652 GST FANCI S556D S559D S565D S596D pGEX 
DU22653 GST TEV FANCI S556A S559A S565A S596A pGEX 
DU33428 GST-FANCI pFB 
DU25063 FLAG-FANCI (Xenopus) pFastBac 
DU25094 FLAG-FANCI S557A S560A S566A S597A (Xenopus) pFB 
DU25095 FLAG-FANCI S557D S560D S566D S597D (Xenopus) pFB 
DU20249 FLAG UBXD7 pCMV5 
DU20281 FLAG UBXD7 (No ATG) pCMV5 
DU20293 FLAG UBXD7 P459G pCMV5 
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DU21457 FLAG UBXD7 S297A (No ATG) pCMV5 
DU21458 FLAG UBXD7 A293Q (No ATG) pCMV5 
DU21459 FLAG UBXD7 S297H (No ATG) pCMV5 
DU20294 FLAG UBXD7 del UBA Domain pCMV5 
DU20296 FLAG UBXD7 del UAS Domain pCMV5 
DU20297 FLAG UBXD7 del UIM Domain pCMV5 
DU20258 FLAG CUL2 pCMV5 
DU20288 FLAG CUL2 K689R pCMV5 
DU20291 FLAG CUL2 K719R pCMV5 
DU21544 FLAG-RAD23B pCMV5 
 
	  
2.1.6 Small interfering (si) RNA oligos 
All small interfering RNA oligos used in this thesis were purchased from Dharmacon. 
The sequences are listed in Table 2.3. 
 
Table 2.3: Small interfering RNA oligos 
 
Target protein siRNA name siRNA target sequence (5’-3’) 
UBXN8 UBXN8 ♯1 UUGACUGGAUGACGAGAAC 
UBXN8 UBXN8 ♯2 AACUGAUGUUUGCGAUUUA 
FANCI FANCI siGENOME SMARTpool 
FANCD2 FANCD2 siGENOME SMARTpool 
UBE2T UBE2T siGENOME SMARTpool 
FAN1 FAN1-1 GUAAGGCUCUUUCAACGUA 
Luciferase Luc CAUUCUAUCCUCUAGAGGAUG 
 
	  
2.1.7 Antibodies 
Table 2.4 lists the source and catalogue numbers of all antibodies used in this thesis. In-
house rabbit or sheep polyclonal antibodies were produced by the Division of Signal 
Transduction Therapy (DSTT, University of Dundee). Antisera were raised in sheep or 
rabbit by Diagnostics Scotland (Carluke - Lanarkshire, UK). All in-house antibodies 
were affinity purified on CH-Sepharose covalently coupled to the corresponding 
antigen.  
The two anti-UBXN8 polyclonal antibodies were raised in rabbits using bacterially-
expressed UBXN8 (amino acids 67-270). The anti-FANCD2 polyclonal antibodies were 
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raised in sheep using bacterially-expressed full-length FANCD2.  
 
Table 2.4: Antibodies 
Antibody Catalogue No. Source Species 
FK1 poly-Ubiquitin BML-PW8805 BIOMOL (ENZO) mouse 
FK2 mono-poly Ubiquitin BML-PW8810 BIOMOL (ENZO) mouse 
Flag M2 F3165 Sigma mouse 
p97 10R-P104A Fitzgerald mouse 
Tubulin T6199 Sigma mouse 
UFD1L 611642 BD mouse 
FANCD2 NB100-182 Novus rabbit 
FANCI A301-254A Bethyl rabbit 
FITC donkey anti-mouse IgG 751-095-151 Jackson Immuno Research  
Rhodamine Red donkey anti-rabbit 
IgG 
711-296-152 Jackson Immuno Research  
Alexa Fluor® 594 Chicken Anti-
Rabbit IgG (H+L) 
A21442 Invitrogen  
Alexa Fluor® 488 Chicken Anti-
Rabbit IgG (H+L) 
A21441 Invitrogen  
CUL2 51-1800 Invitrogen rabbit 
Nedd8 341400 Invitrogen rabbit 
UBXN7  courtesy of Millipore rabbit 
UBXN8 R2823 DSTT rabbit 
UBXN8 R2824 DSTT rabbit 
FANCD2 S099D (3. Bleed) DSTT sheep 
FAN1 S420C (4. Bleed) DSTT sheep 
Elongin C 610760 
BD Transduction 
Laboratories 
mouse 
VHL sc-5575 Santa Cruz Biotechnology rabbit 
RBX1 PIPA529149 Thermo rabbit 
HIF1α NB100-449 Novus rabbit 
 
2.1.8 Proteins 
The proteins used in this thesis as well as the sources are described in Table 2.5. 
 
Table 2.5: Proteins 
Protein Source 
Human Flag-UBXN8 (62 – 260aa) PPAD 
Murine FANCD2 provided by KJ Patel Laboratory 
Murine FANCI provided by KJ Patel Laboratory 
Xenopus lavis Flag-FANCI wild-type PPAD 
Xenopus lavis Flag-FANCI S557D S560D S566D S597D PPAD 
Xenopus lavis Flag-FANCD2 wild-type provided by Helen Warden laboratory 
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Xenopus Tropicalis FANCL provided by Helen Warden laboratory 
Human UBE2T PPAD 
Human UBE1 PPAD 
HA-Ubiquitin Boston Biochem 
 
PPAD: Protein Production and Assay Development in the ubiquitylation system 
 
2.1.9 Buffers and solutions 
The following buffers were used in this thesis: 
• IP lysisbuffer (milder to preserve protein-protein interactions): 50 mM 
HEPES/KOH pH 7.2, 5 mM Mg(OAc)2, 70 mM KOAc, 0.2% Triton X-100, 10% 
Glycerol, 0.2 mM EDTA (add fresh protease inhibitors and 750 Units (U)/ml 
benzonase) 
• Extracts lysisbuffer (stronger – mainly used for extracts): 50 mM HEPES (pH 
7.2), 400 mM NaCl, 1% NP-40, 0.2 mM EDTA, 10% Glycerol (add fresh protease 
inhibitors) 
• CSK buffer (pre-extraction for immunofluorescence microscopy): 100 mM 
NaCl, 300 mM Sucrose, 10 mM PIPES pH7, 3 mM MgCl2, 1 mM EGTA (add fresh 
0.5% Triton X-100 and protease inhibitors) 
• In vitro binding buffer: 50 mM HEPES/KOH, pH 7.5, 60 mM KOAc, 5 mM 
MgCl2, 5 % glycerol, 0.1 % Triton X-100 
• In vitro ubiquitylation buffer: 50 mM Tris pH 7, 100 mM KCl, 2 mM MgCl2, 2 
mM ATP and 0.5 mM DTT 
• 3x SDS Sample Buffer: 187.5 mM Tris-HCl (pH 6.8), 6% SDS, 30% Glycerol, 
Bromphenolblue 
• 10x SDS Running Buffer : 250 mM Tris-HCl, 1.92 M glycine, 0.1% (w/v) SDS 
• 25x Novex® Tris-Glycine Transfer Buffer: 300 mM Tris-Base (pH 8.3), 2.4 M 
glycine 
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• 6x DNA gel loading dye: 75% Glycerol, Bromphenolblue 
• Tris buffered saline (TBS): 50 mM Tris/HCl pH 7.6, 150 mM NaCl 
• Phosphate-buffered saline (PBS) (1x): 137 mM NaCl, 2.7 mM KCl, 4.3 mM 
Na2HPO4, 1.47 mM KH2PO4. Final pH was adjusted to pH 7.4 
• TBS-Tween Buffer: 1x TBS, 0.2% (v/v) Tween 
• Blocking Buffer: 5% milk or 1% BSA in 1x TBS, 0.1% (v/v) Tween 
• Staining Solution for FACS sample: 1% FBS/PBS with 50 µg/ml propidium 
iodide, 50 µg/ml ribonuclease A 
• Fixing Solution for Silver Staining: 30% ethanol, 10% acetic acid 
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2.2 Methods 
	  
2.2.1 Molecular Biology Methods 
	  
2.2.1.1 Transformation of Escherichia coli cells 
Competent Escherichia coli (E. coli) DH5α cells were obtained from the DSTT and 
stored at -80°C. For the transfection, 30 µl aliquots were thawed on ice and mixed with 
approximately 100 ng plasmid DNA. The cells were incubated on ice for 10 min. To 
facilitate the uptake of DNA, cells were heat-shocked at 42°C for 1 min and were 
placed back on ice for 1 min. Finally, the cells were diluted with 1 ml LB medium and 
50–100 µl streaked onto LB agar plates containing 200 µg/ml ampicillin. Plates were 
then incubated overnight at 37°C to allow colony growth. 
	  
2.2.1.2 Preparation of plasmid DNA from bacteria 
To prepare small amounts of plasmid DNA in microgram quantities (termed ‘mini-
prep’), E. coli DH5α cells were transformed with plasmid DNA, and a single colony 
was inoculated in LB/ ampicillin (5 ml). The transformed cells were grown in LB media 
containing appropriate antibiotics to stationary phase by incubation at 37°C overnight in 
a shaking incubator. The cells were harvested by centrifugation (4000 rpm, 15min) and 
the plasmid DNA purified using the Qiagen plasmid MiniPrep kit according to the 
manufacturer’s instructions. The DNA was eluted in elution buffer (EB) (60 µl) and the 
typical yield achieved was around 30 µg of plasmid DNA. 
To prepare larger quantities of plasmid DNA, transformed E. coli DH5α were cultured 
in 300 ml LB containing 200 µg/ml ampicillin at 37°C while shaking at 200 rpm 
overnight. Cells were pelleted by centrifugation at 4000 rpm for 15 min. Plasmid DNA 
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was purified using the NucleoBond Xtra Maxi Plus Kit (Machery-Nagel) according to 
the manufacturer’s instructions. Overnight cultures of 300 ml typically yielded 1.5–
2 mg of plasmid DNA. 
	  
2.2.1.3 Determination of DNA concentration 
The absorbance of DNA in EB buffer was measured via NanoDrop using the OD260/280 
of EB buffer as zero. The integrity of plasmid DNA was assessed by agarose gel 
electrophoresis. 
 
2.2.1.4 DNA agarose gels 
The size and the purity of plasmids were verified by agarose gels electrophoresis (1% 
agarose) containing ethidium bromide (0.2 µg/ml). The gels were placed in an agarose 
gel tank filled with 1x TAE running buffer. The plasmid DNA was mixed with DNA 
loading dye (1x) and loaded onto the agarose gel. The Quick load DNA ladder (1kbp) 
from BioLabs was used as a standard. Gels were run at 100 V for approximately 30 
min. DNA/ethidium bromide complexes were visualised using a UV transilluminator. 
 
2.2.1.5 DNA sequencing 
Sequencing of plasmid DNA was performed by The Sequencing Service, School of Life 
Sciences, University of Dundee, using DYEnamic ET terminator chemistry (Amersham 
Pharmacia Biotech) on Applied Biosystems automated DNA sequencers. 
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2.2.2 Mammalian Cell Culture 
	  
2.2.2.1 Cell culture 
All procedures were carried out under aseptic conditions meeting biological safety 
category 2. The media and buffers used for mammalian cell culture were pre-warmed to 
37ºC prior to use. Cells were cultured and maintained at 37ºC in a 5% CO2 water-
saturated incubator. For the routine maintenance of the different cell lines, cells were 
grown until 80-90% confluency, washed with sterile PBS, detached with Trypsin/EDTA 
(3 min at 37ºC) and transferred into fresh plates.  
HeLa cells were maintained in MEM containing 10% fetal bovine serum, 1% 
penicillin/streptomycin, 1% L-glutamine, and 1% sodium pyruvate. U2OS cells were 
maintained in McCoy’s 5A medium containing 10% fetal bovine serum, 1% 
penicillin/streptomycin, and 1% L-glutamine. 
 
2.2.2.2 Cell counting using a haemocytometer 
Cells were detached with Trypsin/EDTA as described before and pelleted by 
centrifugation at 1000 rpm for 4 min. The cell pellet was re-suspended in growth media. 
To differentiate between cells that are alive or dead, 50 µl of cell suspension was added 
to 50 µl of trypan-blue, and 10 µl of this mixture was placed on a haemocytometer. 
Cells within a 1 mm2 area, delimited by a double line (9 small squares) were counted. 
Four 1 mm2 areas were counted. Cells stained by trypan-blue represented dead cells and 
were not counted. The counted cell number was divided by the number of counted areas 
and multiplied by the dilution factor and 104, providing the total number of cells per ml. 
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2.2.2.3 Freezing / thawing cells 
Cells (approximately 70% confluent) were detached with Trypsin/EDTA and pelleted 
by centrifugation at 1000 rpm for 4 min. The supernatant was aspirated and the cells 
were resuspended in growth media supplemented with 10% DMSO. Aliquots of cell 
suspension (1 ml) were transferred into 1.5 ml cryogenic screw top vials (Corning) and 
stored at -80°C in an insulated box for 24h, before transfer to the liquid nitrogen cell 
freezer.  
Cells were thawed in a 37°C water bath, plated into fresh growth medium and allowed 
to adhere overnight prior to medium change. 
 
2.2.2.4 Plasmid transfection of mammalian cells 
Transient transfection of HeLa and U2OS cells was performed using TransIT-LT1 
according to the manufacturer’s instructions. Cells were grown to 50-60% confluency 
for transfection. For the transfection of cells growing in a 15 cm dish, 20 µl TransIT-
LT1 were diluted in 3 ml OptiMEM and incubated for 10 min. Then 10 µg plasmid was 
added, mixed and incubated for an additional 20 min at RT before the transfection mix 
was evenly distributed into the 15 cm dish containing 20 ml media without antibiotics. 
After 24h, cells were further treated with e.g. cisplatin or harvest post plasmid 
transfection. 
 
2.2.2.5 siRNA transfection of mammalian cells 
The siRNA oligonucleotides were purchased from Dharmacon and 5 nM siRNA/plate 
transfected into HeLa cells using Lipofectamine RNAiMax (Invitrogen) according to 
the manufacturer’s instructions. The cells were lysed 48 - 72 h after siRNA transfection. 
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2.2.2.6 Generation of stable cell lines 
To ensure low-level uniform expression of recombinant proteins, manufacturer's 
instructions (Invitrogen) were followed to generate stable cell lines that express FLAG-
tagged forms of proteins (cDNA subcloned into pcDNA5-FRT/TO plasmid) in a 
tetracycline inducible manner. Flp-In T-Rex U2OS host cells containing integrated FRT 
recombination site sequences and Tet repressor were co-transfected with 9 µg of pOG44 
plasmid (which constitutively expresses the Flp recombinase) and 1 µg of pcDNA5-
FRT/TO vector containing a hygromycin resistance gene for selection of the gene of 
interest with FLAG tag under the control of a tetracycline-regulated promoter. Cells 
were selected for hygromycin and blasticidin resistance two days after transfection by 
adding new medium containing hygromycin (100 µg/ml) and blasticidin (15 µg/ml). To 
have a cell population with homogneous expression, the cells were colony purified. For 
this purpose, the cells were seeded in a low density and grown for 8 days to allow 
colony formation. The colonies were then trypsinized and expanded. The homogenous 
expression of the integrated gene was validated by microscopy. Expression of the 
protein was induced with tetracycline for 12-24 hours. 
 
2.2.2.7 Cell treatment with genotoxins 
Cells were treated with a variety of genotoxins at a range of concentrations as indicated. 
Cisplatin and MG132 were dissolved in DMSO to make 33.3 mM and 20 µM stock 
solutions, respectively. MMC was dissolved in Milli-Q water to make a 0.5 mg/ml stock 
solution. All three drugs were stored at -80oC. Stock solutions of thymidine, 
hydroxyurea or nocodazole were made fresh in water.  
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Cells were treated with 1 µM MMC for 24h, 3 µM cisplatin for 24h, 1 mM 
Hydroxyurea for 24h, 10 µM MG132 for 2h, 2.5 mM thymidine for 24h, or 40 ng/ml 
nocodazole for 12h, unless indicated otherwise. 
  
2.2.2.8 Preparation of protein extracts from mammalian cells 
Cells were detached with Trypsin/EDTA, pelleted by centrifugation at 1000 rpm for 
4 min and washed twice with cold 1x PBS. The cell pellet was resuspend in lysis buffer 
containing protease inhibitors. The experiments performed for the UBXN8 project, 
750 U/ml benzonase was freshly added to the lysis buffer to allow the efficient 
extraction of DNA-bound proteins. The lysis was performed for 30 min on the rotator at 
4°C. The lysate was centrifuged at 13 000 rpm for 10 min to pellet the debris. The 
supernatant was either used for immunoprecipitations or 3x SDS sample buffer was 
added to denature the protein. In case of the UBXN7 experiments, the samples were 
incubated 20 min at 37°C prior loading on the polyacrylamide gel. For the UBXN8 
project, the samples were incubated 5–10 min at 70°C prior loading. 
 
2.2.3 Protein Biochemistry 
2.2.3.1 Recombinant protein expression and purification 
The Protein Production and Assay Development Team (PPAD) produced the various 
recombinant proteins in bacteria, as follows.  
Expression vectors for full length, UBA- or UIM-deleted UBXN7 were transformed 
into BL21 DE3 cells. Overnight cultures were grown in LB medium (1% tryptone, 0.5% 
yeast extract, 1% NaCl) supplemented with carbenicillin. Autoinduction medium was 
inoculated and the cells were left to grow at 37°C until the OD600 reached about 1.5. 
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The temperature was then dropped to 15°C and the cells were left for about 16 hours to 
express the protein. The cells were collected by centrifugation and resuspended in 
50 mM Tris-HCl pH 7.5, 250 mM NaCl, 0.4% Triton X-100, 0.1 mM EDTA, 0.1 mM 
EGTA, 1 mM DTT and protease inhibitors. The suspension was sonicated and the 
insoluble material was pelleted by centrifugation at 4°C, 28,000 g for 20 min. The 
supernatant was incubated with Glutathione (GSH)-sepharose for one hour. The 
sepharose was washed four times and UBXN7 was recovered upon cleavage with 
Tobacco etch virus (TEV) protease. The proteins were further purified by 
chromatography over a Superdex 75 column after which protein purity exceeded 90%.  
The dual expression vector encoding GST-CUL2/HIS6-RBX1 was used to generate 
recombinant baculoviruses using the Bac-to-Bac system (Invitrogen) following the 
manufacturer’s protocol. These baculoviruses were used to infect Spodoptera frugiperda 
21 cells (1.5 ×106/ml) at a multiplicity of infection of 5 and the infected cells were 
harvested 48 hours post-infection. GST-CUL2/RBX1 was purified on GSH-Sepharose 
and dialysed into 50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 150 mM NaCl, 270 mM 
sucrose, 0.03% Brij-35, 0.1% 2-mercaptoethanol, 1 mM benzamidine, 0.1 mM PMSF. 
 
BL21 cells were transformed with pGEX-TEV-FLAG-UBXN8 (67-270) DU22438. A 
clone was picked and grown overnight, in LB medium supplemented with 50µg/ml 
carbenicillin. Two litre cultures were set up and grown to OD600= 0.6. Expression was 
induced by supplementing the medium with 0.5 mM IPTG (Isopropyl β-D-
thiogalactopyranoside) and further grown for 16h at 15ºC. The cells were collected by 
sedimentation for 15 min at 4ºC in a Beckmann J6 centrifuge. The cells were 
resuspened in the buffer: 50 mM Tris/HCl pH 7.5, 250 mM NaCl, 0.5% Triton, 0.5 mM 
EDTA, 0.5 mM EGTA, 1 mM Pefabloc, 10 µg/ml Leupeptin, 1 mM DTT. The lysate 
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was sonicated and insoluble material was removed by centrifugation for 20 min at 
40000 x g. The supernatant was incubated with 2 ml GSH-Sepharose for 1h at 4ºC and 
then washed 5 times with 12 ml 50 mM Tris/HCl pH 7.5; 250mM NaCl; 0.5% Triton; 
1mM DTT. The GSH beads were incubated with 150 ug of TEV-protease for 2 hours at 
room temperature in 50 mM HEPES pH 7.5, 150 mM NaCl, 10 % glycerol, 1 mM DTT.  
The beads were washed 3 times with 1 ml of ubiquigent buffer + 0.03% Brij-35 to 
collect all cleaved material. This gave 5.5 ml at 2.4 mg/ml (13.2 mg). The protein was 
incubated for a further hour with 1 ml GSH beads to deplete the eluate of partially 
cleaved material and other contaminants. This gave 5.5 ml at 2.2 mg/ml (12.1 mg). The 
protein was left on ice over night. The following morning, it was slowly concentrated 
down to 2.1 ml using a 10 kDa MWCO filter. There was slight precipitation, but this 
was centrifuged into a small pellet and the sample was chromatographed on a SD75 
column, which had been pre-equilibrated with 50 mM HEPES, pH 7.5, 150 mM NaCl, 
10% glycerol, 0.03% Brij-35, 1 mM DTT. There were 2 peaks one with an apex at 
50.5 ml and a second with an apex at 65 ml, the latter of which is dimerised UBXN8. 
Each peak was pooled and vialed separately.  
 
Xenopus Flag-FANCI wild type and the phospho-mimicking mutant 4SD (S557D 
S560D S566D S597D) were expressed in insect express SF21 cells (Invitrogen) using 
the Sf900II virus (Invitrogen). Cells were collected by centrifugation at 3500 rpm for 15 
min. The sediment was resuspended in 25 ml of 50 mM HEPES, pH 7.4, 150 mM NaCl, 
0.1 mM EDTA, 0.1 mM EGTA, 0.2% Triton. After lysis, the cell suspension was 
diluted to 80 ml and spun at 40 000 x g for 20 min. Clarified lysate was incubated with 
500 µl of pre-equilibrated anti-FLAG-M2 affinity gel for 1.5 h at 4ºC. Resin was 
washed 3 times with 12 ml of 50 mM HEPES, pH 7.5, 500 mM NaCl, 0.03% Brij-35 
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and twice with 50 mM HEPES, 150 mM NaCl, 0.03% Brij-35. The pulldown was 
repeated with fresh resin, because the protein yield was somewhat low, due to restricted 
resin capacity. Bound protein was eluted using 3 x 500 µl of FLAG peptide (100 µg/ml) 
in 50 mM HEPES pH 7.5, 150 mM NaCl, 0.03% Brij-35. The first elution was 1.2 h 
and the other elution 30 min. All protein was recovered with three elutions and the 
subsequent elutions diluted the prep to 0.11 mg/ml. 
 
2.2.3.2 Determination of protein concentrations 
Protein concentrations were measured by the Bradford method (Bradford, 1976). A 
standard curve was prepared according to the manufacturer’s protocol, by adding 
increasing amounts of BSA (0.5, 1, 2, 3, 4, 6, 8 and 10 µg) to a final volume of 1 ml 
Bradford reagent. The mixture was allowed to stand at room temperature for 5 min. The 
optical density of the standards was measured at 595 nm (OD595) in 1.5 ml plastic 
cuvettes against a reference cuvette containing Bradford reagent only. This was used to 
construct a standard curve that was employed to determine protein concentrations of 
cell lysates. On average the linear range of protein Bradford measurements lies between 
OD595 0.1 and OD595 0.3. 
 
2.2.3.3 Size exclusion chromatography and multi angle light scattering 
Size exclusion chromatography and multi-angle light scattering (SEC–MALS) 
experiments were performed on a Dionex Ultimate 3000 HPLC system with an inline 
Wyatt miniDAWN TREOS MALS detector and Optilab T-rEX refractive index 
detector. 50uLs of 2 mg/mL of protein was injected into Superdex S75 CL 10/300 (GE 
Healthcare) column. Buffer conditions were 40mM Tris pH 7.5 and 150mM sodium 
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chloride. Molar masses spanning elution peaks were calculated with ASTRA v6.0.0.108 
(Wyatt). 
 
2.2.3.4 Covalent coupling of antibodies to Protein A Sepharose  
Protein A-Sepharose [500 µl] was incubated with 200 µg anti-UBXN7 antibody for 2 h 
at room temperature to allow the antibodies to bind protein A (non-covalently). After 
washing with 10 ml 1x PBS and 10 ml 0.2 M Na-borate pH 9, the beads were incubated 
with 5 ml of 20 mM DMP (in Na-borate pH 9) to crosslink the antibody to protein A. 
The reaction was stopped after 30 min by washing the beads twice with 10 ml of 0.2 M 
ethanolamine pH 8. The beads were then incubated 2h with 5 ml 0.2 M ethanolamine 
pH 8. After incubation, the beads were briefly washed with 100 mM glycine pH 2.8 to 
remove the antibody that is not covalently bound, followed by three washes with 10 ml 
50 mM Na-borate pH 9 to equilibrate the pH and two washes with 10 ml 1x PBS. The 
beads were resuspended in PBS with 0.02% sodium azide and stored at 4°C. The 
efficiency of the coupling was investigated by silver staining. 
 
2.2.3.5 Immunoprecipitation 
For immunoprecipitation experiments, the cells were lysed in IP lysis buffer containing 
50 mM HEPES/KOH (pH 7.5), 5 mM Mg(OAc)2, 70 mM KOAc, 0.2% Triton X-100, 
10% glycerol, 0.2 mM EDTA and protease inhibitors. To pull down Flag-tagged 
proteins, 60 µl anti-Flag M2 agarose (Sigma) 50% slurry was added to 2–3 mg total cell 
lysate and incubated for 2 h at 4°C. To pull down endogenous UBXN7, 60 µl anti-
UBXN7 beads were added to the lysis buffer and incubated for 2h at 4°C. To pull down 
endogenous FANCD2, 1 µg anti-FANCD2 antibody (S099D, 3. Bleed) was added to 1 
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mg lysate and incubated for 90 min at the rotator at 4°C. 70 µl Protein-A Sepharose 
beads (50% slurry) were added to the antibody-lysate mix and were incubated for 
additional 1h at 4°C.  
After incubating the beads with the lysate, the beads were washed three times with lysis 
buffer. The beads were then transferred to a Spin Chromatography column (BioRad). 
The column was closed and the beads incubated with 60 µl 3x SDS-Sample buffer for 
10 min at room temperature. The column was opened after incubation and the eluates 
collected by centrifugation. 4 µl β-mercaptoethanol was added to the samples, which 
were then heated at 70°C for 10 min before loaded on the gel. 
 
2.2.3.6 Separation of proteins by sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) 
Protein samples were denatured in SDS sample buffer (1x) and β-mercaptoethanol (2% 
(v/v)). Samples were boiled at 70°C for 5-10 min before loading onto polyacrylamide 
gels.  
For FANCD2-detection, the samples were separated in NuPAGE 3-8% Tris-Acetate 
pre-cast gels in 1x Tris-Acetate running buffer. To allow the separation of the modified 
and unmodified form of FANCD2, the gels were run for 30 min at 80V followed by 2h 
at 160V. For FANCI detection, the samples were separated in Novex 4-20% Tris-
Glycine pre-cast gels in 1x Novex Tris-Glycine runing Buffer. To allow the separation 
of the modified and unmodified form of FANCI, the gels were run at constant 24 mA 
current for 2h 15min.  The detection of the other proteins was performed using Novex 
4-20% or 8% Tris-Glycine gels, which were run at 24 mA for 1h 30min.  
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2.2.3.7 Staining of protein gels 
Coomassie 
To visualize proteins after SDS-PAGE, gels were stained in Coomassie stain for 60 min 
at room temperature with continual agitation on a rocking platform.  
 
Silver staining 
 
Silver staining was performed using Pierce Silver Stain Kit following the manufacture’s 
protocol. The gel was stored in ultrapure water or dried using the DryEase Mini-Gel 
Drying system (Invitrogen). 
 
2.2.3.8 Transfer of proteins to nitrocellulose membrane 
Protein gels were assembled into a gel-membrane sandwich as described in the 
manufacturer’s protocol. Nitrocellulose membrane was placed on a gel, this assembly 
was placed between two pieces of filter paper (3MM), and this structure placed between 
two sponges. All components were pre-soaked in transfer buffer. This assembly was 
placed into a BioRad cell-tank filled with transfer buffer, and proteins were transferred 
to nitrocellulose at 150 mA for 2h. 
 
2.2.3.9 Immunoblotting 
The nitrocellulose membranes were blocked in TBS-T containing skimmed milk (5% 
(w/v)) for 45 min at room temperature. Primary antibodies were diluted in TBS-T 
containing 5% (w/v) skimmed milk, and incubated with the membrane for 1h or o/n. 
After the incubation with the primary antibodies, membranes were washed, and 
incubated with secondary antibodies conjugated to HRP for 45 min at room 
temperature. All secondary antibodies were used at 1:3000 dilutions in TBS-T 
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containing 5% (w/v) skimmed milk. After washing three times for 10 min with TBS-T, 
membranes were developed with ECL reagent. The membrane was covered with a clean 
piece of polythene roll and placed into a film cassette. The membrane was then exposed 
to Kodak BioRad films (strong signals) or Amersham HyperfilmTM ECL films (weak 
signals) and developed in an automatic processor. 
 
2.2.4 In vitro Assays 
2.2.4.1 In vitro binding assays 
The in vitro binding assays were performed with recombinant Flag-UBXN8 (62-270aa) 
and murine FANCD2 and FANCI (provided by Michael Hodskinson/KJ Patel 
Laboratory). The binding assay was performed in 400 µl in vitro binding buffer. For the 
assays, fixed amounts of Flag-UBXN8 were incubated with increasing molar ratios of 
monomeric FANCD2 or FANCI. 0.1 µM Flag-UBXN8 was incubated with 0.01 µM, 
0.025 µM, 0.05 µM and 0.1 µM monomeric murine FANCD2 or FANCI. 20 µl sample 
were taken as input, diluted with 20 µl buffer and 20 µl 3x SDS sample buffer. 20 µl 
anti-Flag beads (50% slurry) were added 30 min after adding Flag-UBXN8 and the 
protein-beads mix was incubated for an additional one hour. 20 µl sample were taken to 
determine efficiency of the immunoprecipitation and were processed as the input 
sample described before. The beads were washed 3x with 1 ml in vitro binding buffer 
and Flag-UBXN8 eluted from the beads using 60 µl 3x SDS Sample buffer. All samples 
were heated at 70°C before loading on the gel. 
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2.2.4.2 In vitro ubiquitylation assays 
The ubiquitylation assay was performed to study the mono-ubiquitylation of FANCD2 
and FANCI in the presence of Flag-UBXN8.  
The 25 µl reactions were performed in reaction buffer 50 mM Tris pH 7, 100 mM KCl, 
2 mM MgCl2, 2 mM ATP and 0.5 mM DTT. The following proteins were included in 
the assay: 13 nM UBE1, 640 nM human UBE2T, 5.6 µM HA-ubiquitin (Boston 
Biochem), 1.5 µM Xenopus Tropicalis FANCL, 0.2 µM Xenopus lavis Flag-FANCD2 
and/or 0.2 µM Xenopus lavis Flag-FANCI. When indicated 0.5, 2 or 4 µM human Flag-
UBXN8 was added to the reaction. The reactions were incubated at 25°C for 90 min 
and then stopped by adding 12.5 µl 3x SDS Sample buffer containing β-
mercaptoethanol. 5 µl of each sample were analysed by Western Blot. The 
immunoblotting was performed using anti-HA and anti-Flag antibodies. 
 
2.2.5 Mass Spectrometry 
2.2.5.1 Sample preparation 
 
For the Mass Spectrometry (MS) analysis, the immunorecipitations were performed as 
described in section 2.2.3.4 with small changes. After washing the beads three times 
with lysis buffer, the beads were washed an additional two times with 100 mM Tris-
HCl, pH 8.5. Bound-proteins were eluted by incubating the beads with 8 M Urea 
(saturated) in 100 mM Tris-HCl, pH 8.5 for 15 min at 37°C.  
 
Trypsin-digestion in solution 
The eluted proteins (40 µl) were reduced by incubating with 3 mM TCEP for 20 min 
and then alkylated with 11 mM iodoacetamide for 15 min. Both incubations were 
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performed at room temperature and in the dark. The samples were pre-digested with 0.1 
µg Lys-C for 4 h at 37°C. The Samples were then diluted to the final concentration of 
2 M urea by adding 100 mM Tris-HCl, pH 8.5. To enhance trypsin activity 100 mM 
CaCl2 was added to a final concentration of 1 mM CaCl2 and then 0.5 µg/µl trypsin 
added. Trypsin-digestion was performed at 37°C for 16h. The digested peptides were 
acidified to pH < 3 using 1% trifluoroacetic acid (TFA) and then purified using C18 
Silicia microspin columns. The peptides were eluted in 0.1% TFA, 50% acetonitrile 
(ACN), dried in Speed-Vac and stored at -80°C till required. 
 
In-gel trypsin digestion 
The protein bands were excised from the silver stained gel using a sterile scalpel. The 
protein bands were destained using the ‘Silver Stain Kit’ from Pierce following the 
manufacture’s protocol. Once colourless, the gel pieces were shrunk with 0.3 ml ACN 
for 15 min, the ACN was then removed and were dried using a Speed-Vac. Gel pieces 
were then swollen in 30 µl 25 mM Triethylammonium bicarbonate containing 5 µg/ml 
trypsin and incubated over-night at 30oC on a shaker. After 14h an equivalent volume of 
ACN was added to the digest and incubated for a further 15 min. The supernatants were 
transferred to a clean tube, frozen using dry ice and concentrated to dryness by Speed 
Vac. Meanwhile 100 µl 50% ACN/2.5% formic acid was added to the gel pieces. This 
second extraction was combined with the dried first extract. The samples were stored at 
-20oC. 
2.2.5.2 Mass Spectrometry analysis 
Patrick Pedrioli’s group performed the MS analysis for the samples that were trypsin-
digested in solution. The dried pellets were resuspended in 20 µl 0.1% (v/v) TFA and 
separated on a Dionex UltiMate 3000 LC system (Thermo Scientific) using a 25 cm 
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column packed with 3 mm Magic C18 material (Michrom Bioresource). Mass spectra 
were acquired on an LTQ Orbitrap Velos mass spectrometer (Thermo Scentific) 
operating in data-dependent mode. After conversion to mzXML the raw data were 
searched using Comet against version 3.87 of the IPI human protein database using 
static carboxamidomethylation of cysteine residues, variable oxidation of methionine 
residues and accounting for up to 2 missed tryptic cleavages. 
Matthias Trost’s group performed the MS analysis for the samples that were in-gel 
trypsin digested. The MS analysis was performed by LC-MS-MS using a linear ion 
trap-orbitrap hybrid mass spectrometer (Orbitrap-Classic, Thermo) equipped with a 
nanoelectrospray ion source (Thermo) and coupled to a Proxeon EASY-nLC 
system.  Peptides were injected onto a Thermo (Part No. 160321) Acclaim PepMap100 
reverse phase C18 3 µm column, 75 µm x 15 cm, with a flow of 300 nl/min and eluted 
with a 30 min linear gradient of 95% solvent A (2% ACN, 0.1% formic acid in H2O) to 
40% solvent B (90% acetonitrile, 0.08% formic acid in H2O), followed by a rise to 
80%B at 32min. The instrument was operated with the “lock mass” option to improve 
the mass accuracy of precursor ions and data were acquired in the data-dependent mode, 
automatically switching between MS and MS-MS acquisition.  Full scan spectra (m/z 
340-1800) were acquired in the orbitrap with resolution R = 60,000 at m/z 400 (after 
accumulation to an FTMS Full AGC Target; 1,000,000; MSn AGC Target; 100,000). 
The 5 most intense ions, above a specified minimum signal threshold (5,000), based 
upon a low resolution (R = 15,000) preview of the survey scan, were fragmented by 
collision induced dissociation and recorded in the linear ion trap (Full AGC Target; 
30,000. MSn AGC Target; 5,000). 
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2.2.6 Other methods 
 
2.2.6.1 Measurement of genotoxin hypersensitivity of mammalian cells by clonogenic 
survival assay  
U2OS cells grown in 10 cm dishes were transfected with the indicated siRNA duplexes 
according to the protocol described in 2.2.2.1. After 48 h cells were counted using a 
haemocytometer and seeded into new 10 cm2 dishes at approximately 2000 - 4000 cells 
per dish. Cells were allowed to adhere to the dish for a minimum of 8h before they were 
treated with the DNA damage-inducing agent cisplatin or MMC. Cells were incubated 
with the drugs for 24h before the media was exchanged with fresh drug free media. The 
cells were then incubated for 10 days to allow colony formation of surviving cells. To 
count the colonies, the media was removed and the cells were dried overnight. The 
following day, the cells were fixed and stained with 2% Giemsa (in methanol) and 
washed with tap water. Colonies of more than 50 cells were counted. 
 
2.2.6.2 Cell cycle analysis by flow cytometry 
Cells were harvested using standard trypsinisation, washed once in PBS and 
resuspended in ice-cold 70% (v/v) ethanol while vortexing. Samples were then stored at 
-20°C until required. To prepare samples further for the cell cycle analysis by flow 
cytometry, samples were brought to room temperature and washed twice in PBS with 
1% (w/v) FBS. After washing, the cells were resuspended in 300–500 µl PBS 
containing 1% (w/v) FBS, 50 µg/ml propidium iodide, and 50 µg/ml ribonuclease A. 
Samples were then incubated at room temperature for 20 min in the dark. The DNA 
content of cells was quantified on the basis of propidium iodide fluorescence using a 
FACSCalibur flow cytometer (BD Biosciences) and CellQuest software for data 
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acquisition. Red fluorescence (585±42 nm) was acquired on a linear scale, and pulse 
width analysis was used to exclude doublets. Cell cycle distribution was determined by 
applying the Watson (pragmatic) model for cell cycle distribution using FlowJo 
software (Tree Star Inc.).  
 
2.2.6.3 Immunoflourescence microscopy 
Cells were grown on sterile coverslips in 6-well plates. For FANCD2 immunostaining, 
the cells were fixed with 2% Paraformaldehyde for 10 min and permeabilized with 
0.2% Triton X-100 for 10 min. For Flag-UBXN8 and Flag-UBXN7 immunostaining, 
the cells were fixed with ice-cold methanol at -20°C for at least 8 min. After 
fixation/permeablisation, cells were blocked in 3% BSA/PBS for 30 min at room 
temperature and subsequently incubated with primary antibodies: 1:300 mouse M2 anti-
Flag primary antibody, 1:5000 anti-Lamin B1, or 1:1000 anti-FANCD2 (in 3% 
BSA/PBS) for 1hr at room temperature. After washing with 1x PBS, cells were 
incubated with the secondary antibody for 45 min at room temperature. In case of co-
immunostaining, the cells were incubated with the first primary and secondary followed 
by the second primary and secondary. The cell nuclei were stained with DAPI. The 
coverslips were mounted onto glass slide using Hydromount mounting media. 
Images were obtained with a DeltaVision Spectris microscope (Applied Precision), 
using a CoolSNAP HQ camera (Roper) and a 60x 1.4 numerical aperture (NA) 
objective (Olympus). SoftWoRx software (Applied Precision) was used for acquisition 
and deconvolution. 
 
3D-SIM images were acquired on a DeltaVision OMX Blaze (GE Healthcare) fitted 
with an Olympus PlanApo N 60x 1.42 NA oil objective. Laser light from solid state 
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lasers (405, 488 and 564nm), shuttered by high-speed tilt mirrors and coupled into a 
broadband single mode optical fibre was split into three beams. 3D interference pattern 
in the sample plane are generated by focusing of the beams onto the back focal plane of 
the objective lens. Striped illumination patters are shifted by five phase steps and 
rotated by 3 angles (-60˚, 0˚ and +60˚), providing a set of 15 images per unprocessed z-
section. 
Interference patterns were phase shifted by directing the outer two beams through a 
separate pair of windows with individual tilt control. Phase of the interference pattern at 
the sample plane was shifted due to the change in the path length for the respective 
outer beam, while lateral refractive beam translation was canceled by tilting a given 
window pair in complementary directions. Angles of pattern orientation were shifted by 
a tilt mirror, directing the three beams pattern to one of three mirror clusters; the beam 
pattern from each of the three rotation paths was redirected back to a common exit path 
by reflecting a second time from the tilt mirror. 
Exposure times were typically between 100 and 200 ms, and the power of each laser 
was adjusted to achieve optimal intensities of between 1,000 and 3,000 counts in a raw 
image of 15-bit dynamic range of Edge sCMOS camera (PCO AG, Germany). The 
lowest possible laser power was chosen for each channel to minimize photo 
bleaching. Unprocessed image stacks were composed of 15 images per z-section (five 
phase-shifted images per each of three interference pattern angles). The microscope was 
routinely calibrated by measuring of channel specific optical transfer functions (OTFs) 
to optimise lateral and axial image resolution (channel dependent and typically ~120 
and ~300nm, resp.). Super-resolution three-dimensional image stacks were 
reconstructed with SoftWoRx 6.0 (GE) using channel specific OTFs and Wiener filter 
setting of 0.002 (0.005 for the DAPI channel) to generate a super-resolution three-
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dimensional image stack. Images from the different colour channels, recorded on 
separate cameras, were registered with SoftWorx 6.0 alignment tool (GE), based on 
alignment parameters obtained from calibration measurements with 100nm-diameter 
TetraSpeck beads (Life Technologies). 	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Chapter 3 
3.   UBXN7 docks on neddylated cullin complexes using its UIM and 
causes HIF1α  accumulation (Bandau et al., 2012) 
 
3.1 Introduction 
The proteins from the UBA–UBX family interact with ubiquitylated proteins via their 
UBA domain and with p97 via their UBX domain, thereby acting as substrate-binding 
adaptor for the p97 ATPase (Alexandru et al., 2008). 
Alexandru et al. (2008) established that the UBA-UBX protein UBXN7 mediates the 
interaction between p97 and the transcription factor HIF1α that is continuously 
expressed and is actively targeted for ubiquitin-mediated degradation through the CRL2 
complex during normoxia. Furthermore, the MS analysis of UBA-UBX protein 
immunoprecipitates showed that they interact with a multitude of E3 ubiquitin ligases. 
Among human UBA-UBX proteins, UBXN7 is the most proficient in interacting with 
CRL subunits, in particular CUL2. It was shown that the interaction between UBXN7 
and CUL2 does not depend on p97. Therefore, the aim of this project was to determine 
whether UBXN7 interaction with cullins is direct or mediated by its ubiquitylated 
targets bound to the UBA domain. 
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3.2. Results 
 
3.2.1 Endogenous UBXN7 stably interacts with the core subunits of the CRL2 
complex 
As described in the introduction, all core CRL2 subunits (CUL2, elongin B/C, RBX1 
and VHL)  have been identified in Flag-UBXN7 immunoprecipitates by mass 
spectrometry (Alexandru et al., 2008). The Flag-UBXN7 interactions with CUL2, VHL 
and the CRL2 substrate HIF1α were analysed further by Western blotting. The UBXN7 
binding to CUL2 was unaffected by inhibition of the proteasome suggesting a substrate 
independent regulation. In contrast, the UBXN7 interaction with VHL and HIF1α was 
only be observed upon brief proteasome inhibition. The interaction between UBXN7 
and the remaining CRL2 complex component was not analysed further (Alexandru et 
al., 2008).  
To confirm the interactions between the endogenous UBXN7 and all CRL2 subunits 
including its substrate HIF1α, endogenous UBXN7 was immunoprecipitated from HeLa 
cells using UBXN7-specific antibodies. The cells were grown in the presence or 
absence of proteasome inhibition (10 µM MG132, 2h), to allow the detection of VHL 
and the CRL2 substrate HIF1α (constitutively degraded under normoxia conditions).  
Endogenous UBXN7 effectively co-immunoprecipitated CUL2, elongin C and RBX1, 
which constitute the core CRL2 complex (Figure 3.1). Consistent with the results 
obtained upon UBXN7 overexpression, endogenous UBXN7 interacts with VHL and 
polyubiquitylated-HIF1α only upon brief inhibition of the proteasome. Thus, the results 
suggest that the UBXN7 interactions with CUL2, elongin C and RBX1, which 
constitute the core CRL2 complex, are more stable compared to the UBXN7 interaction 
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with VHL and HIF1α, which seem to be more transient and can only be captured after 
proteasome inhibition. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: UBXN7 stably interacts with the core subunits of the CRL2 complex 
Endogenous UBXN7 was immunoprecipitated from HeLa cells untreated or treated with 
10 µM MG132 for 2h. Endogenous UBXN7 co-immunoprecipitated CUL2, elongin C and 
RBX1 from cells grown in the presence and absence of MG132, whereas VHL and HIF1α 
are only detected upon inhibition of the proteasome. 
 
3.2.2 Active ubiquitylation is not necessary for UBXN7 interaction with CUL2 
To test the assumption that the UBXN7 interaction with CUL2 is mediated by 
ubiquitylated substrates, Flag-UBXN7 was immunoprecipitated from A31N–ts20 cells 
(performed by Gabriela Alexandru). These mouse embryo fibroblasts are 
thermosensitive for ubiquitin-E1, leading to the inhibition of the initial step in the 
protein-ubiquitylation cascade when grown at the non-permissive temperature (Salvat et 
al., 2000).  
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Growth of the cells at 39°C led to a dramatic reduction of ubiquitylated protein levels 
(including HIF1α) compared to control cells grown at 35°C (Figure 3.2, right panel). 
Although ubiquitin binding to Flag-UBXN7 was drastically reduced, its binding to 
CUL2 was not affected (Figure 3.2, left panel), demonstrating that UBXN7 interaction 
with CUL2 is not mediated by ubiquitylated CRL2 substrates. 
 
Figure 3.2: CUL2 interaction is independent of ubiquitin-binding 
Flag-UBXN7 was immunoprecipitated from A31N–ts20 cells (mouse embryo 
fibroblasts) that are thermosensitive for the ubiquitin-E1. The cells were grown at the 
indicated temperatures for 20h and Flag-UBXN7 was immunoprecipitated using anti-
Flag beads. Upon growth at 39°C, the protein ubiquitylation was drastically reduced 
compared to control cells (right panel). Although the ubiquitin binding to Flag-UBXN7 
is clearly reduced, it did not affect binding to CUL2 (left panel). 
 
 
3.2.3 Cullin-neddylation is required for the interaction with UBXN7 
Interestingly, the Western blot analysis of protein extracts obtained from HeLa cells 
overexpressing Flag-UBXN7 revealed a clear up-shift of CUL2 to a slower migrating 
form (Figure 3.3, compare lanes 1 and 3). The inhibition of neddylation using the 
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chemical inhibitor of the NEDD8-E1 (Brownell et al., 2010) further confirmed that the 
slower migrating form is neddylated CUL2 (data not shown). 
Furthermore, the comparison of protein extracts before and after Flag-UBXN7 
immunoprecipitation showed that mainly neddylated CUL2 was depleted from the 
extracts (Figure 3.3, compare lane 3 and 4), indicating that Flag-UBXN7 preferentially 
interacts with the neddylated form of CUL2 (Experiments performed by Gabriela 
Alexandru). 
 
                Figure 3.3: Flag-UBXN7 preferentially 
interacts with neddylated-CUL2 
Protein extracts retained from HeLa cells 
overexpressing Flag-UBXN7 were compared 
before (In) and after (Sup) Flag-UBXN7 
immunoprecipitation. 
 
 
 
 
To investigate if CUL2 neddylation is required for the interaction between UBXN7 and 
CUL2, two neddylation-defective CUL2 mutants, K689R and K719R, were created. 
Lys689 is the site of NEDD8 conjugation in human CUL2, and mutating this residue to 
arginine abolishes neddylation (Wada et al., 1999). Lys719 is a conserved residue 
among cullins, and its equivalent in yeast, Cdc53, is part of the interaction surface with 
DCN1 (Kurz et al., 2008, Wada et al., 1999).  
The CUL2 neddylation was completely abolished in the K689R mutant, and partially 
defective in the K719R mutant, as shown in an anti-NEDD8 Western blot (Figure 3.4). 
However, both mutations did not affect CUL2 interaction with RBX1. Interestingly, the 
loss of neddylation on CUL2 correlated with its ability to bind UBXN7. The UBXN7 
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binding was completely abolished in the K689R mutant and strongly reduced in the 
K719R mutant. Thus neddylation was required for CUL2 interaction with UBXN7. 
 
Figure 3.4: Neddylation of CUL2 
isrequired for its interaction with 
UBXN7 
Flag-CUL2 wild type and two 
neddylation-defective mutants (K689R 
or K719R) were immunoprecipitated 
from HeLa cells treated or not with     
10 µM MG132 for 2h. The immuno-
precipitated proteins were visualised by 
Western blot using specific antibodies.  
The neddylation-defective CUL2 
variants are similarly defective in 
interacting with endogenous UBXN7. 
 
 
It was previously shown that UBXN7 can interact, albeit less efficiently, with the other 
cullins CUL1, CUL3 and CUL4 (Alexandru et al., 2008). Since neddylation is a 
common feature among cullins, treatment with the neddylation inhibitor MLN4924 
prevented not only UBXN7 interaction with CUL2, but also with CUL1, CUL3 and 
CUL4A (data not shown; experiment performed by Gabriela Alexandru). 
 
3.2.4 The UIM of UBXN7 is required to engage the NEDD8 modification on cullins 
The data presented so far suggest that the neddylation on CUL2 is required for the 
interaction with UBXN7. Next, we wanted to explore which of the UBXN7 domains are 
required for this interaction. There are four signature domains present within UBXN7. 
The N-terminus of UBXN7 harbours an UBA domain, followed by a UAS domain, a 
UIM and a UBX domain at the C-terminus. 
	  	  	  	  
69	  
To investigate which of these domains were required for UBXN7 interaction with 
CUL2, we compared the ubiquitin- and CUL2-binding capability of several UBXN7 
variants, including wild type, a point mutant in the UBX domain (P459G), and 
truncation mutants lacking either the UBA, UAS, UIM or UBX domains (Figure 3.5A 
and B, performed by Gabriela Alexandru). 
Figure 3.5A shows that UBA or UIM truncation mutants are partially defective in 
ubiquitin binding (Figure 3.5A, compare lanes 1, 2 and 4). Although both UBA and 
UIM contribute to ubiquitin binding, only the UIM truncation is strongly reduced in 
CUL2-binding (Figure 3.5B, compare lanes 1 and 4). Thus the UIM of UBXN7 is 
required for its interaction with CUL2. Consistent with the reduced binding of UBXN7 
ΔUIM to CUL2, overexpression of this mutant failed to cause an up-shift of CUL2 to its 
neddylated form (Figure 3.5B, compare lanes 8 and 11). 
The truncation of the UAS domain did not alter UBXN7 interaction with ubiquitin or 
CUL2 compared to wild type UBXN7 (Figure 3.5A/B, compare lanes 1 and 3). As 
previously shown by Alexandru et al., the truncation of the UBX domain completely 
disrupted the binding to ubiquitylated substrates. Similar results were obtained with the 
P459G mutant that introduces a conformational re-arrangement of the UBX domain 
resulting in defective p97 binding. The defect in binding to p97 or ubiquitinated 
substrates did not affect UBXN7 interaction with CUL2, confirming that this interaction 
does not depend on its binding to p97 or ubiquitin. 
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Figure 3.5: The UIM of UBXN7 is required for CUL2 binding 
Flag-UBXN7 wild type and various mutants were immunoprecipitated from HeLa cells and 
immunoprecipitated proteins visualised by Western blot using specific antibodies.  
(A) The UBA or UIM deletion caused a reduction in ubiquitin binding to UBXN7, whereas 
the UBX mutants were severely impaired in their ubiquitin binding (left panel).  
(B) Flag-UBXN7 ΔUIM was the only mutant that caused a strong reduction in CUL2 binding 
to UBXN7 (left panel) and abolished the CUL2 up-shift caused by UBXN7 overexpression 
(right panel). 
 
The UIM was identified as the CUL2 interaction site. The sequence alignment of 
UBXN7 UIM with various described UIMs confirmed that UBXN7 contains the 
conserved residues characteristic for a UIM (L290, A293, S297 and E300) (Figure 3.6, 
dark purple). These residues were also shown to be important for UIM interaction with 
ubiquitin (Bilodeau et al., 2002, Hirano et al., 2006). Notably, the hydrophobic patch in 
ubiquitin, that is required for its interaction with UIMs, is conserved in NEDD8. To 
A 
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exclude the possibility that truncation of the whole UIM causes defect in binding to 
CUL2 due to protein misfolding, we generated two point mutants in the conserved 
residues, substituting Ala293 with glutamine, or Ser297 with either alanine or histidine.  
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Figure 3.6: The UIM of UBXN7 contains the conserved residues characteristic for a UIM 
The sequence alignment of UBXN7 UIM with various described UIMs confirmed that the 
UIM of UBXN7 contains the conserved residues characteristic for a UIM. Conserved amino 
acids of the UIM domain are indicated below the alignment, where Φ represents a large 
hydrophobic residue (typically Leu), Ac represents an acidic residue (Glu, Asp), and X 
represents residues that are less well conserved. The sequence alignment was performed using 
Jalview. 
 
To analyse their binding to CUL2, I performed immunoprecipitations of Flag-UBXN7 
wild type, ΔUIM, and both point mutants.  The residue S297 changed either to alanine 
or histidine caused a defect in binding to neddylated-CUL2 similar to the truncation of 
the whole UIM (Figure 3.7, compare lanes 3 with 4/5). The mutant Flag-UBXN7 
A293Q was also defective in its binding, but slightly less pronounced than the ΔUIM or 
the S297A/H mutant (Figure 3.7, compare lane 3 and 6). The p97 binding was not 
affected by any of these mutations. 
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Figure 3.7: UIM-defective mutants of UBXN7 show reduced binding to neddylated-CUL2 
HeLa cells were transfected with the indicated variants of Flag-UBXN7 and 
immunoprecipitated using anti-Flag beads. The lysate inputs (right) and the 
immunoprecipitates (left) were analysed by Western blot and the indicated proteins were 
detected using specific antibodies. The overexpression of the UIM-defective mutants did not 
cause the up-shift of CUL2 to its neddylated form and showed reduced binding to neddylated 
CUL2 compared to Flag-UBXN7 wild type. 
 
 
To further substantiate the ability of the UBXN7 UIM to interact with NEDD8 rather 
than ubiquitin, we performed in vitro binding assays using NEDD8- or ubiquitin-
agarose.  
Wild type UBXN7 was pulled-down efficiently with both types of beads (Figure 3.8). 
Deletion of the UIM caused a clear reduction in NEDD8 binding and had no effect on 
ubiquitin-binding. The UBA deletion abolished ubiquitin binding and caused some 
reduction in NEDD8 binding as well. 
These data strongly support the notion that the UIM of UBXN7 is specialised in 
recognising NEDD8 and can directly engage the NEDD8 modification on cullins. 
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Figure 3.8: The UIM of UBXN7 directly recognises NEDD8 
NEDD8- or ubiquitin-agarose beads were incubated with the indicated recombinant variants 
of UBXN7. The truncation of the UIM exclusively reduces UBXN7 binding to NEDD8 
while deletion of the UBA domain abolishes the interaction with ubiquitin. 
 
 
3.2.5 UBXN7 interacts with cullin-RING complexes in vitro 
To check whether UBXN7 could interact with cullin complexes in vitro, Flag-UBXN7 
was incubated with either unmodified or neddylated CUL2 and then 
immunoprecipitated using anti-Flag beads (performed by Gabriela Alexandru). 
Figure 3.9A shows that wild type UBXN7 could interact efficiently with CUL2 
irrespective of its neddylated status. A UBXN7 variant lacking the UIM was equally 
proficient in interacting with both forms (Figure 3.9B). Therefore, under these 
conditions, UBXN7 interaction with CUL2 does not appear to depend strictly on either 
UIM or NEDD8. 
 
 
A B 
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Figure 3.9: Wild type UBXN7 interacts with CUL2 irrespective of its neddylated status in vitro 
A) Bacterially-expressed Flag-UBXN7 was pre-incubated with full-length CUL2 either 
unmodified or partially neddylated and then immunoprecipitated using anti-Flag beads. Wild-
type UBXN7 efficiently pulls-down CUL2 irrespective of its modification status. 
B) Wild-type or UIM-deleted Flag-UBXN7 was incubated with a mixture of neddylated and 
non-neddylated CUL2 and then immunoprecipitated using anti-Flag beads. The in vitro 
interaction of UBXN7 with full-length CUL2 is not affected by UIM deletion. 
 
 
3.2.6 UBXN7 overexpression causes HIF1α accumulation in a UIM-dependent 
manner  
The data provided so far suggest that the UIM in UBXN7, as well as the neddylation on 
CUL2 are required to mediate interaction between the two proteins. Furthermore, the 
overexpression of UBXN7 causes an up-shift of CUL2 to its neddylated form, 
indicating that UBXN7 might affect CUL2 neddylation.  
To investigate whether overexpression of Flag-UBXN7 wild type or the UIM mutant 
has an effect on CRL2 substrates, we decided to look more closely at the levels of the 
hypoxia-inducible factor 1-alpha (HIF1α). HIF1α is constitutively degraded by the 
CRL2 complex under normoxia (Ivan and Kaelin, 2001) and, furthermore, was shown 
to co-immunoprecipitate with UBXN7 (Alexandru et al., 2008). 
Figure 3.10 shows that overexpression of the wild type UBXN7 caused a significant 
accumulation of HIF1α especially in its non-ubiquitylated form (compare lanes 6 and 
7), suggesting that the CUL2-mediated HIF1α ubiquitylation might be hampered. Most 
importantly, this defect was dependent on the UIM, as HIF1α levels in cells 
overexpressing a UIM-deleted or mutated version of UBXN7 (S297A and S297H) were 
similar to untransfected cells (Figure 3.10, compare lane 6 and 8-10). Furthermore, wild 
type UBXN7 interacted with HIF1α having various degrees of ubiquitylation, while 
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UIM-defective UBXN7 (UIM deletion or point mutation at Ser297) only interacted with 
slow-migrating, poly-ubiquitylated HIF1α (Figure 3.10, compare lanes 2 with 3–5).  
          1        2       3       4        5      6       7       8       9      10 
 
Figure 3.10: UBXN7 overexpression causes HIF1α  accumulation in a UIM-dependent manner  
Experiment in figure 3.8 blotted for HIF1α. The lysate inputs (right) and the 
immunoprecipitates (left) were analysed by Western blot. 
 
3.2.7 Overexpression of another UIM-containing protein, PSMD4, does not alter 
HIF1α levels 
The UIM of UBXN7 is required for its binding to neddylated CUL2, and the 
overexpression of wild type UBXN7 leads to the accumulation of the CRL2 substrate 
HIF1α. Besides UBXN7, there are other ubiquitin receptors harbouring UIMs. 
To investigate whether the overexpression of any other UIM-containing ubiquitin 
receptor causes accumulation of HIF1α, the proteasome subunit PSMD4 (UIM-
containing protein) was overexpressed in HeLa cells (Figure 3.11, lane 3). Notably, the 
two UIMs of PSMD4 contain the conserved residues characteristic for a UIM, including 
the alanine and serine residues that caused a reduced binding of neddylated-CUL2 when 
mutated in the UIM of UBXN7. 
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The comparison of HIF1α levels in Flag-UBXN7- or Flag-PSMD4-expressing cells 
showed that UBXN7 seems to be specific in its ability to cause UIM-dependent 
accumulation of HIF1α, as overexpression of the UIM-containing ubiquitin receptor 
PSMD4 had no effect on HIF1α levels (Figure 3.11, lanes 2 and 3). 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      1     2      3 
 
Figure 3.11: UBXN7 is specific in its ability to cause UIM-dependent accumulation of HIF1α  
Protein extracts from Flag-UBXN7 and Flag-PSMD4 overexpressing HeLa cells were 
analysed by Western blot. The indicated proteins were detected using specific antibodies. 
 
3.2.8 Long ubiquitin chains on HIF1α cause reduced ubiquitin receptor selectivity 
Wild type UBXN7 binds non-ubiquitylated, and various degrees of poly-ubiquitylated 
HIF1α, whereas UIM-defective UBXN7 only interacts with its slow-migrating, poly-
ubiquitylated form (Figure 3.10). This ΔUIM interaction with ubiquitylated HIF1α is 
likely to be mediated via its UBA domain. This is consistent with the fact that other 
UBA–UBX proteins can also interact, albeit inefficiently, with HIF1α carrying long 
ubiquitin chains (Alexandru et al., 2008). 
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The degradation of UBA–UBX protein substrates depends on p97. To investigate if 
HIF1α can be degraded by other ubiquitin receptors that are p97 independent, Flag-
RAD23B immunoprecipitates were analysed for HIF1α binding. RAD23B (RAD23-
like protein B) is an UBA domain-containing ubiquitin receptor, and is involved in 
ubiquitin-dependent proteolysis as well as nucleotide excision repair (Hiyama et al., 
1999, Glockzin et al., 2003, Yokoi et al., 2000). Furthermore, RAD23B is nuclear 
localised (van der Spek et al., 1996), similar to Flag-UBXN7, which localises 
exclusively in the nucleus in HeLa cells (Figure 3.12).  
 
 
Figure 3.12: Flag-UBXN7 localises into the nucleus of HeLa cells 
HeLa cells were transfected with wild-type Flag-UBXN7 and its subcellular localisation was 
analysed by immunofluorescence microscopy. The DNA was stained with DAPI (blue). Flag-
UBXN7 was detected using mouse anti-Flag antibodies and a FITC-conjugated secondary 
(green). Images were obtained with a DeltaVision Spectris microscope. The scale bar 
represents 15 µm. 
 
To check whether RAD23B can also interact with HIF1α, I performed 
immunoprecipitations with Flag-RAD23B and Flag-UBXN7. 
Like the UBA–UBX proteins, RAD23B was able to co-immunoprecipitate only 
HIF1α carrying longer ubiquitin chains (Figure 3.13, compare lanes 2 and 3) and its 
overexpression failed to cause accumulation of unmodified HIF1α, as observed upon 
UBXN7 overexpression (Figure 3.13, compare lanes 5 and 6).  
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Figure 3.13: Long ubiquitin-chains on HIF1α  cause reduced ubiquitin-receptor selectivity 
Hela cells were transfected with either Flag-UBXN7 or Flag-RAD23B, both of which are 
nuclear UBA domain-containing proteins. The Flag-tagged proteins were 
immunoprecipitated using anti-Flag beads and the lysate inputs (right), as well as the 
immunoprecipitates (left) were analysed by Western blot. The indicated proteins were 
detected using specific antibodies. 
 
 
Hence, as the ubiquitin chains get longer, the substrate appears less selective in its 
interaction with ubiquitin receptors. These results suggest that poly-ubiquitylated 
HIF1α might be less selective in its interaction with ubiquitin receptors and that 
UBXN7 may compete with receptors like RAD23B for the binding to poly-
ubiquitylated HIF1α in the nucleus. However, its ability to cause accumulation of non-
ubiquitylated HIF1α, which might be a consequence of its inhibitory effect on CUL2, 
seems to be specific for UBXN7.   
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3.3 Discussion 	  
3.3.1 UBXN7 interaction with cullins is independent of the ubiquitylated substrate 
Multiple lines of evidence indicate that the UBXN7 interaction with cullins is not 
mediated by its ubiquitylated targets bound to the UBA domain.   
1) The inhibition of the ubiquitin-E1 strongly reduces ubiquitin binding to UBXN7 but 
has no affect on CUL2 binding to UBXN7. 
2) The interaction between UBXN7 and HIF1α/VHL is clearly enhanced after 
proteasome inhibition, whereas UBXN7 interaction with the core CRL2 complex is 
stable. 
3) The truncation of the UBA domain reduces ubiquitin binding to UBXN7, but it does 
not affect the interaction with CUL2. 
 
3.3.2 UBXN7 binds the NEDD8 modification on CUL2 via its UIM 
The data illustrate that UBXN7 binds the neddylated form of CUL2 by directly 
engaging the NEDD8 modification. Hence, the neddylation-defective CUL2 mutants are 
defective in UBXN7 binding, and the chemical inhibition of NEDD8-E1 abolished the 
UBXN7 interaction with multiple cullins. 
Furthermore, we found that the binding of UBXN7 to the neddylated form of CUL2 is 
mediated through its UIM. The UIM and UBA domains recognize ubiquitin through a 
hydrophobic surface (formed by Leu8, Ile44, His68 and Val70) on ubiquitin, which is 
conserved in NEDD8. Therefore, in principle, both UIM and UBA domains could have 
served as docking site for neddylated cullin. However, the UBXN7 mutant lacking the 
UBA domain interacts with neddylated CUL2 similar to the wild type, ruling out its 
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involvement in cullin-binding. In contrast, UBXN7 lacking the UIM or carrying point 
mutations therein is strongly defective in cullin-binding.  
The in vitro assays supports that the UIM contributes to the direct binding of UBXN7 to 
neddylated CUL2. UBXN7 variant lacking the UIM becomes defective in binding to 
NEDD8 – but not ubiquitin–agarose. Furthermore, this experiment illustrated that the 
UIM recognizes the NEDD8 modification per se rather than the neddylated 
conformation of cullins. 
However, our in vitro assays also show that UBXN7 can interact with non-neddylated 
cullins, suggesting that UIM-NEDD8 may not be the only link between UBXN7 and 
CRLs. We used a simplified CRL complex containing only cullin and RBX1. Hence, 
the structural arrangement might expose contributing binding sites that are normally 
only accessible upon neddylation. Thereby, the strict requirement for neddylation that 
we observed for the native form of CUL2 present in cell extracts might be revoked. 
We therefore propose that UBXN7 binds the NEDD8 modification on cullins, and that 
additional sites in UBXN7 and the CRLs contribute to stabilize the binding.  
 
At the same time as our paper, den Besten et al. (2012) published a paper on UBXN7 
also describing (consistent with our data) that UBXN7 interacts with neddylated cullins 
via its UIM. By studying more closely the UIM–NEDD8 interaction, den Besten et al. 
demonstrated that UBXN7’s UIM could be swapped with the second UIM of 
proteasome subunit PSMD4 with no effect on UBXN7-CRL association in vitro. 
However, our data show that overexpression of the PSMD4 does not cause an 
accumulation of the CRL2 substrate HIF1α in cell extracts, as seen upon UBXN7 
overexpression (further discussed below). Therefore, although one of the UIMs of 
PSMD4 is able to bind neddylated cullins in the context of UBXN7 in vitro, it does not 
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bestow on PSMD4 the ability to affect CRL substrate levels, as shown with UBXN7 in 
vivo. These results indicate that the NEDD8 specificity of the UBXN7 UIM, as well as 
its flanking regions, contribute to the interaction between UBXN7 and the neddylated 
cullins. 
 
3.3.3 UBXN7 sequesters the CRL2 complex in its neddylated form in a UIM-
dependent manner 
The UBXN7 overexpression causes the accumulation of neddylated CUL2, suggesting 
that UBXN7 binding sequesters CUL2 in its neddylated form. Furthermore, UBXN7 
binding reduces the processivity of the CRL2 ubiquitin ligase, since UBXN7 
overexpression leads to the accumulation of the CRL2 substrate HIF1α, mainly in its 
non-ubiquitylated form. These data suggest that UBXN7 is not only an ubiquitin-
binding adaptor for p97 as described by Alexandru et al., but it may also embody a 
novel mechanism of CRL inhibition. This is in agreement with previous observations 
that UBXN7 silencing by siRNA causes a reduction in HIF1α levels, not HIF1α 
accumulation (Alexandru et al., 2008). 
The regulatory effect on the CRL2 complex activity is UIM dependent. UIM-defective 
UBXN7 mutants do not shift the balance towards neddylated-CUL2 or cause 
HIF1α accumulation. Based on these observations, it is tempting to propose that, by 
sequestering CUL2 in its neddylated form, UBXN7 might sterically hinder the 
transition of the CRL2 complex to an open conformation and thereby mitigate the 
positive effect of NEDD8 on the CRL E3 activity. 
Furthermore, Emberley et al. (2012) showed that UBXN7 strongly inhibits 
deneddylation of CUL1–RBX1 through CSN, in vitro. Together with the observed 
accumulation of NEDD8-conjugated CUL2 upon UBXN7 overexpression in vivo, this 
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could suggest that UBXN7 binding to neddylated-CUL2 not only sequesters CUL2 in 
its neddylated state but also shields CUL2 from CSN; thus preventing NEDD8-
deconjugation (Emberley et al., 2012). 
However, the data obtained by den Besten in yeast, point to a positive role for the 
UBXN7 orthologue Ubx5 in the UV-induced degradation of polyubiquitylated Rbp1 
(large subunit of RNA polymerase II). While upon UV-treatment, Rpb1 was rapidly 
degraded in the wild type strain, its degradation was delayed in the ubx5uimΔ mutant, 
and further impaired in an ubx5Δ background (den Besten et al., 2012). Therefore, the 
knockout of the UBXN7 orthologue Ubx5 has the opposite effect on the CRL2 
substrate, as observed upon UBXN7 silencing in mammalian cells (Alexandru et al., 
2008). The paper by den Besten et al. did not show the effect on Rbp1 upon Ubx5 
overexpression. This conflicting result might suggest that UBXN7’s function depends 
on the substrate. HIF1α is a transcription factor that is soluble under normoxia 
conditions, and poly-ubiquitinated-HIF1α might be targeted for degradation by p97-
independent pathways. In contrast, the RNA polymerase subunit Rpb1 is part of a 12-
subunit complex that is bound to DNA, and its degradation is induced only upon UV 
treatment. Therefore, the p97 recruitment through Ubx5 might be essential for the Rpb1 
extraction prior to its degradation. 
 
3.3.4 UBXN7 recruits p97 to nuclear HIF1α  
The data presented here show that ubiquitin-receptor selectivity is compromised when 
HIF1α carries long ubiquitin chains. However, upon UBXN7 binding to neddylated 
cullins, the CRL processivity is reduced, resulting in non-ubiquitylated and short 
ubiquitin chains on HIF1α. Hence, we suggest that reduced CRL processivity would 
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favour p97 recruitment to the UBX-domain of UBXN7 rather than recruitment of 
alternative ubiquitin receptors, such as RAD23B, to a fast-growing ubiquitin chain. The 
binding of UBXN7 to the neddylated CRLs would be ideally poised to modulate 
substrate ubiquitylation and to shift the balance towards p97 recruitment. 
To recruit p97 to the CRL substrates could be particularly important in the nucleus, 
where HIF1α forms complexes with HIF1β and associates with the promoters of its 
target genes (Jiang et al., 1996). Among the various ubiquitin receptors, p97 uniquely 
provides the segregase activity to dissociate nuclear HIF1α from its protein partner 
and/or from chromatin prior to its degradation. Endogenous HIF1α is found in the 
nuclei of normoxic cells from normal and tumour tissues (Stroka et al., 2001) and poly-
ubiquitylated HIF1α, as well as VHL/ubiquitinated-HIF1α complexes, are found solely 
in the nuclear compartment of normoxic HeLa cells (Groulx and Lee, 2002). That 
UBXN7 and p97 target specifically the nuclear pool of HIF1α is further supported by 
our finding that Flag-UBXN7 localises in the nucleus of HeLa cells under normoxia. 
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Chapter 4 
4. The p97-cofactor UBXN8 has an inhibitory effect on the Fanconi 
anaemia proteins FANCD2 and FANCI 
 
4.1 Introduction 
The UBX-only protein UBXN8 is an ER membrane protein that binds p97 via its UBX 
domain. UBXN8 is required for ER-associated degradation of misfolded proteins by 
tethering p97 at the ER membrane (Madsen et al., 2011). Furthermore, a recent 
publication introduced UBXN8 as a target gene for HBV (hepatitis B virus) integration 
and showed that its overexpression in hepatocellular carcinoma cells induces a delay in 
the G1/S transition via a p53/p21WAF1/CIP1 – dependent mechanism (Li et al., 2014). 
Our identification of the FA proteins FANCD2 and FANCI in Flag-UBXN8 
immunoprecipitates (unpublished results by Gabriela Alexandru) suggests a new 
function of UBXN8 in the DNA damage response. This may link UBXN8 to the genetic 
disease FA, which is caused by mutations in at least 15 FA genes, resulting in defective 
DNA crosslink repair and predisposition to cancer. DNA interstrand crosslinks (ICL) 
covalently link both strands of the helix thereby blocking DNA replication and 
transcription (Scharer, 2005, German et al., 1987). Because the FA pathway plays a 
major role in removing these crosslinks, FA proteins are involved in a novel DNA 
repair mechanism required for maintaining genomic stability and preventing cancer 
(Kee and D'Andrea, 2010). A better understanding of the molecular details and the 
regulation of the FA pathway can therefore help to improve or develop therapies for FA 
patients as well as non-FA cancer patients. 
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This chapter of my thesis describes the identification of the p97-cofactor UBXN8 as 
new interaction partner of the FA proteins FANCD2 and FANCI and sheds light on the 
functional relevance of these interactions. 
 
4.2 Results 
 
PART I - Identification of the key FA proteins FANCD2 and FANCI as UBXN8 
binding partners 
 
4.2.1. Analysis of Flag-UBXN8 immunoprecipitates by mass spectrometry identified 
FANCD2 and FANCI as UBXN8 interaction partners 
The initial mass spectrometry (MS) analysis of Flag-UBXN8 immunoprecipitates was 
performed by my supervisor Gabriela Alexandru and identified the FA proteins 
FANCD2 and FANCI as potential UBXN8 interaction partners. These interactions 
implicate UBXN8 in the FA pathway and raise the question whether UBXN8 has a 
broader role in DNA damage response. Therefore, to identify novel UBXN8 
interactions that might help us to address this question, we carried out MS analyses of 
Flag-UBXN8 immunoprecipitates from HeLa cells treated or not with the DNA 
damaging agent hydroxyurea (HU). As an inhibitor of ribonucleotide reductase, HU 
inhibits replication and activates several DNA repair pathways. Immunoprecipitates 
from cells that were not transfected with Flag-UBXN8 were used as negative control.  
The MS analysis of Flag-UBXN8 immunoprecipitates identified numerous potential 
binding-partners, however the qualitative comparison between non-damaged and DNA-
damaged cells did not reveal significant differences. The proteins identified were 
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grouped based on their function and at least two of these groups might be particularly 
relevant for the role of UBXN8 in mammalian cells: proteins involved in DNA damage 
response (Table 4.1) and proteins required for nuclear import/export (Table 4.2). 
In the DNA repair category, besides FANCD2 and FANCI, we identified proteins 
required for: DSB repair (FIGNL1, RIF1, BRAT1) (Yuan and Chen, 2013, Kumar and 
Cheok, 2014, Aglipay et al., 2006), DNA damage resistance by regulating the 
ATM/ATR abundance (TTT-complex: TELO2, TTI1, TTI2) (Hurov et al., 2010) and 
p53 activation upon DNA damage (ATM-dependent phosphatase PPM1G) 
(Khoronenkova et al., 2012); as well as proteins that are phosphorylated upon DNA-
damage (Table 4.1).  
 
	  	  	  	  
87	  
 
The column “No. of peptides identified” shows the number of unique peptides and the total number of 
peptides is indicated in parenthesis, which takes into account that some peptides were identified multiple 
times. Light grey: identifications with only one unique peptide. 
 
Table 4.2 indicates proteins required for protein transport to/from the nucleus, including 
several importins, exportins, and nuclear pore complex components. The number of 
peptides identified for each import/export protein is significantly high and suggests that 
UBXN8 might play a role in nuclear import/export. 
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The column “No. of peptides identified” shows the number of unique peptides and the total number of 
peptides is indicated in parenthesis, which takes into account that some peptides were identified 
multiple times. Light grey: identifications with only one unique peptide. 
 
The identification of other DNA damage-related proteins supports the assumption that 
UBXN8 might have a broader role in the DNA damage response. 
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4.2.2 Membrane-anchored isoforms of UBXN8 interact with FANCD2 and FANCI 
To confirm the interaction between Flag-UBXN8 and the FA proteins FANCD2 and 
FANCI by Western blot, Flag-immunoprecipitations from Flag-UBXN8 transfected 
U2OS cells were performed. There are three predicted UBXN8 isoforms, based on 
alternative splicing: isoform 1 as full-length UBXN8, isoform 2 that lacks a region 
between the coiled-coil and the UBX-domain, and isoform 3 that lacks the 
transmembrane domain.  We therefore decided to perform Flag-immunoprecipitation 
with each splice variant of UBXN8 to investigate which one of them co-
immunoprecipitates FANCD2 and FANCI.  
The immunoprecipitation of full-length Flag-UBXN8 confirmed its interaction with 
FANCD2 and FANCI (Figure 4.1, lane 2). Furthermore, comparing the binding ability 
of all three UBXN8 isoforms, only the membrane-anchored isoforms of UBXN8 (1 and 
2) co-immunoprecipitated the endogenous FA proteins (Figure 4.1, lanes 2 and 3). 
UBXN8 isoform 1 appeared to interact best with FANCD2 and FANCI, while isoform 2 
only showed a weak interaction to both proteins.  
Transmembrane domains consist of amino acids carrying hydrophobic side chains that 
allow their insertion in the hydrophobic layers of the cell membrane (Borgese and 
Fasana, 2011). In the case of UBXN8, it is therefore unlikely that its (embedded) 
transmembrane domain mediates the interaction with soluble FANCD2 and FANCI. 
Therefore, our results rather suggest that the membrane localisation of UBXN8 is 
important for its interaction with both FA proteins. 
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Figure 4. 1: Membrane-anchored isoforms of UBXN8 interact with FANCD2 and FANCI 
 U2OS cells were transfected with the three predicted Flag-tagged UBXN8 isoforms (1–3, top), 
with isoform 1 being full-length UBXN8. Flag-tagged UBXN8 was immunoprecipitated using 
anti-Flag beads and the indicated proteins detected by Western blot. Cells expressing no Flag-
tagged protein were used as negative control. Left: Flag-IP; right:  Lysate Input  
 
The subcellular localisation of the three UBXN8 isoforms was analysed in HeLa cells 
using immunofluorescence microscopy (Figure 4.2). The images obtained confirmed the 
ER localisation of full-length Flag-UBXN8 as described by Madsen et al. (2012). 
Notably, I also observed a distinct staining of Flag-UBXN8 at the nuclear envelope, 
which will be further addressed in the next section. Isoform 2 showed the same 
subcellular localisation as isoform 1, whereas isoform 3 showed a diffused staining all 
over the cell.  
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Figure 4.2: Membrane-anchored isoforms of Flag-tagged UBXN8 localise at the ER and around 
the nucleus  
HeLa cells were transfected with Flag-tagged UBXN8 isoform 1–3 and processed for 
immunostaining after 24 h. Flag-tagged proteins were detected with an anti-Flag antibody 
(green) and the nuclei stained using DAPI (blue). The scale bars represent 15 µm. 
 
 
4.2.3 UBXN8 is anchored in the inner nuclear membrane 
The immunofluorescence staining of Flag-UBXN8 showed that a fraction of Flag-
UBXN8 distinctly localised at the nuclear envelope.  
The FA proteins FANCD2 and FANCI are mainly nuclear localised (Boisvert et al., 
2013, Colnaghi et al., 2011), which made us wonder whether a fraction of UBXN8 
might actually localise at the inner nuclear membrane and this could be the site where 
UBXN8 interacts with the FA proteins. To address this hypothesis, I performed 
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immunofluorescence microscopy with tetracycline-inducible U2OS cells expressing 
Flag-UBXN8, to compare the UBXN8 localisation with that of lamin B1, an inner 
nuclear envelope marker. 
The images were taken with a DeltaVision deconvolution microscope and processed 
using the visualising and analysing software softWoRx. The image shown in Figure 4.3 
shows a mid-section of a U2OS cell co-immunostained for Flag-UBXN8 (green) and 
lamin B1 (red). The intensity line profile shows the pixel intensity values of both 
channels along the drawn line (across nucleus). The overlap of the intensity peaks at the 
indicated regions, suggest co-localisation of Flag-UBXN8 and lamin B1 at the nuclear 
envelope (indicated with arrows).  
 
 
Figure 4.3: Flag-UBXN8 co-localises with lamin B1 using a conventional deconvolution microscope 
A) Tetracycline-inducible U2OS cells expressing Flag-UBXN8 were co-immunostained for 
lamin B1 (red) and Flag-UBXN8 (green). DNA was counterstained with DAPI (blue). The 
images were taken with a DeltaVision deconvolution microscope and processed using the 
software softWoRx. The scale bars represent 10 µm. 
B) The intensity line profile shows the pixel intensity values of the red and green channels 
along the line across the nucleus. The line profile shows co-localisation of Flag-UBXN8 and 
lamin B1 at the nuclear envelope. The scale bar represents 15 µm. 
 
	  	  	  	  
93	  
One of the limitations of the DeltaVision deconvolution microscope is its low resolution 
relative to the scale of subcellular structures. This means that objects closer together 
than 200–350 nm cannot be resolved, and appear to be merged into one (Schermelleh et 
al., 2008).  
Therefore, the slides were also analysed using the OMX, a super resolution microscope. 
The OMX provides images with twice the resolution of conventional light microscopy 
by implementing three-dimensional structured illumination technology (3D-SIM) 
(Schermelleh et al., 2008). Schermelleh et al. demonstrated the potential of 3D-SIM to 
resolve subtle differences of epitope localisations within the nuclear pore complex 
(NPC). The multicolor imaging of the nuclear periphery with 3D-SIM makes it possible 
to differentiate between Nup proteins that are located in the centre and the cytoplasmic 
side of the NPC (Nup62, Nup214 or Nup358) and Nup proteins that are located on the 
nucleoplasmic side of the NPC (Nup153). The latter show a pore signal in the same 
plane as the lamin B signal (Schermelleh et al., 2008). 
The resolution achieved with OMX structured illumination microscopy should be 
therefore high enough to determine whether membrane-bound UBXN8 faces into the 
nucleoplasm. 
The experiment was performed as described before, and images were taken with the 
help of Markus Posch in the light microscopy facility in the College of Life Sciences, 
Dundee. The softWoRx tools for OMX image processing were used to reconstruct and 
align structured illumination images.  
The image in figure 4.4 shows a mid-section of a U2OS cell co-immunostained for 
Flag-UBXN8 (green) and lamin B1 (red). The single dots (green) representing Flag-
UBXN8 lie in the same plane as the lamin B1 signal, thus confirming that UBXN8 is 
anchored at the inner nuclear membrane (Figure 4.4, a and b). The localisation of 
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UBXN8 to the inner nuclear envelope supports the hypothesis that the interaction 
between UBXN8 and FANCD2/I occurs at this location. 
 
Figure 4.4: Flag-UBXN8 localises at the inner nuclear membrane 
Tetracycline-inducible U2OS cells expressing Flag-UBXN8 were co-immunostained for 
lamin B1 (red) and Flag-UBXN8 (green). DNA was counterstained with DAPI (blue). The 
images were taken with the Dundee OMX microscope implementing three-dimensional 
structured illumination (3D-SIM). The softWoRx tools for OMX image processing were used 
to reconstruct and align structured illumination images. The scale bars in the upper panel of 
images represent 5 µm. The scale bars in the zoomed in images represent 1 µm. 
 
To actually address whether UBXN8 co-localises with FANCD2 and FANCI, I 
performed immunofluorescence microscopy with U2OS cells, tetracycline-inducible for 
Flag-UBXN8. The cells were stained for Flag-UBXN8 and endogenous FANCD2. 
However, the strong signal of overexpressed Flag-UBXN8 and the weak signal of 
FANCD2 did not allow a reliable analysis for co-localisation. Furthermore, the signal 
for endogenous FANCD2 was too weak to analyse samples by OMX microscopy. 
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PART II - Interaction studies between UBXN8 and FANCD2/I 
 
4.2.4 FANCD2 and FANCI are released from UBXN8 upon DNA damage  
As shown in section 4.2.2, full-length Flag-UBXN8 co-immunoprecipitated both FA 
proteins in the absence of DNA damage. In the presence of DNA damage, FANCD2 
and FANCI are localised at the DNA damage site to facilitate DNA repair 
(Smogorzewska et al., 2007). 
Therefore, I wanted to know whether the presence of DNA damage has any effect on 
the interaction between UBXN8 and the FA proteins. The experiment was performed by 
immunoprecipitating Flag-UBXN8 from tetracycline-inducible Flag-UBXN8 U2OS 
cells that were either untreated or treated with DNA damage agent. Since the FA 
pathway is activated mainly through ICLs, the DNA damage was caused using the ICL 
inducing agent cisplatin. To allow the extraction of DNA-bound FANCD2 and FANCI, 
the cells were lysed in the presence of the endonuclease benzonase that degrades all 
forms of DNA and RNA. 
The results show that, in the absence of DNA damage, Flag-UBXN8 co-
immunoprecipitated FANCD2 and FANCI (Figure 4.5, lane 3). However, upon DNA 
damage, these interactions were clearly reduced compared, to non-treatment conditions 
(Figure 4.5, compare lanes 3 and 4). This suggests that the FA proteins are released, at 
least in part, from membrane-anchored UBXN8 upon their activation in response to 
DNA damage. Furthermore, comparing the extracts before and after the 
immunoprecipitation revealed only a small change in FANCD2 and FANCI levels, 
indicating that only a fraction of the FA proteins interacted with Flag-UBXN8 (Figure 
4.5, compare lanes 7 and 8 with 9 and 10). The interaction between Flag-UBXN8 and 
p97 did not change upon DNA damage (Figure 4.5, compare lanes 3 and 4).  
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Figure 4.5: Upon DNA damage, FANCI and FANCD2 get released from wild type UBXN8 
Flag-UBXN8 was immunoprecipitated from tetracycline-inducible U2OS cells expressing full-
length Flag-UBXN8 and were untreated or treated with 3 µM cisplatin for 24h. The expression 
was induced by adding 0.5 µg/ml tetracycline. Uninduced U2OS cells were used as control. 
Flag-tagged proteins were immunoprecipitated with anti-Flag beads. Co-immunoprecipitated 
proteins were detected with specific antibodies. (left: IP, right: Lysate Input/Extracts after IP) 
 
4.2.5 Endogenous FANCD2 co-immunoprecipitates endogenous UBXN8  
The analysis of Flag-UBXN8 immunoprecipitates by mass spectrometry and Western 
blot showed that overexpressed Flag-UBXN8 co-immunoprecipitated endogenous 
FANCD2 and FANCI. To exclude the possibility that UBXN8 interaction with FA 
proteins is an artefact, due to protein overexpression, the interactions between the 
endogenous proteins were further analysed. 
For this purpose, we raised two rabbit anti-UBXN8 polyclonal antibodies (called R2823 
and R2824) against the full-length protein. Both UBXN8 antibodies detect denatured 
UBXN8 in Western blots (Figure 4.6). It should be mentioned that, in the protein 
extracts of UBXN8-silenced cells, only one band for UBXN8 disappeared, indicating 
that only one isoform exists in HeLa cells. 
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Figure 4.6: Both UBXN8 antibodies 
detect endogenous UBXN8 by 
Western blot 
Western blot with cell extracts            
[20 µg/lane] from wild type or UBXN8- 
depleted HeLa cells. Total cell extracts 
were immunoblotted with two different 
purified anti-UBXN8 antibodies (R2823 
and R2824). Binding of the primary 
antibody was detected using peroxidase- 
conjugated goat anti-rabbit IgG antibody 
followed by enhanced chemilumines-
cence.	  
 
 
However, in immunoprecipitations both UBXN8 antibodies showed cross-reactions 
with several other proteins, including FANCD2 and p97. Consequently, neither of the 
two UBXN8 antibodies could be used to study the interaction between the endogenous 
proteins. 
 
Therefore, I decided to use the sheep anti-FANCD2 antibody (S099D) provided by the 
DSTT to study the interaction between the endogenous proteins. 
I immunoprecipitated endogenous FANCD2 from U2OS cells untreated or treated with 
cisplatin using the anti-FANCD2 antibody. The cell lysates were incubated first with 
the antibody, followed by the incubation of the antibody–lysate mix with protein A-
Sepharose beads. Cell lysates incubated with protein A-Sepharose in the absence of the 
FANCD2 antibodies were used as control (Figure 4.7). 
The immunoprecipitation of endogenous FANCD2 shows that FANCD2 interacts 
mainly with modified FANCI (Figure 4.7, lanes 2 and 3), and that this interaction 
dramatically increased upon DNA damage. By comparing the ‘lysate input’ and the 
‘extracts after IP’, the unmodified fraction of FANCI seems mostly unaffected (Figure 
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4.7, lanes 6 and 8). Indeed, FANCD2 co-immunoprecipitates only a small amount of 
unmodified FANCI, and the binding did not change in the presence or absence of DNA 
damage (indicated with arrow). These results suggest that FANCD2 interacts mainly 
with modified FANCI (even in the absence of DNA damage) and that unmodified 
FANCI, except for a small portion, does not interact with FANCD2. 
Furthermore, UBXN8 was detected in endogenous FANCD2 immunoprecipitates, 
confirming the interaction between FANCD2 and UBXN8 at endogenous levels (Figure 
4.7, lanes 2 and 3). Consistent with the data obtained by Flag-UBXN8 
immunoprecipitation, endogenous FANCD2 showed decreased binding to UBXN8 
upon DNA damage, compared to non-damage conditions.  
 
 
Figure 4.7: Endogenous FANCD2 co-immunoprecipitates endogenous UBXN8  
Endogenous FANCD2 was immunoprecipitated from U2OS cells untreated or treated with      
3 µM cisplatin. The immunoprecipitation was performed using anti-FANCD2 antibodies and 
protein A-Sepharose beads. Naked protein A-Sepharose beads incubated with extract were 
used as negative control. Co-immunoprecipitated proteins were detected with specific 
antibodies.    (left: IP, right: Lysate Input and Extract after IP)  
 
 
  
To show that the reduced binding of UBXN8 to FANCD2 is due to the mono-
ubiquitylation/activation of FANCD2 upon DNA damage, I performed an endogenous 
FANCD2 immunoprecipitation with UBE2T-silenced U2OS cells untreated or treated 
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with cisplatin. UBE2T is the E2 enzyme that, together with the E3 ligase FANCL 
facilitates the mono-ubiquitylation of FANCD2 and FANCI in response to DNA 
damage (Longerich et al., 2009, Alpi et al., 2008, Zhang et al., 2008). By silencing 
UBE2T, the activation of FANCD2 in the presence of ICLs should be abolished and, 
therefore, the release from UBXN8 impeded. Cells transfected with Luciferase siRNA 
were used as negative control, and FANCD2-silenced cells were used to analyse non-
specific binding of the FANCD2 antibody to UBXN8. 
Figure 4.8 shows that silencing of the E2 enzyme, UBE2T strongly reduced the mono-
ubiquitylation of FANCD2 and FANCI upon DNA damage (compare lanes 12 with 14). 
Furthermore, in UBE2T-silenced cells, the binding between FANCD2 and UBXN8 
remained unchanged with or without DNA damage (Figure 4.8, lanes 5 and 6). This 
result supports the possibility that the activation/mono-ubiquitylation of FANCD2 (and 
FANCI) reduces the FANCD2-binding to UBXN8. However, the immunoprecipitation 
of Flag-UBXN8 from wild type vs. UBE2T-silenced cells in the presence and absence 
of DNA damage would clarify, whether the activation of FANCD2 and FANCI causes 
their release from membrane-anchored UBXN8. 
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Figure 4.8: Preventing FANCD2 activation upon DNA damage inhibits its release from UBXN8 
Endogenous FANCD2 was immunoprecipitated from U2OS cells that were depleted for UBE2T 
or FANCD2 and either untreated or treated with 3 µM cisplatin. Cells transfected with 
Luciferase siRNA were used as control. The immunoprecipitations were performed using anti-
FANCD2 antibodies and protein A-Sepharose beads. Naked protein A-Sepharose beads 
incubated with extract or anti-FANCD2 antibody/beads incubated with FANCD2-silenced cells 
were used as negative control. Co-immunoprecipitated proteins were detected with specific 
antibodies. (left: IP, right: Lysate Input and Extract after IP) 
 
4.2.6 Release from DNA damage does not increase the binding between FANCD2 and 
UBXN8 
Flag-UBXN8 and endogenous FANCD2 immunoprecipitations showed that only a 
small fraction of UBXN8 interacts with FANCD2 and FANCI. 
The microscopy images obtained with the OMX indicate that only a small fraction of 
UBXN8 is localised to the inner nuclear membrane. If this is the actual site of 
interaction between UBXN8 and FANCD2/I, the small amount of nuclear UBXN8 
would be only able to bind a small pool of the FA proteins. 
Furthermore, the immunoprecipitations of endogenous FANCD2 showed that FANCD2 
interacts mainly with modified FANCI, and that this interaction dramatically increased 
upon DNA damage (Figure 4.7, lanes 2 and 3). Although the majority of non-
ubiquitylated FANCI is not bound to FANCD2, I also observed a minor fraction of it in 
FANCD2 immunoprecipitates (Figure 4.7, lane 2 [arrow]). Since Flag-UBXN8 co-
immunoprecipitates only a small fraction of non-ubiquitylated FANCD2 and FANCI 
(Figure 4.5, compare lanes 7 with 9), I wondered if UBXN8 binds non-ubiquitylated 
FANCD2/I heterodimers. This could be another reason why the interaction between 
UBXN8 and FANCD2/I only involves small fractions of the proteins. 
After the execution of DNA repair, FANCD2 and FANCI are de-ubiquitylated and 
dissociate from chromatin, which might increase the pool of non-ubiquitylated 
FANCD2/I heterodimers. Therefore, to test this assumption and to see whether this 
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leads to an increase in UBXN8 binding, I performed a FANCD2 immunoprecipitation 
from U2OS cells that were released from DNA damage. 
The time window for the release experiment was chosen based on live cell imaging with 
U2OS cells stably expressing GFP-FANCD2 that revealed clear reduction in foci 
between 24h and 48h after release (Figure 4.9). Within the first 24h after release, the 
FANCD2/I dimer formation did not show significant changes. 
 
 
 
Figure 4.9: Foci formation of GFP-FANCD2 is clearly reduced 48h after the release from DNA 
damage 
Tetracycline-inducible U2OS cells expressing GFP-FANCD2 were released from cisplatin 
treatment [3 µM, 24h]. During the release, the reduction in number of foci was monitored via 
live cell imaging using a Delta Vision microscope. 
 
 
Furthermore, the cell cycle progression upon DNA damage release was analysed by 
FACS. The treatment with cisplatin for 24h arrested cells in S-phase, the cell cycle 
stage in which the replication and repair of DNA takes place (Figure 4.10). Twenty-four 
hours after release from DNA damage, the cells are mostly in G2. The G2/M arrest is 
described in the literature and prevents the cells’ progression into mitosis before DNA 
repair is completed (Stark and Taylor, 2004). Forty-eight hours after release, the cells 
partially progress to G1- and S-phase, suggesting that they overcame the induced DNA 
damage and re-entered the cell cycle. 
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Figure 4.10: U2OS cells partially re-enter the cell cycle 48h after DNA damage release 
U2OS cells were treated with 3 µM cisplatin. Fresh medium was added 24h after cisplatin 
treatment to allow DNA repair and cell cycle progression. Cells were harvested before, and at 
the indicated time points after DNA damage. The cells were stained with propidium iodide and 
their cell cycle stages analysed by FACS. For each time point, the FACS profile and the 
percentage of cells in the different cell cycle stages are shown. 
 
For the release experiment, FANCD2 was immunoprecipitated from U2OS cells that 
had been treated for 24h with cisplatin and then lysed at 24h, 36h and 48h after release. 
The immunoprecipitates were analysed by Western blot to monitor changes in the 
FANCD2/I dimer upon release, and its interaction with UBXN8.  
The results of the FANCD2 immunoprecipitation are shown in Figure 4.11. The cell 
lysates prepared at the time points 24h, 36h and 48h after release from DNA damage 
showed gradually reducing levels of modified FANCD2 and FANCI (Figure 4.11, lanes 
8–10). Accordingly, the levels of co-immunoprecipitated modified FANCI decreased as 
well (lanes 2–4) but did not reach the low level of FANCD2/I interaction observed 
under non-treatment conditions (Figure 4.11, compare lanes 4 and 5).  
Interestingly, the reduction in FANCI co-immunoprecipitated with FANCD2 correlates 
with an increased interaction with p97, reaching its peak 36h after release (lane 3). As 
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mentioned in the introduction, p97 is reported to be involved in the DNA damage 
response, by dissociating chromatin-bound proteins (Dantuma and Hoppe, 2012). 
Therefore, it is tempting to speculate that p97 might be required for FANCD2/I dimer 
dissociation from chromatin.  
Probing the FANCD2 immunoprecipitates for UBXN8 with the R2823 antibody led to 
the detection of two protein species that strongly accumulated upon release, but 
migrated higher than expected (Figure 4.11, lanes 3 and 4). These could be modified 
forms of UBXN8, given that ubiquitylation and phosphorylation sites for UBXN8 were 
found in previous proteome analyses (Daub et al., 2008, Dephoure et al., 2008, Kim et 
al., 2011). However, the R2824 antibody showed a better detection of UBXN8, but did 
not detect these slower migrating bands to the same extent, indicating that these bands 
were recognised non-specifically by the R2823 UBXN8 antibody. 
The release from DNA damage caused a reduction in FANCD2 binding to modified 
FANCI, but the binding to unmodified FANCI remained low. Therefore, the initial 
hypothesis that release from DNA damage may lead to an increased pool of soluble, 
unmodified dimer was not confirmed. 
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Figure 4.11: FANCD2/I dimer dissociation correlates with increased p97-binding after release 
from DNA damage   
Endogenous FANCD2 was immunoprecipitated from U2OS cells that were treated with 3 µM 
cisplatin for 24h, released by adding fresh media and harvested at the indicated time points. 
Cells were lysed in the presence of 500U/ml benzonase. The immunoprecipitation was 
performed using anti-FANCD2 antibodies and protein A-Sepharose beads. Naked protein A-
Sepharose beads incubated with extract or lysis buffer/antibody were used as negative controls. 
Co-immunoprecipitated proteins were detected with specific antibodies. Endogenous UBXN8 
was detected using the UBXN8 antibodies R2823 or R2824. (left: IP, right: Lysate Input) 
 
To investigate whether the observed co-immunoprecipitation of p97 depends on 
UBXN8, the time course experiment was repeated with UBXN8-silenced U2OS cells. 
Figure 4.12 shows that silencing of UBXN8 did not change the increase binding of p97 
to FANCD2 upon DNA damage release (lanes 2 and 3). The bands detected between 
37 kDa and 50 kDa did not disappear in UBXN8-silenced cells (lanes 6 and 7), 
confirming that this band did not represent modified UBXN8. UBXN8 detection with 
the R2824 antibody revealed a slight increase in UBXN8 binding 36h after release 
(Figure 4.12, compare lanes 2 and 4).  
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Figure 4.12: FANCD2 co-immunoprecipitates p97 independently from UBXN8   
Endogenous FANCD2 was immunoprecipitated from U2OS cells silenced or not for UBXN8 
that were treated with 3 µM cisplatin for 24h, released by adding fresh media and harvested to 
the indicated time points. Cells were lysed in the presence of 500U/ml benzonase. The 
immunoprecipitation was performed using anti-FANCD2 antibodies and protein A-Sepharose 
beads. Naked protein A-Sepharose beads incubated with extract or lysis buffer/antibody were 
used as control. Co-immunoprecipitated proteins were detected with specific antibodies. 
Endogenous UBXN8 was detected using two different UBXN8 antibodies: R2823 and R2824  
(left: IP, right: Lysate Input and Extract after IP) 
  
 
The silver staining of the FANCD2-immunoprecipitates showed a dramatic increase in 
co-immunoprecipitated proteins after 36h–48h after release from DNA damage. 
Therefore, I decided to analyse bands that changed more dramatically after release by 
MS (Figure 4.13). The MS analysis identified mainly cytoskeletal proteins, including 
alpha- and beta-actin that were assigned to the band cut around 40 kDa, which we 
initially thought to be modified-UBXN8. Filamin A and actin, that build crosslinked 
actin filaments, are reported to be required for DSB repair as well as recovery from 
DNA damage-induced G2 arrest (Andrin et al., 2012, Meng et al., 2004). However, it is 
not obvious why cytoskeletal proteins are so abundant in FANCD2 co-
immunoprecipitates upon DNA damage release. 
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Figure 4.13: FANCD2 binds to multiple cytoskeletal proteins after release from DNA damage 
Endogenous FANCD2 was immunoprecipitated from U2OS cells that were treated with 3 µM 
cisplatin for 24h, released by adding fresh media and harvested at the indicated time points. 
Cells were lysed in the presence of 500U/ml benzonase. The immunoprecipitations were 
performed using anti-FANCD2 antibodies and protein A-Sepharose beads. Naked protein A-
Sepharose beads incubated with extract were used as control. The proteins in the 
immunoprecipitates were separated by gel electrophoresis and protein bands were visualized 
by silver staining. The indicated bands were cut, the proteins in the gel digested, and identified 
by mass spectrometry. The most abundant protein hits identified in each band are listed in the 
boxes on the right. 
 
4.2.7 Flag-FANCI immunoprecipitations to study how changes in the FANCD2/I 
dimer formation affect the interaction to UBXN8 
Ishiai et al. showed that six key serine residues are important phosphorylation sites in 
chicken FANCI and are required for the mono-ubiquitylation of FANCD2 and the 
activation of the FA pathway (Ishiai et al., 2008). They described a sextuple phospho-
mimicking serine to aspartate (Dx6) mutant, and a phospho-dead serine to alanine (Ax6) 
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mutant of chicken FANCI, and showed that the phospho-mimicking mutant induces 
constitutive mono-ubiquitylation and foci formation of FANCI and FANCD2. 
Conversely, the phospho-dead mutant largely abrogated the mono-ubiquitylation and 
foci formation of both FA proteins, resulting in loss of the DNA repair function. 
Based on these data, I attempted an alternative approach to study the interaction 
between UBXN8 and the heterodimer FANCD2/I. I aimed to artificially increase the 
FANCD2/I dimer formation in cells, to study how this affects the interaction to 
UBXN8. 
 
4.2.7.1 Quadruple Flag-FANCI phospho-mimicking mutant constitutively activates 
FANCD2 and induces dimer formation with FANCD2 in the absence of DNA 
damage 
To investigate whether constitutive dimer formation of FANCD2/I changes the binding 
to UBXN8, I used human sextuple FANCI phospho-mutants (Dx6 and Ax6) equivalent 
to the chicken ones described by Ishiai et al. In addition, I included a quadruple mutant 
of human FANCI that harboured only four of the six mutations (Figure 4.14). 
 
 
Figure 4.14: S/Q cluster in human FANCI  
Schematic representation of human FANCI highlighting a S/Q cluster close to the 
ubiquitylation site K523. The table shows the quadruple and sextuple phopho-mimicking and 
phospho-dead mutant used for the experiments described in figure 4.15. 
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In contrast to the data described for chicken FANCI by Ishiai et al, the sextuple 
phospho-mimicking mutant in human FANCI failed to constitutively activate FANCD2 
(Figure 4.15, lanes 14 and 17) and failed to induce dimer formation in mammalian cells 
(lanes 2 and 5). Interestingly, these effects were, however, induced by the quadruple 
phospho-mimicking mutant of human FANCI that we created. This version of FANCI 
increased the levels of mono-ubiquitylated FANCD2 similarly to that observed upon 
DNA damage (compare lanes 15 and 21). In the absence of DNA damage, this mutant 
co-immunoprecipitated high FANCD2 levels comparable to that observed for wild type 
FANCI after DNA damage (lanes 3 and 8). In contrast, the quadruple phospho-dead 
mutant did not show any binding to mono-ubiquitylated FANCD2 either with, or 
without, DNA damage (lanes 4 and 10). However, I found that endogenous UBXN8 
bound to wild type and mutant Flag-FANCI with similar efficiency.  
 
Figure 4.15: Phospho-mimicking mutations in FANCI induce FANCD2/I dimer formation in the 
absence of DNA damage 
 U2OS cells were transfected for 24h with wild type Flag-FANCI or the quadruple [S556A/D, 
S559A/D, S565A/D, S596A/D] or sextuple [S556A/D, S559A/D, S565A/D, S596A/D, 
S617A/D, S629A/D] Flag-FANCI phospho-mutants, which were either phospho-mimicking 
or phospho-dead mutants. The cells were untreated or treated with 3 µM cisplatin (24h) and 
the Flag-tagged proteins were immunoprecipitated with anti-Flag beads. All indicated 
proteins were detected with specific antibodies. Cells expressing no Flag-tagged protein were 
used as negative control. (left: IP, right: Lysate Input) 
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I took advantage of the fact that I could only extract chromatin-bound proteins by using 
benzonase, which degrades all forms of DNA and RNA. By performing the protein 
extraction with or without benzonase, I found that most of the co-immunoprecipitated 
modified FANCD2 was only extracted with benzonase, suggesting that modified 
FANCD2 was DNA-bound (Figure 4.16A, right panel). This indicates that the 
ectopically formed FANCD2/I dimer binds to the DNA even though DNA damage was 
not induced. Hence, the artificially induced dimer of FANCD2/I did not lead to an 
increase of dimer that was not bound to the DNA. It is likely that DNA-bound 
FANCD2/I is not accessible to interact with UBXN8 that is anchored at the nuclear 
membrane. The reduced UBXN8 interaction with FANCD2 and FANCI upon DNA 
damage supports this idea. 
The dimer with unmodified FANCD2 was extracted equally well either with or without 
benzonase, suggesting that it is not bound to the DNA. This pool of FANCD2/I dimer is 
soluble and could therefore be accessible for UBXN8 for interaction. 
In FANCI, the conserved lysine residue K523 was shown to be the site of mono-
ubiquitylation (Smogorzewska et al., 2007). The mutation K523R in human FANCI that 
prevents its mono-ubiquitylation strongly reduced the interaction with modified 
FANCD2 but did not affect its binding to unmodified FANCD2 (Figure 4.16A, compare 
lanes 6 and 7). In DT40 cells, the mono-ubiquitylation of chicken FANCI was described 
to be largely dispensable for FANCD2 binding and mono-ubiquitylation (Ishiai et al., 
2008). However, studies in mammalian cells suggested that FANCD2/I mono-
ubiquitylation might stabilise the ID complex formation (Joo et al., 2011, Rego et al., 
2012). The K523R mutation, in combination with the 4SD mutations, could not restore 
the FANCI interaction with modified FANCD2 to the wild type FANCI level (Figure 
4.16B, compare lanes 9 and 11). This suggests that the ubiquitylation of FANCI is 
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essential for the dimer formation with modified FANCD2. Furthermore, the dimer 
containing unmodified FANCD2 was extracted equally well in the presence and 
absence of benzonase, indicating that the ubiquitylation of FANCI might be required to 
stabilise the FANCD2/I dimer on the chromatin. 
 
 
 
 
Figure 4.16: Ectopically formed FANCD2/I dimer binds to the DNA in the absence of DNA 
damage 
 A) U2OS cells were transfected for 24h with wild type Flag-FANCI or the quadruple 
[S556A/D, S559A/D, S565A/D, S596A/D] Flag-FANCI phospho-mutants, which were either 
phospho-mimicking or phospho-dead. The cells were lysed in the presence or absence of 
benzonase, and Flag-tagged proteins were immunoprecipitated using anti-Flag beads. All 
indicated proteins were detected with specific antibodies. Cells expressing no Flag-tagged 
protein were used as negative control. 
 B) Same experimental setup as described in A, including the Flag-FANCI phospho-
mimicking or phospho-dead mutant, with the additional K523R mutation. 
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4.2.7.2 Attempt to increase the soluble pool of FANCD2/I dimer using a DNA-
binding deficient quadruple Flag-FANCI phospho-mimicking mutant 
We generated the quadruple mutant with two additional amino acid changes (K898E 
and K980E) at putative DNA binding region of FANCI (Joo et al., 2011), in an attempt 
to increase the dimers that are not targeted to the DNA. 
Figure 4.17 shows the Flag-FANCI immunoprecipitations performed in the presence 
and absence of benzonase. As described before, the overexpression of the quadruple 
phospho-mimicking mutant (4SD) led to increased dimer formation (Figure 4.17, 
compare lanes 6 and 7). The DNA binding mutations (2KE) had a negative effect on 
dimerization both alone and in combination with 4SD (Figure 4.17, compare lanes 6 
with 8 and 7 with 9). However, when comparing the results with and without 
benzonase, it appears that the 2KE mutants are still able to bind the DNA. We therefore 
cannot determine whether the defect in dimerization is due to partially defective DNA 
binding, or if the 2KE mutations directly affect dimerization. 
 
 
 
Figure 4.17: The DNA binding mutations (K898/K980) had a negative effect on FANCD2/I 
dimerization  
 U2OS cells were transiently transfected with wild type or different mutants of Flag-FANCI 
[4SD = S556D, S559D, S565D, S596D; 2KE = K898E K980E; 4SD/2KE: 4SD + 2KE]. The 
pellet was divided into two tubes and the cells lysed in the presence or absence of 750U/ml 
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benzonase. Flag-tagged proteins were immunoprecipitated with anti-Flag beads. Co-
immunoprecipitated proteins were detected with specific antibodies. Cells expressing no Flag-
tagged protein were used as negative control.  (top: IP, bottom: Lysate Input) 
 
 
Taken together, the results obtained with the quadruple Flag-FANCI mutants show that 
phosphorylation of the four serine residues S556D, S559D, S565D, S596D in human 
FANCI constitutively activate FANCD2 and induce FANCD2/I dimer formation in the 
absence of DNA damage. However, this artificially induced dimer was targeted to 
chromatin even in the absence of DNA damage. The additional mutations at putative 
DNA binding regions of FANCI caused a defect in FANCD2/I dimerization and 
therefore did not increase the soluble pool of FANCD2/I dimer. The increase in DNA-
bound dimer did not change UBXN8 binding to FANCI.  
 
4.2.8 Small changes in UBXN8 levels after release from double-thymidine block 
To analyse if UBXN8 levels are cell cycle regulated, cells were arrested in S-phase 
using a double thymidine block. After thymidine release, the cells were harvested at 
two-hour intervals for the next 18h (Figure 4.18). To monitor the cell cycle stages, a 
small fraction of cells were stained with propidium iodide and analysed by FACS. The 
rest of the cells were used to prepare protein extracts, which were analysed by Western 
blot. The detection of the phosphorylation of serine 10 in histone H3 was used as a 
mitosis marker. 
The FA proteins FANCD2 and FANCI showed a strong mono-ubiquitylation, due to the 
thymidine treatment, that gradually decreased after release as cells progressed through 
the cell cycle, and was not re-induced when cells re-entered S-phase (Figure 4.18). The 
increased levels of mono-ubiquitylated FANCD2 and FANCI were caused by 
thymidine, which is described to induce DNA damage response (Bolderson et al., 
2004). The total FANCD2 and FANCI levels in the cells seemed not to change during 
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the cell cycle. The increased levels of mono-ubiquitylated FANCD2 and FANCI after 
thymidine treatment are accompanied by reduced UBXN8 levels compared to 
asynchronised cells, or cells harvested at later time points (10–18h). This could suggest 
that UBXN8 levels are reduced upon DNA damage to allow the additional 
release/activation of repair proteins. Under non-damage conditions, normal UBXN8 
levels might be required to capture these proteins at the membrane. The p97 level did 
not change throughout the cell cycle. 
 
Figure 4.18: UBXN8 shows cell cycle dependent regulation   
U2OS cells were arrested in S-phase by using a double thymidine block. After releasing the 
cells from the arrest, cells were harvested at different time points for the next 18 hours. A small 
cell-fraction was stained with propidium iodide and analysed by FACS. The rest of the cells 
were used to prepare protein extracts. Phosphorylation of serine 10 in histone H3 was used as a 
mitotic marker.  
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Top: Western blot with protein extracts isolated from synchronized U2OS cells at different cell 
cycle stages. 
 Bottom: FACS analysis of the synchronized U2OS cells. The percentages of cells in the 
different cell cycle stages are indicated. 
 
 
4.2.9 Increased UBXN8 and FANCD2 interaction in cell populations with the highest 
percentage of cells in S-phase 
To address whether the interaction between UBXN8 and both FA proteins, FANCD2 
and FANCI, is cell cycle regulated, endogenous FANCD2 was immunoprecipitated 
from U2OS cells that were either arrested in G1-phase via serum starvation or in mitosis 
via nocodazole treatment (Figure 4.19). The optimisation for S-phase arrest with a drug 
that does not induce FANCD2/I activation/mono-ubiquitylation (as e.g. observed with 
thymidine) was still in progress while writing this thesis. 
The FANCD2 immunoprecipitations from asynchronised U2OS cells with the largest 
percentage of cells in S-phase might show the highest UBXN8/FANCD2 interaction.  
(Figure 4.19, compare lanes 2 with 3 and 4). This correlates with increased UBXN8 
levels in the lysate input compared to G1 and mitosis-arrested cells (Figure 4.19, 
compare lane 6 with lanes 7 or 8). This suggests that UBXN8 levels are higher during 
S-phase under non-damage conditions, compared to those in G1 and mitosis.  
During mitosis, only the interaction between unmodified FANCD2 and FANCI was 
detected (Figure 4.19, lane 4). Interestingly, the mitotic arrest led to the detection of two 
bands for UBXN8 in the extracts (Figure 4.19, lane 8), corresponding to full-length 
UBXN8 and a slower migrating form that could be phosphorylated UBXN8. Indeed, 
phosphorylation sites were identified for UBXN8 in phospho-proteome analyses of 
mitotic cells (Daub et al., 2008, Dephoure et al., 2008, Kim et al., 2011). FANCD2 co-
immunoprecipitated both forms of UBXN8. Furthermore, the binding pattern of 
UBXN8 to FANCD2 mimicked the binding of FANCD2 to unmodified FANCI, and 
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could indicate that UBXN8 binds unmodified dimer. However, it is also possible that 
UBXN8 was co-immunoprecipitated with monomeric FANCD2. 
The cells arrested in G1 showed a decreased interaction between FANCD2 and FANCI, 
as well as FANCD2 and UBXN8 compared to asynchronous cells (Figure 4.19, 
compare lanes 2 and 3). 
 
A 	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Figure 4.19: Increased UBXN8 and FANCD2 interaction in cell populations with the highest 
percentage of cells in S-phase 
FANCD2 was immunoprecipitated from U2OS that were either arrested in G1-phase via serum 
starvation, or mitosis via nocodazole treatment. Asynchronised cells (AS) were used as control. 
A) Immunoprecipitates and lysate inputs were analysed by Western blot using specific 
antibodies. 
B) FACS analysis of the described samples. 
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4.2.10 Coiled-coil domain in UBXN8 is required for the interaction with FANCD2 
and FANCI 
The transmembrane domain of UBXN8 is required for its membrane localization, while 
the UBX domain is required for its interaction with p97. Besides these two domains, 
UBXN8 harbours a predicted coiled-coil domain located close to the transmembrane 
domain. Coiled-coil domains are described as protein–protein interaction domains (Hu, 
2000) and I speculated whether it is required for FANCD2 and FANCI binding.  
I performed Flag-immunoprecipitations from U2OS cells transfected with wild type and 
Flag-UBXN8 Δ67–91 (Δcoil), lacking the coiled-coil domain. Interestingly, both FA 
proteins showed reduced binding to Flag-UBXN8 Δcoil, compared to wild type UBXN8 
(Figure 4.20), suggesting that the coiled-coil domain is required for UBXN8 interaction 
with FANCD2 and FANCI. In contrast, binding to p97 was not affected. 
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Figure 4.20: The coiled-coil domain of UBXN8 is required for the binding to FANCD2 and FANCI 
U2OS cells were transfected with either wild type Flag-UBXN8 or Flag-UBXN8 Δ67–91 
(Δcoil) and the Flag-tagged proteins were immunoprecipitated using anti-Flag beads. The 
immunoprecipitates were analysed by Western blot using specific antibodies. 
 
To exclude the possibility that the reduced interaction was due to protein 
mislocalisation, I performed immunofluorescence microscopy with Flag-UBXN8 Δcoil- 
transfected U2OS cells. 
Figure 4.21 shows that Flag-UBXN8 Δcoil, localized at the ER membrane and at the 
nuclear envelope, as described for wild type Flag-UBXN8. The reduced binding of 
Flag-UBXN8 Δcoil to FANCD2 and FANCI was therefore not due to changes in the 
subcellular localisation of UBXN8. 
 
 
 
Figure 4.21: The truncation of the coiled-coil domain in UBXN8 did not change its subcellular 
localization to the ER membrane and the nuclear envelope 
U2OS cells were transfected with Flag-tagged UBXN8 Δcoil and after 24h were processed 
for immunostaining. Flag-tagged proteins were detected with a anti-Flag antibody (green) 
and the nuclei stained using DAPI (blue). The scale bar represents 10 µm. 
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4.2.11 UBXN8 forms homodimers independent from its coiled-coil domain 
Size-exclusion chromatography (SEC) with bacterially-expressed and purified Flag-
UBXN8 aa67–270 (truncated transmembrane domain) was performed using a Superdex 
75 column (performed by Dr. R. Sundaramoorthy/Prof. T. Hughes laboratory). The 
analysis was done in reference to two protein standards, BSA (MW 66 kDa) and the 
DNA binding domain (DBD) of S. cerevisiae Chd1 (MW 25 kDa). The estimated 
theoretical molecular mass of Flag-UBXN8 (aa67–270) is approximately 24kDa. 
Therefore, the elution profile should be closer to ScChd1 DBD than to BSA. 
Interestingly, the elution profile of Flag-UBXN8 was closer to BSA than to ScChd1 
DBD (Figure 4.22), suggesting that Flag-UBXN8 forms a higher oligomer, possibly a 
dimer.  
 
 
Figure 4.22: UBXN8 forms a higher oligomer in vitro  
Gel filtration analysis with recombinant Flag-UBXN8 (performed by Dr. R. 
Sundaramoorthy). The gel filtration analysis was performed in reference to two protein 
standards, BSA (MW 66 kDa) and the DNA binding domain (DBD) of S. cerevisiae Chd1 
(MW 25 kDa). 
A) Gel filtration profile of bacterially-expressed and purified Flag-UBXN8 aa67–270. 
The fractions of the peak were run on a SDS-PAGE gel and stained with coomassie. 
B) Gel filtration profile of Flag-UBXN8 (blue) along with the two protein standards BSA 
(black) and Chd1 DBD (pink). 
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To determine the molecular weight of the Flag-UBXN8 oligomeric form, gel-filtration 
chromatography coupled to multi-angle light scattering (SEC-MALS) was performed. 
The molecular weight estimated using SEC-MALS was 49 kDa (Figure 4.23), 
suggesting that in vitro purified UBXN8 forms homodimer in solution. 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.23: UBXN8 forms homodimer in vitro 
SEC–MALS analysis of Flag-UBXN8. The elution profile of Flag-UBXN8 is drawn in red 
and the molar mass over elution peaks is shown in black. The molecular weight estimated 
using SEC-MALS was 49 kDa, suggesting that in vitro purified UBXN8 forms homodimers. 
 
To check, whether UBXN8 forms homodimer in cells, and whether this dimerization 
depends on its coiled-coil domain, I performed Flag-immunoprecipitations from U2OS 
cells co-transfected with wild type HA-UBXN8 and one of the following Flag-UBXN8 
variants: wild type Flag-UBXN8, truncated Flag-UBXN8 Δcoil that lacks the coiled-
coil domain, or the mutant Flag-UBXN8 P238G that is defective in p97 binding. The 
latter is used as control to exclude the possibility that HA-UBXN8 co-
immunoprecipitates due to binding to the same p97 hexamer. 
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Figure 4.24 shows that wild type Flag-UBXN8 as well as Flag-UBXN8 Δcoil co-
immunoprecipitated HA-UBXN8 (lane 2 and 3), and that reduced p97 binding did not 
affect this binding (lane 4). Hence, these results indicate that UBXN8 forms oligomers 
in cells, most likely dimers, but that its coiled-coil domain does not mediate this 
interaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24: UBXN8 forms homodimer independently from its coiled-coil domain in vivo 
Flag-immunoprecipitations were performed from U2OS cells co-transfected with wild type 
HA-UBXN8 and either wild-type Flag-UBXN8, truncated Flag-UBXN8 Δcoil or the mutant 
Flag-UBXN8 P238G that is defected in p97-binding. Flag-tagged proteins were 
immunoprecipitated using anti-Flag beads, and the immunoprecipitates were analysed by 
Western blot using specific antibodies. 
 
 
 
4.2.12 UBXN8 interacts with monomeric FANCD2 and FANCI in vitro 
To study whether the interaction between UBXN8 and the FA proteins is direct, I 
performed in vitro binding assays using recombinant human Flag-UBXN8 (without the 
transmembrane domain) and murine FANCD2 and FANCI (provided by Michael 
Hodskinson/KJ Patel laboratory).  
The in vitro binding assays were done by incubation of Flag-UBXN8 with increasing 
amounts of monomeric FANCD2 or FANCI. Flag-UBXN8 was immunoprecipitated 
using anti-Flag beads.  
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Figure 4.25 shows that Flag-UBXN8 incubated with monomeric FANCD2 or FANCI 
can bind either FA protein independently from each other (Figure 4.24). Furthermore, 
the interaction occurs even when there is ten times less monomeric FANCD2 or FANCI 
(Figure 4.24A/B, lane 3), suggesting a stable complex formation between UBXN8 and 
the two FA proteins. Furthermore, Flag-UBXN8 interacts with increasing amounts of 
FANCD2 or FANCI, up to a 1:1 ratio, indicating that one molecule of Flag-UBXN8 can 
bind one molecule of FANCD2 or FANCI. This means that, for dimeric Flag-UBXN8, 
one dimer harbours binding sites for two molecules of the FA proteins (Figure 4.25). 
Furthermore, UBXN8 shows no specific binding preferences for either FANCD2 or 
FANCI, since it co-immunoprecipitated both with similar efficiency. 
Taken together, UBXN8 can bind either FA proteins, FANCD2 or FANCI, 
independently from each other. 
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Figure 4.25: UBXN8 binds monomeric FANCD2 or FANCI independently  
The in vitro binding assays were performed by incubating Flag-UBXN8 with increasing 
amounts of monomeric FANCD2 (A) or FANCI (B). Flag-UBXN8 was 
immunoprecipitated using anti-Flag beads. The indicated proteins were detected by 
Western blot using specific antibodies. The cartoons below the Western blots show the 
binding scenarios between dimeric UBXN8 and monomeric FANCD2 or FANCI. 
 
 
4.2.13 Investigating the role of p97 in the interaction between UBXN8 and the FA 
proteins FANCD2 and FANCI  
The experiments described in section 4.2.6 revealed that upon release from DNA 
damage, the FANCI interaction with FANCD2 was reduced, which correlated with an 
increased in binding to p97. The ATPase p97 is described to be involved in the DNA 
damage response by extracting chromatin-bound proteins (Dantuma and Hoppe, 2012). 
Therefore, it is tempting to speculate that p97 might be required for FANCD2/I dimer 
dissociation from chromatin. Although, the increased p97 binding to FANCD2 upon 
DNA damage release was UBXN8 independent, I wanted to know whether p97 
regulates the interaction between UBXN8 and the FA proteins. 
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4.2.13.1 Preventing the UBXN8/p97 interaction causes an increased FANCI binding 
to UBXN8 under non-damage conditions 
To investigate if p97 regulates the interaction between UBXN8 and the two FA 
proteins, U2OS cells were transfected with either wild type Flag-UBXN8 or the mutant 
Flag-UBXN8 P238G. As shown in figure 4.24 (Section 4.2.11), the P238G mutation in 
the FPR motif nearly abolishes the interaction between UBXN8 and p97. 
The results of the Flag-immunoprecipitations show that the P238G mutant interacts 
with FANCI more strongly than wild type UBXN8 (Figure 4.26). In contrast, FANCD2 
binds wild type and mutant UBXN8 to a similar extent. Hence, p97 seemed to be 
especially required for the release of FANCI from UBXN8. 
Furthermore, the results suggest two scenarios: either that p97 dissociates monomeric 
FANCI from UBXN8, or that p97 dissociates the FANCD2/I dimers while bound to 
UBXN8. 
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Figure 4.26: p97-binding is required for dissociation of FANCI from UBXN8  
U2OS cells were transfected with Flag-UBXN8 wild type or the P238G mutant and grown for 
24h. Flag-tagged proteins were immunoprecipitated with anti-Flag beads. All indicated 
proteins were detected with specific antibodies. Cells expressing no Flag-tagged protein were 
used as negative control. (left: IP, right: Lysate Input) 
  
 
 
4.2.13.2 Preventing the UBXN8/p97 interaction causes an impaired FANCI release 
from the mutant Flag-UBXN8 P238G upon DNA damage 
The immunoprecipitation of wild-type Flag-UBXN8 and its mutant P238G indicated 
that preventing the UBXN8/p97 interaction caused an increased FANCI binding to 
UBXN8. 
The experiments described in section 4.2.4 show that FANCD2 and FANCI are released 
from UBXN8 upon DNA damage. To investigate whether the P238G mutant affects 
FANCD2 and FANCI release after DNA damage, the experiment was repeated with 
U2OS cells stably expressing wild type Flag-UBXN8 or the P238G mutant under a 
tetracycline-inducible promoter in the presence or absence of DNA damage. For this 
experiment, tetracycline-inducible cells were used instead of transfection, because 
transfection in combination with cisplatin treatment reduced cell viability (data not 
shown). 
Figure 4.27A shows that FANCD2 and FANCI were released from wild type UBXN8 
upon DNA damage. The FANCI release from the UBXN8 mutant was impaired 
compared to wild type Flag-UBXN8 (compare Figure 4.27A, lanes 3 and 4 with 4.27B, 
lanes 3 and 4). This suggests that p97 binding to UBXN8 is particularly important for 
FANCI release upon DNA damage.  
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Figure 4.27: Upon DNA damage, the release of FANCI from Flag-UBXN8 P238G is impaired 
Wild type Flag-UBXN8 or the P238G mutant were immunoprecipitated from tetracycline-
inducible U2OS cells and were either untreated or treated with 3 µM cisplatin (24h). The 
expression was induced by adding 0.5 µg/ml tetracycline to the cells. Uninduced U2OS cells 
were used as control. Flag-tagged proteins were immunoprecipitated with anti-Flag beads. Co-
immunoprecipitated proteins were detected with specific antibodies (left: IP, right: Lysate 
Input). 
 
PART III – The role of UBXN8 in regulating the DNA damage response and the 
FA proteins FANCD2 and FANCI 
The data presented so far, illustrate that UBXN8 interacts with FANCD2 and FANCI 
and that both FA proteins are partially released from UBXN8 upon DNA damage. 
Furthermore, in vitro binding assays with the recombinant proteins show that UBXN8 
can directly interact with FANCD2 and FANCI. However, since UBXN8 can form 
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homodimers it may also interact with FANCD2/I heterodimers. Super resolution 
microscopy showed that a small fraction of Flag-UBXN8 localises at the inner nuclear 
membrane, which suggests that UBXN8 interaction with FANCD2 and FANCI may 
occur at the inner nuclear membrane. 
The experiments in the following section address the role of UBXN8 in regulating the 
activation and the interaction of the FA proteins FANCD2 and FANCI. 
 
4.2.14 UBXN8 depletion increases U2OS cell resistance to ICL-inducing reagents  
In order to understand whether UBXN8 affects the DNA damage response to ICL, I 
performed clonogenic survival assays with wild type and UBXN8-depleted cells upon 
treatment with mitomycin C (MMC) or cisplatin (Figure 4.28). These agents induce ICL 
that are recognized and repaired by the FA pathway.  
For the clonogenic survival assay, U2OS cells were transfected with siRNA (UBXN8 
♯1 and ♯2) specifically targeting UBXN8. Luciferase siRNA was used as a negative 
control. The depletion of FAN1, a DNA repair nuclease recruited to DNA damage sites 
by mono-ubiquitylated FANCD2, was used as positive control (MacKay et al., 2010). 
After 48h of siRNA treatment, the cells were seeded at low density and treated with 
varying drug concentrations. Twenty-four hours after treatment, the medium was 
changed to drug-free medium and cells were grown for a further eight days to allow 
colony formation of the surviving cells. 
The clonogenic survival assays with MMC and cisplatin were repeated in three 
independent experiments, each performed in triplicate. The results of the assays show 
that UBXN8 silencing caused increased cell survival compared to luciferase siRNA 
transfected cells (Figure 4.28). Thus, UBXN8 silencing increases resistance to ICL-
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inducing agents compared to control cells. These results suggest that UBXN8 acts as a 
negative regulator of the DNA damage response. 
 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28: UBXN8 depletion causes an increasd cell resistance to ICL-inducing agents  
 A) U2OS cells, transfected with indicated siRNAs, were seeded at low density and were 
treated for 24 h with different concentration of mitomycin (A) or cisplatin (B). The medium 
was changed to drug-free medium 24h after treatment and the cells were grown for a further 
eight days to allow colony formation of surviving cells. Cell survival was assessed by a 
colorimetric assay using Giemsa stain. Colonies with more than 50 cells were counted. For 
each siRNA-treated sample, cell viability of untreated cells was set as 100%. Each data point 
indicates the mean value ± standard deviation. 
Only small fractions of silenced cells were used for the clonogenic survival assay, and the 
remainder of the cells were harvested and cell extracts were prepared. The extracts were 
analysed by Western blot using specific antibodies to confirm the successful silencing of the 
proteins (right panels). 
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4.2.15 UBXN8 silencing causes an increase in FANCD2 and FANCI mono-
ubiquitylation 
To analyse whether depletion of UBXN8 alters FANCD2 and/or FANCI levels or their 
mono-ubiquitylation in the presence and absence of DNA damage, total cell extracts 
were prepared from U2OS cells treated with two different UBXN8 siRNA 
oligonucleotides (♯1 and ♯2) (Figure 4.29). After 48 h siRNA treatment, the cells were 
incubated for additional 24h with cisplatin and were harvested after 0, 12, 16, 20 and 24 
hours. Cells transfected with luciferase siRNA (Luc) were used as a negative control. 
The changes in FANCD2 and FANCI levels were quantified using the LI-COR imaging 
system/software. 
UBXN8 silencing of UBXN8 was efficient with both UBXN8 siRNAs (Figure 4.29). 
The depletion of UBXN8 caused a reduction in the levels of non-ubiquitylated 
FANCD2 and FANCI throughout the time course, compared to control cells treated 
with luciferase siRNA. This was accompanied by a slight increase in the ubiquitylated 
form of FANCD2 and FANCI compared to control cells (Figure 4.29, compare Luc 
with UBXN8si ♯1 and ♯2 for each time point). However, the decrease in the levels of 
the non-ubiquitylated FA proteins was not equivalent to the increase in their 
ubiquitylated form. This is likely due to an incomplete extraction of DNA-bound 
modified FANCD2 and FANCI. 
The results were confirmed in three independent experiments. The band intensities of 
the lower (non-ubiquitylated) and upper (mono-ubiquitylated) bands of FANCD2 and 
FANCI were quantified for each time point and the ratio of ubiquitylated (Ub) /non-
ubiquitylated (non-Ub) was calculated. The mean value for the ratios from all three 
experiments was plotted, and the standard deviation is shown as error bars (Figure 29B). 
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Furthermore, the calculation of the p-value (indicated with stars) confirmed that the 
obtained results are statistically significant. 
Taken together, these results suggest that depletion of UBXN8 affects the modification 
state of FANCD2 and FANCI, by increasing the ratio of ubiquitylated over non-
ubiquitylated FANCD2 and FANCI in the presence and absence of DNA damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure 4.29: UBXN8 silencing causes an increase in the ratio of modified/unmodified FANCD2 
and FANCI 
Total cell extracts were prepared from U2OS cells treated with two different UBXN8 siRNA 
oligonucleotides (♯1 and ♯2). Luciferase siRNA (Luc) was used as negative control. After 
48h siRNA treatment, 3 µM cisplatin was added for an additional 24h. Cells were harvested at 
the indicated time points and protein extracts were prepared. 
A) The protein extracts were analysed by Western blot using specific antibodies. The detection 
of FANCD2 and FANCI was performed with a fluorophore-conjugated secondary antibody 
and the bands were visualized using the LI-COR imaging system. The intensities of the upper 
(Ub) and lower (non-Ub) bands for FANCD2 and FANCI were quantified. Ub/non-Ub 
indicates the ratio of the mono-ubiquitylated over non-ubiquitylated FANCD2 and FANCI. 
Tubulin is shown as loading control. 
(B) The Ub/non-Ub ratios from three independent experiments were combined and the mean 
value for each time point was plotted. The error bars indicate the standard deviations. The 
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asterisks indicate the statistical significance of the mean differences as calculated by t-test: * = 
statistically significant (p < 0.05), ** = very statistically significant (p < 0.01, *** = extremely 
statistically significant (p < 0.001), NS = not significant (p  > 0.05) 
 
 
 
4.2.16 UBXN8 silencing increases FANCD2/I dimer formation 
UBXN8 silencing increases the shift of both FA proteins from their non-ubiquitylated to 
their mono-ubiquitylated state. The modification of FANCD2 requires FANCI and 
suggests that mono-ubiquitylation requires their prior dimerization (Sato et al., 2012b). 
Therefore, I wanted to analyse whether the increase in modified FA proteins upon 
UBXN8 silencing had any effect on FANCD2/I dimerization under normal and DNA 
damage conditions.  
To address this question, I immunoprecipitated endogenous FANCD2 from wild type 
and UBXN8-silenced U2OS cells, using anti-FANCD2 antibodies. The silencing of 
UBXN8 was performed with two oligonucleotides (♯1 and ♯2) as before. 
Figure 4.30A shows that UBXN8 silencing increased the FANCD2/I dimer formation 
both under normal conditions (compare lanes 2 with 3 and 4), and upon DNA damage 
(compare lanes 5 with 6 and 7). The levels of FANCD2 and FANCI in the 
immunoprecipitates were quantified using the LI-COR imaging system/software.  
FANCI levels were normalised to account for minor differences in the amount of 
FANCD2 immunoprecipitated. The value for luciferase was set at one, and the values 
for the UBXN8 silencing were reported relative to it. This allows comparison of the 
data from three independent experiments. The mean value of the three independent 
experiments was plotted (Figure 4.30B). The standard deviation is shown as error bars. 
Furthermore, the calculated p-values indicate that the results were statistically 
significant. 
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The results show that the upshift of FANCD2 and FANCI caused by UBXN8 silencing 
in the extracts correlates with an increased dimer formation between the two FA 
proteins. Although, the increase of modified FANCD2 and FANCI was not very marked 
in the extracts, as discussed in section 4.2.15, the extracts of the IPs clearly showed that 
the decrease of the non-ubiquitylated FA proteins upon UBXN8 silencing causes an up-
shift to their mono-ubiquitylated state (Figure 30A, see Lysate Inputs). The better 
extraction of the FA proteins in this case could be due to lysis in a larger volume that 
allows the continuous rotation during cell lysis, resulting in better access of benzonase 
to DNA. 
 
 
B 
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Figure 4.30: UBXN8 silencing increases FANCD2/I dimer formation under normal and DNA-
damage conditions 
A) Endogenous FANCD2 was immunoprecipitated from U2OS cells that were depleted for 
UBXN8 using two independent oligonucleotides (♯1 and ♯2) and untreated or treated with       
3 µM cisplatin [24h]. The immunoprecipitations were performed using anti-FANCD2 
antibodies and protein A-Sepharose beads. Naked protein A-Sepharose beads incubated with 
extract were used as control. The immunoprecipitates and lysate inputs were analysed by 
Western blot using the indicated antibodies. The asterisk marks an unspecific band detected by 
the FANCI antibodies (left: IP, right: Lysate Input). 
 B) The detection of FANCD2 and FANCI in the immunoprecipitates was also performed with 
the LI-COR imaging system using fluorophore-conjugated secondary antibodies. The bands 
were quantified and the normalized FANCI levels relative to the luciferase control were 
calculated. The graphs shown in B represent the mean value of ‘normalized FANCI levels 
relative to the Luciferase control’ from three independent experiments. The error bars represent 
the standard deviation. The asterisks indicate the statistical significances of the means as 
calculated by t-test: * = statistically significant (p < 0.05), ** = very statistically significant 
(p < 0.01), *** = extremely statistically significant (p < 0.001) 
 
4.2.16.1 UBXN8 silencing does not alter cell cycle progression 
The FA proteins FANCD2 and FANCI are mono-ubiquitylated/activated during S-
phase, resulting in their dimerization and localisation to ICL (Taniguchi et al., 2002, 
Smogorzewska et al., 2007). Therefore, to exclude the possibility that the increased 
dimer formation of FANCD2/I observed upon UBXN8 silencing is due to a defect in S-
phase progression, the samples of the immunoprecipitations discussed above were 
analysed by FACS. 
The FACS profiles of this analysis are shown in figure 4.31 and revealed that the 
changes observed in FANCD2 and FANCI dimer formation, upon UBXN8 silencing, 
were not due to altered cell cycle progression. 
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Figure 4.31: UBXN8 silencing did not alter cell cycle progression 
FACS analysis with the samples of the endogenous FANCD2 immunoprecipitation described in 
figure 4.30. The percentage of cells for the different cell cycle stages is shown. 
 
 
4.2.17 UBXN8 silencing increases FANCD2 foci formation 
FANCD2 and FANCI are mono-ubiquitylated in response to DNA damage, resulting in 
their localisation to nuclear foci at the DNA damage sites (Smogorzewska et al., 2007). 
Furthermore, in vitro experiments show that mono-ubiquitylation of the FANCD2/I 
dimer is stimulated by DNA (Longerich et al., 2014). 
To address whether the excess FANCD2/I dimers observed upon UBXN8 silencing 
affects foci formation, I performed immunofluorescence microscopy with wild type and 
UBXN8 silenced U2OS cells in the presence and absence of DNA damage. The cells 
were stained for endogenous FANCD2. To reduce background staining, the soluble 
nuclear proteins were pre-extracted prior to staining. The number of FANCD2 foci per 
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cell was determined using the analysis software Imaris. For each condition, 
approximately 100 cells were analysed. 
The results of the immunofluorescence experiment are shown in figure 4.32. The 
distribution plots created represent the percentage of cells that correspond to each foci 
number interval (Figure 4.32). 
Under non-treatment conditions, approximately 74% of cells treated with luciferase 
siRNA had below 40 foci per cell, while the majority of UBXN8-silenced cells had 
more than 40 foci per cell (60% for UBXN8 ♯1 and 69% for UBXN8 ♯2; Figure 
4.32A). The validation of the number of foci upon DNA damage showed that 
approximately 60% of cells treated with luciferase siRNA had below 110 foci per cell, 
while the UBXN8 silenced cells had more than 110 foci per cell (app. 66% for UBXN8 
♯1 or UBXN8 ♯2; Figure 4.32B). These results suggest that U2OS cells silenced for 
UBXN8 have more foci per cell, both under normal conditions and upon DNA damage, 
than control cells. Furthermore, the results obtained without damage suggest that the 
ectopically formed dimer caused by UBXN8 silencing localises to chromatin even in 
the absence of ICLs. 
Since I did not have antibodies for endogenous UBXN8 that work for microscopy, cells 
were harvested to confirm the UBXN8 silencing by Western blot (Figure 4.32C). The 
extracts in figure 4.32C show that the UBXN8 silencing was very efficient; therefore it 
is safe to assume that UBXN8 was depleted in most of the cells. 
The results obtained suggest that the availability of more FANCD2/I dimer that can be 
targeted to the DNA damage sites might explain the increased resistance of UBXN8- 
silenced cells to ICL-inducing agents, compared to control cells. 
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Figure 4.32: UBXN8 silencing stimulates FANCD2 foci formation  
U2OS cells were seeded on coverslips and were silenced for UBXN8 using two different 
siRNA oligonucleotides (♯1 and ♯2). The silencing was performed for 72h. To induce ICLs, 
cells were treated with 3 µM cisplatin for 24h, added after 48h of siRNA transfection. 
Luciferase siRNA (Luc) transfected cells were used as negative control.  
To analyse the FANCD2 foci number, non-chromatin bound proteins were pre-extracted and 
the cells were fixed and stained for endogenous FANCD2 using a specific anti-FANCD2 
antibody. The images were taken with a DeltaVision deconvolution microscope (100x lens) 
and the number of foci in each cell determined using the Imaris software. For each condition, 
approximately 100 cells were analysed. 
A-B) Graphs show the percentage of cells for each foci number interval. 
C) To show that the silencing was successful, cell were seeded into additional wells without 
coverslips and treated as described. The extracts were then analysed by Western blot using the 
indicated antibodies. 
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4.2.18 UBXN8 overexpression causes an increase in the level of unmodified FANCI  
UBXN8 silencing results in increased levels of modified FANCD2 and FANCI, which 
correlates with increased FANCD2/I dimer and FANCD2 foci formation in the presence 
and absence of DNA damage. Therefore, I wanted to know whether UBXN8 
overexpression might have the opposite effect. 
The FANCD2 and FANCI levels were analysed in total cell extracts obtained from 
U2OS cells expressing Flag-UBXN8 from a tetracycline-inducible promoter (Figure 
4.33). As negative control, I used tetracycline-inducible U2OS cells with integrated 
empty vector and tetracycline-inducible U2OS cells expressing Flag-VAPB. Like 
UBXN8, VAPB is an ER protein and was included to help assess non-specific changes 
due to protein overexpression. After 12h of induction/overexpression, cells were 
incubated for additional 12h with cisplatin and were harvested at 0, 4, 8 and 12 hours 
(Figure 4.33). A shorter cisplatin treatment was chosen, since the upshift to mono-
ubiquitylated FANCD2 and FANCI reaches its plateau at 12 hours of treatment. 
Furthermore, the Flag-UBXN8 levels decreased dramatically after 24h induction/12h of 
DNA damage (Figure 4.33). However, the decrease of Flag-UBXN8 was not due to the 
DNA damage, since it was also observed under normal conditions (data not shown). 
The Western blots for FANCD2 and FANCI were developed and quantified using the 
LI-COR imaging system/software, as before. 
Figure 4.33A shows that Flag-UBXN8 overexpression led to increased levels of 
unmodified FANCI in the extracts collected at the indicated time points. The increased 
levels of unmodified FANCI were accompanied by a slight decrease in the ubiquitylated 
form, compared to control cells. Hence, the results obtained for FANCI upon UBXN8 
overexpression show the opposite effect to that observed upon UBXN8 silencing. The 
combined quantification of three independent experiments and the calculation of the p-
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values illustrate that these changes are statistically significant (Figure 4.33B). UBXN8 
overexpression also caused slightly reduced levels of mono-ubiquitylated-FANCD2 
compared to control cells, but the changes observed are not statistically significant, 
except for the 4h time point (Figure 4.33A). This might indicate a stronger regulation of 
UBXN8 on FANCI than FANCD2. The tetracycline-inducible Flag-VAPB cells did not 
show changes in the FANCD2 or FANCI modifications compared to control cells.  
These results suggest that Flag-UBXN8 overexpression affects mainly FANCI, by 
shifting the balance from mono-ubiquitylated to non-ubiquitylated FANCI under 
normal and DNA damage conditions. 
 
 
 
B  
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Figure 4.33: UBXN8 overexpression causes a decrease in the levels of modified FANCI  
Total cell extracts were prepared from tetracycline-inducible U2OS cells expressing either 
Flag-UBXN8 or Flag-VAPB. VAPB as well as U2OS cells with integrated empty vector were 
used as negative controls. After 12h induction with 0.5 µg/ml tetracycline, cells were treated 
with 3 µM cisplatin for an additional 12h. Cells were harvested at the indicated time points and 
protein extracts were prepared. 
A) The protein extracts were analysed by Western blot using specific antibodies. The detection 
of FANCD2 and FANCI was performed with a fluorophore-conjugated secondary antibody 
and the bands were visualized using the LI-COR imaging system. The intensities of the upper 
(Ub) and lower (non-Ub) bands for FANCD2 and FANCI were quantified. Ub/non-Ub 
indicates the ratio of the mono-ubiquitylated to non-ubiquitylated forms of FANCD2 and 
FANCI. Tubulin is shown as loading control. 
(B) The Ub/non-Ub ratios of three independent experiments were combined and the mean 
values were plotted for each time point. The error bars represent the standard deviation of the 
means. The asterisks indicate the statistical significances of the differences as calculated by t-
test: * = statistically significant (p < 0.05), NS = not significant (p  > 0.05) 
 
 
4.2.19 UBXN8 overexpression decreases FANCD2/I dimer formation  
The analysis of cell extracts obtained from Flag-UBXN8 overexpressing cells showed 
increased levels of unmodified FANCI. To investigate whether this results in changes in 
FANCD2/I dimer formation, I performed immunoprecipitation of endogenous 
FANCD2 from U2OS cells expressing Flag-UBXN8 from a tetracycline-inducible 
promoter, under normal and DNA damage conditions.  
Figure 4.34A shows the endogenous FANCD2 immunoprecipitation from undamaged 
cells. Upon Flag-UBXN8 overexpression, the lysate inputs show reduced levels of 
modified FANCD2 and FANCI (compare lanes 10 and 11), which correlates with a 
slight decrease in FANCD2/I dimer formation in the immunoprecipitates, compared to 
that in the control cells (compare lanes 4 and 5). The levels of FANCD2 and FANCI in 
the immunoprecipitates were quantified and the FANCI levels normalised, as previously 
described, to account for minor differences in the amount of FANCD2 
immunoprecipitated. The experiment was performed twice, and the mean value of the 
two experiments was plotted in Figure 4.34A (right panel). The calculated p-values 
show that the changes observed between Flag-UBXN8 overexpressing cells and control 
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cells in the absence of DNA damage were statistically significant. Although Flag-VAPB 
overexpression did not change FANCD2 and FANCI modifications in the cell extracts, 
FANCD2/I dimer formation was moderately reduced in Flag-VAPB overexpressing 
cells compared to control cells. Therefore, taking the changes due to overexpression 
into account, the clear reduction in dimer formation observed upon Flag-UBXN8 
overexpression might actually be less pronounced than indicated. However, it must be 
noted that the expression levels of Flag-VAPB are much higher compared to Flag-
UBXN8 (compare levels in the anti-Flag Western blot). 
The FACS profiles of this analysis are shown in figure 4.34B and revealed that the 
changes observed in FANCD2/I dimer formation upon UBXN8 overexpression were 
not due to altered cell cycle progression. 
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Figure 4.34: UBXN8 overexpression causes a decrease in FANCD2/FANCI dimer formation in the 
absence of DNA damage  
A) Endogenous FANCD2 was immunoprecipitated from tetracycline-inducible U2OS cells 
expressing either Flag-UBXN8 or Flag-VAPB. VAPB as well as U2OS cells with integrated 
empty vector were used as negative controls. Immunoprecipitations were performed 24h after 
induction using anti-FANCD2 antibodies and protein A-Sepharose beads. Naked protein A-
Sepharose beads incubated with extracts from tetracycline-induced cells were used as a 
negative control. The immunoprecipitates and lysate inputs were analysed by Western blot 
using the indicated antibodies (left). 
 The detection of FANCD2 and FANCI in the immunoprecipitates was additionally performed 
with the LI-COR imaging system using fluorophore-conjugated secondary antibodies. The 
bands were quantified and the FANCI levels normalized relative to the luciferase control. The 
graphs shown in the right panel represent the means of ‘normalized FANCI levels relative to 
the luciferase control’ from two independent experiments. The error bars represent the standard 
deviation. The asterisks indicate the statistical significances in means as calculated by t-test: * 
= statistically significant (p < 0.05), ** = very statistically significant (p < 0.01) (right). 
B) Samples discussed in panel A were analysed by FACS. The FACS profiles as well as the 
percentage of cells for the different cell cycle stages are shown for each condition. 
 
 
Figure 4.35A shows the endogenous FANCD2 immunoprecipitation from DNA 
damaged U2OS cells. Similarly to the results obtained without DNA damage, Flag-
UBXN8 overexpression caused a decrease in FANCD2/I dimer formation compared to 
control cells. The corrections of FANCI levels to account for minor differences in the 
levels of immunoprecipitated FANCD2 were performed as described (Figure 4.35A, 
right panel). In contrast, the overexpression of Flag-VAPB (again much higher 
expression levels than with Flag-UBXN8) did not change the FANCD2/I dimer 
formation compared to control cells. 
The FACS profiles of this analysis are shown in figure 4.35B, and confirmed that the 
changes observed in FANCD2/I dimer formation upon DNA damage in the presence of 
UBXN8 overexpression were not due to altered cell cycle progression. 
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Figure 4.35: UBXN8 overexpression causes a decrease in FANCD2/I dimer formation in the 
presence of DNA damage    
A) Endogenous FANCD2 was immunoprecipitated from tetracycline-inducible U2OS cells 
expressing either Flag-UBXN8 or Flag-VAPB. VAPB as well as U2OS cell with integrated 
empty vector were used as negative controls. After 12h induction with 0.5 µg/ml tetracycline, 
the cells were treated with 3 µM cisplatin for an additional 24h. To maintain Flag-UBXN8 
levels, the cells were reinduced with 0.5 µg/ml tetracycline after 12h cisplatin treatment. 
Immunoprecipitations were performed 24h after DNA damage using anti-FANCD2 antibodies 
and protein A-Sepharose beads. Naked protein A-Sepharose beads incubated with extract from 
tetracycline-induce cells were used as a control. The immunoprecipitates and lysate inputs 
were analysed by Western blot using the indicated antibodies (left). 
 The detection of FANCD2 and FANCI in the immunoprecipitates was additionally performed 
with the LI-COR imaging system using fluorophore-conjugated secondary antibodies. The 
bands were quantified and the normalized FANCI levels relative to the luciferase control were 
plotted. 
B) Samples discussed in panel A were analysed by FACS. The FACS profiles as well as the 
percentage of cells for the different cell cycle stages are shown for each condition. 
  
 
 
Taken together, UBXN8 silencing shifted the balance of FANCD2 and FANCI from 
their non-ubiquitylated to their mono-ubiquitylated state, and this correlates with 
increased FANCD2/I dimer and FANCD2 foci formation. The results obtained with 
Flag-UBXN8 overexpression showed the opposite effect by reducing FANCI mono-
	  	  	  	  
142	  
ubiquitylation and FANCD2/I dimer formation. Hence, these results indicate that 
UBXN8 controls the balance between modified and unmodified FANCD2 and FANCI 
in the presence and absence of DNA damage. 
 
4.2.20 UBXN8 reduces FANCD2/I mono-ubiquitylation in vitro 
The experiments discussed in the previous section indicate that UBXN8 has a negative 
regulatory effect on the mono-ubiquitylation of FANCD2 and FANCI. 
To investigate whether UBXN8 directly affects the FANCD2/I mono-ubiquitylation, I 
performed in vitro ubiquitylation assays with recombinant proteins. Jennifer Miles, 
from Helen Walden’s laboratory, provided the protocol as well as the protein 
preparations of Xenopus laevis FANCD2 and Xenopus tropicalis FANCL (E3 ligase).  
For the ubiquitylation assay, FANCD2 and FANCI were used either individually or 
mixed together in equimolar ratios to form dimers (Figure 4.36). These were incubated 
with UBE1 as E1, UBE2T as E2, FANCL as E3 and HA-ubiquitin. Parallel reactions 
were performed with an up to 20-fold excess of human Flag-UBXN8 (without the 
transmembrane domain) over substrates, and corresponded to a 2.5 times excess of 
FANCL (Figure 4.36).  
Figure 4.36 shows the HA-ubiquitin blots of the experiments. Interestingly, the mono-
ubiquitylation of FANCD2 and FANCI, both individually and as part of a dimer, was 
gradually reduced upon incubation with increasing amounts of Flag-UBXN8. This 
indicates that UBXN8 might directly inhibit the mono-ubiquitylation of FANCD2 and 
FANCI in their monomeric state or in the FANCD2/I heterodimer.  
An inhibitory effect of wild-type Flag-UBXN8 on FANCD2 and FANCI mono-
ubiquitylation in vitro is consistent with my data showing that UBXN8 overexpression 
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reduces FANCI mono-ubiquitylation in cells, while UBXN8 silencing causes an 
increase in the level of FANCD2 and FANCI modifications. 
 
 
Figure 4.36: UBXN8 reduces the mono-ubiquitylation of monomeric and dimeric FANCD2/I in 
vitro  
 The in vitro ubiquitylation assays were performed by incubating X. laevis FANCD2 and 
FANCI were used either individually or mixed together in equimolar ratios to form dimers. 
These were incubated with human UBE1 as E1, human UBE2T as E2, X. tropicalis FANCL as 
E3 and HA-ubiquitin. Parallel reactions were performed with up to 20 fold excess of human 
Flag-UBXN8 (without the transmembrane domain) over substrates and corresponded to 2.5 
times excess to FANCL FANCD2 and FANCI either individually or mixed together in 
equimolar ratios with the E3 ligase FANCL. Parallel reactions were performed with increasing 
molar ratios of human Flag-UBXN8 wild type. The reactions were incubated for 1.5h at 26°C 
and were stopped by adding SDS buffer. The mono-ubiquitylations of FANCD2 and FANCI 
were analysed by Western blot using anti-HA antibodies to detect HA-ubiquitin. Flag-UBXN8 
was detected using anti-Flag antibodies. The molar ratios of UBXN8 to the FA protein 
substrates are indicated. 
 
 
Interestingly, performing the ubiquitylation assays with the FANCD2/I mixtures 
containing the phospho-mimicking mutant FANCI 4SD (described in section 4.2.7.1) 
completely abolished the mono-ubiquitylation of FANCD2 and FANCI (Figure 4.37). 
This was surprising, since the overexpression of this mutant in cells induced the mono-
ubiquitylation of FANCD2 in the absence of DNA damage. A possible explanation for 
this result could be that FANCD2 and the phospho-mimicking mutant of FANCI form 
such a tight dimer that it prevents the ubiquitylation of the proteins in vitro. The 
structure of the FANCD2/I dimer shows that the ubiquitylation sites are embedded 
within the interface between the FA proteins and that it requires a conformational 
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change of the dimer to allow modification with ubiquitin (Joo et al., 2011). In cells, this 
could be facilitated through binding to DNA, which is shown to stimulate mono-
ubiquitylation on FANCD2 and FANCI within the dimer (Longerich et al., 2014).  
Additionally, the experiment with the FANCI 4SD mutant shows that by merely 
incubating FANCD2 and FANCI together, they can form heterodimers in our reactions. 
Otherwise, if FANCD2 exists as monomer it would be mono-ubiquitylated.  
 
 
Figure 4.37: Phospho-mimicking FANCI abolishes the mono-ubiquitylation of FANCD2 in vitro  
The in vitro ubiquitylation assays were performed by incubating X. laevis FANCD2 with wild 
type FANCI or its phospho-mimicking mutant (4SD), in equimolar ratios, to form dimers. For 
the ubiquitylation reaction, I used UBE1 as E1, UBE2T as E2, FANCL as E3 and HA-
ubiquitin. Parallel reactions were performed with up to 20-fold excess human Flag-UBXN8 
over substrates. The reactions were incubated for 1.5h at 26°C and were stopped by adding 
SDS buffer. The mono-ubiquitylation of FANCD2 and FANCI was analysed by Western blot 
using anti-HA antibodies. Flag-UBXN8 was detected using anti-Flag antibodies. The molar 
ratios of UBXN8 to the FA protein substrates are indicated. 
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4.6 Discussion 
The UBX-only protein UBXN8 is an ER membrane protein that binds p97 via its UBX 
domain. UBXN8 is required for ER-associated degradation of misfolded proteins by 
tethering p97 at the ER membrane (Madsen et al., 2011). Furthermore, a recent 
publication introduced UBXN8 as a target gene for HBV integration, and implicated 
UBXN8 as a new tumour suppressor candidate (Li et al., 2014). 
The analysis of Flag-UBXN8 immunoprecipitates by MS identified several DNA 
damage-related proteins as potential UBXN8 interaction partners, including FANCD2 
and FANCI (ICL repair), BRAT1, RIF1, and the three components of the TTT complex 
Telo2, TTI1 and TTI2 (DSB repair). These interactions raised the possibility that 
UBXN8 has a broader role in the DNA damage response. 
The identification of the two key FA proteins, FANCD2 and FANCI, in Flag-UBXN8 
immunoprecipitates may link UBXN8 to the rare genetic disease FA that is caused by 
defects in the ICL repair. Therefore, the aim of this project was to investigate the 
interaction between UBXN8 and the FA proteins FANCD2 and FANCI, to shed light on 
the functional relevance of these interactions, as well as to gain a better understanding 
of the role of UBXN8 in the DNA damage response. 
 
4.6.1 UBXN8 captures unmodified FANCD2 and FANCI away from the DNA 
I showed that full-length UBXN8 interacts with non-ubiquitylated FANCD2 and 
FANCI, and that both proteins are released from UBXN8 in the presence of DNA 
damage. This suggests that UBXN8 binds both FA proteins in their inactive state in the 
absence of DNA damage. These interactions were confirmed between the endogenous 
proteins. Furthermore, in vitro binding assays showed that UBXN8 can bind both FA 
proteins, FANCD2 and FANCI directly and independently from each other. However, I 
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was unable to clarify whether UBXN8 can also interact with heterodimeric FANCD2 
and FANCI. A SEC-MALS (Size-exclusion chromatography and multi angle light 
scattering) experiment with recombinant Flag-UBXN8 and co-purified FANCD2/I 
heterodimer might answer this question, and is currently in progress. 
The immunoprecipitations with each of the Flag-UBXN8 isoforms show that only the 
membrane-anchored isoforms 1 and 2 interact with FANCD2 and FANCI, suggesting 
that the membrane localization of UBXN8 is important for its interaction with both FA 
proteins. Furthermore, the in vitro binding assays performed with Flag-UBXN8 lacking 
the transmembrane domain showed a stable complex formation between UBXN8 and 
monomeric FANCD2 or FANCI, implicating that the transmembrane region is not 
required for the interaction. 
The subcellular localization of UBXN8 was analysed in HeLa cells using 
immunofluorescence microscopy. The images obtained confirmed the ER localisation 
of full-length Flag-UBXN8 as described by Madsen et al. (2012). Furthermore, I 
observed that a fraction of Flag-UBXN8 distinctly localised at the nuclear envelope. By 
using OMX structured illumination microscopy, I showed that a small fraction of 
UBXN8 localises inside the nucleus to the inner nuclear membrane. Because FANCD2 
and FANCI are mainly nuclear-localised (Smogorzewska et al., 2007, Garcia-Higuera et 
al., 2001), the inner nuclear membrane could be the actual site of interaction between 
UBXN8 and both FA proteins. The small fraction of nuclear localised UBXN8 would 
only be able to bind a small pool of FANCD2 and FANCI, and could explain why only 
minor fractions of these proteins interact. 
However, my first attempts to show co-localisation between UBXN8 and FANCD2 
using microscopy were not successful and require further improvement of the 
experimental setup. Alternatively, Flag-UBXN8 immunoprecipitation or size 
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fractionation (using SEC) from nuclear cell fractions could be performed to investigate 
whether UBXN8 interacts with FANCD2 and FANCI in the nucleus. 
 
4.6.2 The coiled-coil domain in UBXN8 is required for the interaction with FANCD2 
and FANCI 
Full-length UBXN8 contains a transmembrane domain at the N-terminus, followed by a 
predicted coiled-coil region, and a UBX domain at the C-terminus. It has been shown 
that the transmembrane domain anchors UBXN8 at the ER membrane, while the UBX 
domain mediates its interaction with the N-terminus of p97 (Madsen et al., 2011).  
Coiled-coil domains are, in general, described as mediating protein-protein interactions. 
However, the function of the predicted coiled-coil region in UBXN8 was unknown. 
My results show that UBXN8 forms a homodimer in vitro, and in cells, independent 
from its coiled-coil domain. However, the truncation of this region nearly abolished 
UBXN8 binding to FANCD2 and FANCI, suggesting that the coiled-coil domain in 
UBXN8 is required for the interaction with both FA proteins. The reduced binding of 
Flag-UBXN8 Δcoiled-coil to FANCD2 and FANCI was not due to changes in the 
subcellular localisation of UBXN8, since this mutant still localises at the ER membrane 
and the nuclear envelope, as is wild type UBXN8.  
It is true that also UBXN8 isoform 2, which lacks a region between the coiled-coil and 
UBX domain, showed a clear reduction in FANCD2 binding and a small reduction in its 
interaction with FANCI compared to wild-type UBXN8. Therefore, it is possible that 
residues within the missing region of isoform 2 contribute to the binding of FANCD2 
and FANCI.  
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The determination of the minimal region or residues of the interaction interface between 
UBXN8 and the FA proteins FANCD2 and FANCI would require the crystal structure 
of the UBXN8–FANCD2 and/or –FANCI complex. 
The finding that UBXN8 binds FANCD2 and FANCI via its coiled-coil domain 
supports the notion that UBX-only proteins, because of their lack of the UBA domain, 
bind their substrates more specifically in an ubiquitin-independent manner. Hence, 
UBXN8 only interacts with non-ubiquitylated FANCD2 and FANCI; their 
ubiquitylation is not necessary for the interaction with UBXN8. 
 
4.6.3 UBXN8 prevents ectopic activation of FANCD2 and FANCI 
The clonogenic survival assays showed that UBXN8 silencing caused increased 
resistance to the ICL-inducing agents MMC or cisplatin compared to control cells. 
These results suggest that UBXN8 is a negative regulator of the DNA damage response.  
The mono-ubiquitylation of FANCD2 and FANCI is considered to be the essential step 
in the activation of the FA pathway. The results presented in this thesis give multiple 
lines of evidence that UBXN8 negatively regulates the activation of FANCD2 and 
FANCI, namely: 
(1) The silencing of UBXN8 in U2OS cells caused an increase in the levels of FANCD2 
and FANCI mono-ubiquitylation under normal and DNA damage conditions. Consistent 
with the increase in FANCD2 and FANCI mono-ubiquitylation in UBXN8-depleted 
cells, I also observed an increase in FANCD2/I dimer formation between the mono-
ubiquitylated proteins, as well as an increase in the FANCD2 foci formation under 
normal and DNA damage conditions.  
(2) The overexpression of UBXN8 led to the opposite effect compared to UBXN8 
silencing. UBXN8 overexpression caused a reduction in the levels of FANCI mono-
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ubiquitylation and the FANCD2/I dimer formation in the presence and absence of DNA 
damage.  
(3) The in vitro ubiquitylation assays showed that UBXN8 reduces FANCD2 and 
FANCI mono-ubiquitylation in their monomeric state as well as in the context of the 
FANCD2/I dimer. This result suggests an inhibitory effect of UBXN8 on FANCD2 and 
FANCI mono-ubiquitylation in vitro and is consistent with the data showing that 
UBXN8 overexpression reduces FANCI mono-ubiquitylation in cells, while UBXN8 
silencing causes an increase in the level of FANCD2 and FANCI modification. 
 
The structure of the murine ID complex revealed that the ubiquitylation site Lys561 and 
Lys523 in FANCD2 and FANCI, respectively, are embedded within the interface of the 
ID complex. Therefore, it was suggested that the ubiquitylation of both FA proteins 
either happens on the monomeric proteins before their dimerization, or that the ID 
complex has to undergo a conformational change to allow the access of the E3 ligase to 
the lysine residues. Although it is still controversial whether FANCD2 and FANCI 
dimerize before DNA-binding or on the chromatin, recent findings support the notion 
that dimerization is required for DNA binding and mono-ubiquitylation. For example, 
the DNA binding activity of FANCI is important for the mono-ubiquitylation of 
FANCD2 within the ID complex in vitro. This suggests that FANCD2 and FANCI have 
to form a heterodimer for efficient DNA binding and consequently this is prior to 
FANCD2 mono-ubiquitylation (Longerich et al., 2014). Furthermore, it has been shown 
that DNA stimulates the mono-ubiquitylation of FANCD2 and FANCI in vitro, 
suggesting that DNA binding occurs prior to the ubiquitylation of the FA proteins (Sato 
et al., 2012b, Longerich et al., 2014).  
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Taking these findings into account, the results obtained upon UBXN8 silencing could 
suggest the following scenario (Figure 4.38):  
UBXN8 tethers FANCD2 and FANCI at the membrane (most likely at the nuclear 
membrane) to prevent their binding to DNA and to keep them in their inactive 
(unmodified) state.  
Several studies indicate that proteins at the nuclear periphery contribute to genome 
stability (Nagai et al., 2011, Misteli and Soutoglou, 2009). This has been investigated 
mainly in yeast and it was shown that certain types of DNA damage, such as persistent 
DSBs or collapsed replication forks, are recruited to the nuclear pores or sites along the 
inner nuclear envelope to be repaired by an alternative type of recombination repair 
(Nagai et al., 2008, Palancade et al., 2007, Kalocsay et al., 2009). Although the MS 
analysis of Flag-UBXN8 immunoprecipitates identified nucleoporins, such as Nup43, 
Nup85 and Nup160 as potential UBXN8 interaction partners, my data does not indicate 
that the DNA repair machinery localises to membrane-anchored UBXN8. Further, 
UBXN8 shows reduced FANCD2 and FANCI binding upon DNA damage, and does 
not interact with the mono-ubiquitylated form of FANCD2 and FANCI, which 
according to my data seems to represent the active and chromatin-bound state of both 
FA proteins. Hence, UBXN8 seems not to bind chromatin-associated FANCD2 and 
FANCI. This suggests that UBXN8 does not positively co-operate with FANCD2 and 
FANCI in DNA damage repair. It also has to be mentioned, that DSBs in mammalian 
cells seem to undergo no or limited motion in the nuclear space, therefore canonical HR 
events seem to occur preferentially in intranuclear foci, and are not sequestered to the 
nuclear periphery (Misteli and Soutoglou, 2009, Soutoglou et al., 2007, Oza et al., 
2009). This further negate the possibility that UBXN8 interaction with FANCD2 and 
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FANCI at the membrane is to facilitate the repair of damaged DNA near the nuclear 
periphery.  
Therefore, the silencing of UBXN8 would consequently result in an increased pool of 
free/soluble FANCD2 and FANCI. Because I was unable to clarify whether UBXN8 
binds monomeric and/or heterodimeric FANCD2/I, UBXN8 silencing might either 
increase the monomeric pool and/or the heterodimeric pool of FANCD2/I. Nonetheless, 
the free FANCD2 and FANCI are recruited to the DNA, where they get activated 
through mono-ubiquitylation, independently of DNA damage. Hence, the increased 
dimer formation and mono-ubiquitylation of FANCD2 and FANCI observed upon 
UBXN8 depletion might be a consequence of the increased amount of DNA localised 
FANCD2/I. 
The inhibitory effect of wild type UBXN8 on FANCD2 and FANCI mono-
ubiquitylation observed in vitro suggests that the binding of UBXN8 to the FA proteins 
prevents their mono-ubiquitylation. It has been shown that FANCL, similar to FANCD2 
and FANCI, is mainly nuclear localised and not chromatin bound in the absence of 
DNA damage (Tremblay et al., 2008). Furthermore, the core complex that includes 
FANCL is constitutively assembled and stable throughout the cell cycle (Alpi et al., 
2007). Therefore, the specific binding of UBXN8 to FANCD2 and FANCI might 
represent an additional mechanism to prevent FANCD2 and FANCI mono-
ubiquitylation away from the DNA.  
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Figure 4.38: UBXN8 prevents the ectopic activation of FANCD2 and FANCI  
Proposed model: UBXN8 homodimers capture monomeric FANCD2 (D2) and FANCI (I) or 
the ID complex at the nuclear membrane. This consequently keeps both proteins away from 
the DNA and prevents their ectopic dimerization and mono-ubiquitylation. This may be 
particularly important in the absence of DNA damage, when unrestricted activation of the FA 
pathway likely has deleterious effects for the cell. 
TM: transmembrane domain, UBX: Regulatory X domain, coiled-coil domain (orange), D2: 
FANCD2, I: FANCI, L: FANCL, Ub: ubiquitin. 
 
 
In the presence of DNA damage, the increased amounts of active/mono-ubiquitylated 
FANCD2 and FANCI in UBXN8-silenced cells might have a positive effect and could 
explain the increased resistance to ICL-inducing reagents. That an increase in mono-
ubiquitylated and DNA-bound FANCD2 might be an advantage in the presence of DNA 
damage was also described for USP1-silenced cancer cells. Similar to the UBXN8 
silenced cells, USP1 silencing increased FANCD2 mono-ubiquitylation and its 
chromatin-association (Nijman et al., 2005). Upon DNA damage, the silencing of USP1 
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in HEK293 cells caused reduced MMC-induced chromosomal aberrations and provided 
relative resistance compared to control cells. It was therefore suggested that the 
increased levels of FANCD2 mono-ubiquitylation might protect cells from ICL-induced 
DNA damage (Nijman et al., 2005). However, it must be mentioned that USP1 
knockdown in chicken DT40 cells, as well as Usp1-/- mouse embryonic fibroblasts, 
show an increased FANCD2 mono-ubiquitylation and chromatin-association, but cells 
are hypersensitive to DNA damaging agents (Kim et al., 2009, Oestergaard et al., 2007). 
The reason for the contradicting observation could be that silencing of USP1 with 
siRNA does not lead to complete depletion of USP1 as a knockout does. Therefore, de-
ubiquitylation of FANCD2 is not completely abolished in USP1-silenced cells. 
 
In the absence of DNA damage ectopic activation of FANCD2 and FANCI and the 
possible recruitment of downstream factors, such as the endonucleases FAN1 and SLX4 
through mono-ubiquitylated FANCD2 could cause an increase in mutation frequency 
and genome instability. Therefore, it will be important to test whether silencing of 
UBXN8 causes reduced cell viability in the absence of DNA damage. If this were the 
case, it would show the importance of UBXN8 in maintaining genome integrity by 
regulating the availability of DNA-targeted FANCD2 and FANCI. 
Furthermore, the inhibitory effect of UBXN8 would be in line with numerous other 
mechanisms that control the FA pathway activity to ensure its activation only when it is 
required. Other control mechanisms are for example: the ATR-dependent 
phosphorylation of FANCI and FANCD2 that restricts the activation of the FA pathway 
to S-phase (Andreassen et al., 2004, Pichierri and Rosselli, 2004, Ishiai et al., 2008); the 
phosphorylation of FANCA, FANCE and FANCG that are important for the activation 
of the FA pathway (Collins et al., 2009, Wang et al., 2007, Mi et al., 2004); the 
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phosphorylation of FANCM is regulated during cell cycle and restricts the recruitment 
of the core complex to the DNA in S-phase (Kim et al., 2008); the de-ubiquitylation of 
FANCD2 and FANCI by USP1/UAF1 inactivates the FA pathway (Nijman et al., 
2005). The presence of these control mechanism also suggests that the unrestricted 
activation of the FA pathway likely has deleterious effects for the cell. However, 
whether unscheduled activation of the FA pathway causes DNA damage is not known.  
 
4.6.4 Reduced UBXN8 levels allow increased FANCD2/I availability upon DNA 
damage 
The double-thymidine block used for S-phase arrest caused a strong mono-
ubiquitylation of FANCD2 and FANCI that gradually decreased after release as cells 
progressed through the cell cycle. The increased levels of mono-ubiquitylated FANCD2 
and FANCI were caused by thymidine, which is described to induce DNA damage 
response (Bolderson et al., 2004). Interestingly, the increased levels of mono-
ubiquitylated FANCD2 and FANCI after the release from thymidine are accompanied 
by reduced UBXN8 levels compared to asynchronous cells, or cells harvested at later 
time points (10–18h) that have similar cell cycle distributions. The time points (12-18h) 
in which cells re-entered S-phase did not re-induce increased mono-ubiquitylation of 
FANCD2 and FANCI, while UBXN8 levels gradually increase to the levels observed 
with asynchronous cells. This result suggests that UBXN8 levels might be reduced upon 
DNA damage to allow the activation of repair proteins such as FANCD2 and FANCI. 
The reduction of UBXN8 levels would release the inhibitory effect that it has upon 
FANCD2 and FANCI in the absence of damage.  
Furthermore, under non-damaged conditions, cell populations with a larger percentage 
of cells in S-phase show higher UBXN8 levels compared to G1 or mitosis-arrested cell 
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populations. The activation of the FA pathway is restricted to S-phase, which is ensured 
by several control mechanisms (Andreassen et al., 2004, Qiao et al., 2004, Wang et al., 
2007, Ishiai et al., 2008). Therefore, during S-phase and in the absence of DNA 
damage, increased UBXN8 levels might allow a tighter control of FANCD2 and 
FANCI to prevent their localisation to DNA, and consequent ectopic activation. 
 
4.6.5 Phosphorylation of four serine residues in FANCI causes ectopic activation of 
FANCD2 
The main upstream regulator of the FA pathway is ATR that coordinates the DNA 
damage response in S-phase. Although ATR phosphorylates several components of the 
FA core complex, its most relevant target in the FA pathway is FANCI.  
Ishiai et al. have shown that six key serine residues are important phosphorylation sites 
in chicken FANCI and are required for the mono-ubiquitylation of FANCD2 and the 
activation of the FA pathway (Ishiai et al., 2008). To investigate whether constitutive 
dimer formation of FANCD2/I changes the binding to UBXN8, I used the human, 
chicken equivalent, sextuple FANCI phospho-mutants (Dx6 and Ax6), as well as a 
quadruple mutant of human FANCI that harboured only four of the six mutations.  
The results obtained with the sextuple mutant in human FANCI failed to induce 
FANCD2 mono-ubiquitylayion and FANCD2/I foci formation, suggesting that there are 
differences in the importants of various phosphorylation sites between human and 
chicken FANCI. Interestingly, I identified the quadruple phospho-mimicking mutant 
(S556D, S559D, S565D, S596D) in human FANCI that constitutively activate 
FANCD2 and strongly induce FANCD2/I dimer formation in the absence of DNA 
damage. In contrast, the quadruple phospho-dead mutant did not show any binding to 
mono-ubiquitylated FANCD2 with or without DNA damage. The equivalent of the 
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quadruple mutant was not tested by Ishiai et al, therefore it is unclear whether these 
phospho-mimicking mutations at the equivalent residues in chicken FANCI would 
cause the same effect as seen with human FANCI. Furthermore, only the first two serine 
residues S556D and S559D have been shown to be phosphorylated in cells (Mu et al., 
2007) and it would be interesting to see whether the phosphorylation of these two 
residues is enough to cause the phenotype observed with the quadruple mutant. 
Preliminary data indicate that these two residues (S556D/S559D) as well as the first 
three residues (S556D/S559D/S565D) induce FANCD2 mono-ubiquitylation similar to 
the quadruple phospho-mimicking FANCI mutant, however both mutants show reduced 
binding to mono-ubiquitylated FANCD2. 
The majority of the FANCD2/FANCI 4SD dimer was only extracted by lysing the cells 
with benzonase, suggesting that this artificially induced dimer was targeted to 
chromatin even in the absence of DNA damage. Hence, the artificially induced dimer of 
FANCD2/I 4SD did not lead to an increase in dimer that was not DNA-bound. The 
mutations in FANCI did not affect its binding to endogenous UBXN8 that bound to 
wild type and mutant Flag-FANCI with similar efficiency. It is likely that DNA-bound 
FANCD2/I is not accessible to interact with UBXN8, which is anchored at the nuclear 
membrane. The reduced UBXN8 interaction with FANCD2 and FANCI upon DNA 
damage supports this idea. To prevent binding to the DNA, I created additional 
mutations (K898E and K980E) at putative DNA binding regions of FANCI. However, 
these mutations caused a defect in FANCD2/I dimerization and therefore did not 
increase the soluble pool of FANCD2/I dimer.  
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The model I propose suggests that UBXN8 acts as a negative regulator by capturing 
FANCD2 and FANCI at the membrane to prevent ectopic activation particularly in the 
absence of DNA damage (Figure 4.38).  
Studying the localisation of the sextuple phospho-mimicking GFP-chFANCI mutant in 
DT40 fanci cells, Ishiai et al. has shown that the phospho-mimicking-mutant (Dx6) 
drastically increases FANCD2/I foci formation on chromatin in the absence of DNA 
damage. These foci only partially localised with γH2AX or RAD51 foci, suggesting that 
these are not DNA damage foci (Ishiai et al., 2008). 
The ectopic activation of the FA pathway induced by the phospho-mimicking FANCI 
4SD mutant represents another example of how important it is to control the 
unrestricted activation of the FA pathway. Furthermore, it supports the notion, that a 
negative regulator such as UBXN8 might be required to prevent the FANCD2 and 
FANCI localisation to DNA and their ectopic activation in the absence of DNA 
damage. It would be interesting to investigate whether the overexpression of Flag-
UBXN8 could suppress the FANCD2 mono-ubiquitylation and foci formation induced 
by the phospho-mimicking FANCI 4SD mutant. 
 
4.6.6 p97 and its dual function in the FA pathway  
The in vitro binding assays have shown that UBXN8 can bind FANCD2 and FANCI in 
the absence of p97, suggesting that binding between these proteins is not mediated by 
p97. However, preventing p97 interaction with UBXN8 through the P238G mutation in 
the FPR motif within the UBX domain caused an increased UBXN8 binding to FANCI 
compared to the wild type. This effect was not observed with FANCD2 that binds wild 
type and mutant UBXN8 to the same extent. Furthermore, I showed that FANCD2 and 
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FANCI get released from Flag-UBXN8 upon DNA damage and that the FANCI release 
was impaired in the case of the P238G mutant compared to the wild type.  
These results suggest the p97 regulates the binding between UBXN8 and FANCI, by 
mediating its release from UBXN8. This might be particularly important upon DNA 
damage – the time in which FANCD2 and FANCI are activated and localise to DNA 
lesions to facilitate DNA repair.  
The in vitro binding assays have shown that UBXN8 can bind monomeric FANCD2 or 
FANCI. However, since UBXN8 forms homodimers both in vitro and in cells, it 
theoretically has two binding sites and could bind the heterodimer FANCD2/I as well. 
Therefore, the results obtained with the P238G mutant suggest two scenarios of how 
p97 regulates the binding of FANCI: (1) UBXN8 binds monomeric FANCD2 and 
FANCI, and p97 dissociates monomeric FANCI from UBXN8, or (2) UBXN8 binds the 
heterodimer FANCD2/I and p97 dissociates FANCI from FANCD2 that remains bound 
to UBXN8. Both scenarios take into consideration that the binding of UBXN8 to 
FANCD2 is regulated in a p97-independent manner. 
The regulatory function of p97 could be studied further using a p97 inhibitor such as 
ML240 or ML241. This would allow the inhibition of p97 ATPase activity in a shorter 
period (Chou et al., 2013) and might reduce the side effects, such as cell cycle arrest and 
decreased cell viability, observed with siRNA treatment.  
 
Interestingly, upon release from DNA damage FANCI interaction with FANCD2 
gradually declined over time, while the binding to p97 drastically increased. Recent 
publications have shown that p97 and its cofactor NPL4-UFD1 are recruited to DNA 
damage sites to extract substrate proteins, such as L3MBTL1 (Acs et al., 2011) or the 
TLS polymerase Polη(Davis et al., 2012) to allow the proper assembly of downstream 
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signalling factors, including Rad51, BRCA1 and 53BP1 (Acs et al., 2011, Meerang et 
al., 2011). Therefore, it is tempting to speculate that p97 might be required for 
FANCD2/I dimer dissociation from chromatin, or the dissociation of the heterodimer 
itself when DNA repair is complete. The increased p97-binding to FANCD2 upon 
release from DNA damage was UBXN8-independent, because UBXN8 silencing did 
not affect the increase in p97-binding. Therefore, p97 might have a dual function in the 
FA pathway: (1) regulating the interaction between UBXN8 and FANCI and (2) 
dissociating the heterodimer FANCD2/I from chromatin or from each other upon 
completion of DNA repair. 
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